

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Smartphone problem-solving and behavioral activation therapy to reduce fear of recurrence among breast cancer patients (SMartphone Intervention to LEssen fear of cancer recurrence: SMILE project): protocol for a randomized control trial

| | |
|-------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2018-024794 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 24-Jun-2018 |
| Complete List of Authors: | Akechi, Tatsuo; Nagoya City University Graduate School of Medical Sciences and Medical School Yamaguchi, Takuhiro; Division of Biostatistics, Uchida, Megumi; Nagoya City University Graduate School of Medical Sciences and Medical School Imai, Fuminobu; Nagoya City University Graduate School of Medical Sciences and Medical School Momino, Kanae; Nagoya City University School of Nursing Katsuki, Fujika; Nagoya City University School of Nursing, Nagoya, Department of Psychiatric and Mental Health Nursing Sakurai, Naomi; Cancer Solutions, Co., Ltd. Miyaji, Tempei; Univ Tokyo Horikoshi, Masaru; National Center of Neurology and Psychiatry Furukawa, Toshi; Kyoto University, Graduate School of Medicine and School of Public Health Iwata, Hiroji; Aichi Cancer Center, Nagoya, Breast Oncology Uchitomi, Yosuke; Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, & Behavioral and Survivorship Research Group, Center for Public Health Sciences |
| Keywords: | neoplasma, fear of recurrence, cancer survivorship, psychosocial intervention, information and communication technology, quality of life |
| | |

SCHOLARONE™
Manuscripts

1
2
3 Study protocol

4
5 Title: Smartphone problem-solving and behavioral activation therapy to reduce fear of recurrence
6
7
8 among breast cancer patients (SMartphone Intervention to LEssen fear of cancer recurrence:
9
10
11 SMILE project): protocol for a randomized control trial
12
13
14
15

16 Tatsuo Akechi, MD, PhD^{1,2}

17 Takuhiro Yamaguchi, PhD³

18
19
20
21
22 Megumi Uchida, MD, PhD^{1,2}

23
24
25 Fuminobu Imai, MD^{1,2}

26
27
28 Kanae Momino, RN, MHIthSci⁴

29
30
31 Fujika Katsuki, RN, PhD⁵

32
33
34 Naomi Sakurai,⁶

35
36
37 Tempei Miyaji,⁷

38
39
40 Masaru Horikoshi, PhD⁸

41
42
43 Toshi A Furukawa, MD, PhD⁹

44
45
46 Hiroji Iwata, MD, PhD¹⁰

47
48
49 Yosuke Uchitomi MD, PhD¹¹

50
51
52
53 1. Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate
54
55
56 School of Medical Sciences, Nagoya, Japan
57

- 1
2
3 2. Division of Palliative Care and Psycho-oncology, Nagoya City University Hospital, Nagoya,
4
5 Japan
6
7
- 8 3. Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan
9
- 10 4. Department of Nursing Administration and Management, Nagoya City University School of
11
12 Nursing. Nagoya, Japan
13
14
- 15 5. Department of Psychiatric and Mental Health Nursing, Nagoya City University School of
16
17 Nursing, Nagoya, Japan
18
19
- 20 6. Cancer Solutions, Co., Ltd., Tokyo, Japan
21
- 22 7. Department of Clinical Trial Data Management, Graduate School of Medicine, The
23
24 University of Tokyo, Tokyo, Japan
25
26
27
- 28 8. National Center for Cognitive Behavior Therapy and Research, National Center of Neurology
29
30 and Psychiatry, Tokyo, Japan
31
32
33
- 34 9. Kyoto University Graduate School of Medicine / School of Public Health Department of Health
35
36 Promotion of Human Behavior, Kyoto, Japan
37
38
- 39 10. Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
40
41
- 42 11. Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center
43
44 Hospital, & Behavioral and Survivorship Research Group, Center for Public Health Sciences,
45
46
47
48
49
50
51 National Cancer Center, Tokyo, Japan
52
53
54
55

56 Corresponding Author: Tatsuo Akechi, MD, PhD
57

1
2 Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate
3

4
5 School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601 Japan
6

7
8 Tel: +81-52-853-8271, Fax: +81-52-852-0837, Email: takechi@med.nagoya-cu.ac.jp
9

10
11
12
13
14 Key words: neoplasma; fear of recurrence; cancer survivorship; psychosocial intervention;
15
16
17 information and communication technology; quality of life
18
19

20
21
22
23 Protocol version 4.2 (June 12, 2018)
24
25

26
27
28 Word count: 4226
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: One of the most common distressing conditions experienced by breast cancer survivors is fear of cancer recurrence (FCR). There is, however, no standard intervention for ameliorating FCR. Our clinical experience and previous studies have suggested the potential benefits of problem-solving therapy (PST) and behavioral activation (BA). Given the huge number of cancer survivors and limited number of therapists to competently conduct PST and BA, we have developed PST and BA smartphone applications. This study aimed to evaluate the efficacy of the smartphone-based PST (Kaiketsu-App) and BA (Genki-App) apps in reducing FCR in breast cancer patients.

Methods and analysis: The SMartphone Intervention to LEssen fear of cancer recurrence (SMILE) project is an open-label, individually randomized, parallel-group trial. Allocation will be managed by a central server, using a computer-generated random allocation sequence provided by an independent data center. Participants will be randomized to smartphone-based intervention plus treatment as usual (TAU) or wait-list control with TAU alone. The primary end point of the study is the Japanese version of the Concerns About Recurrence Scale, which will be administered as an electronic patient-reported outcome on the patients' smartphone after 8 weeks.

Ethics and dissemination: The present study is subject to the ethical guidelines for clinical studies published by Japan's Ministry of Education, Science and Technology and Ministry of Health, Labour and Welfare and the modified Act on the Protection of Personal Information as well as the ethical principles established for research on humans stipulated in the Declaration of Helsinki and

1
2 further amendments thereto. The protocol was approved by the institutional review board of Nagoya
3
4
5 City University on January 15, 2018 (ID: 60-00-1171).
6
7

8 Trial registration: UMIN-CTR: UMIN000031140
9
10
11
12
13
14
15

16 Article Summary

17 Strengths and limitations of this study

18
19
20 -This study is the first trial investigating the efficacy of smartphone-based psychological therapy for
21
22 fear of cancer recurrence (FCR) among breast cancer survivors.
23
24
25

26
27
28 -Because many breast cancer survivors return to their households and work, easily accessible
29
30 therapeutic interventions without hospital visits may offer benefits.
31
32

33
34 -This study focuses on younger breast cancer survivors who are iPhone users; this focus could
35
36 reduce the external validity of the findings obtained.
37
38

39
40 -The use of the wait-list control conditions may overestimate the efficacy of the smartphone-based
41
42 psychotherapy.
43
44

45
46 -We will apply two types of psychotherapy and both interventions consist of complex, multifactorial
47
48 components; thus, we cannot be certain which intervention and components are most beneficial in
49
50 managing FCR; however, we will adopt a mixed-method design to overcome those issues.
51
52
53
54
55
56
57
58
59
60

Introduction

Worldwide, breast cancer is one of the most common cancers among women. In Japan, it is also the most common cancer among women, and the incidence is increasing. At present, approximately 90,000 women in Japan are annually diagnosed with breast cancer. Advances in early detection and individualized medical treatment have improved the survival rate of breast cancer patients. The current 10-year survival rate for breast cancer patients is over 90%, which contributes to the increasing number of breast cancer survivors is increasing.¹

Thus patients with breast cancer have on average a better prognosis than those with many other types of cancer; however, it has been suggested that many breast cancer survivors suffer from uncertainty anxiety and fear over recurrence.²⁻⁴ Our previous study found that the most common unmet needs experienced by ambulatory breast cancer patients are psychological—especially fear of cancer recurrence (FCR); over half of patients complained of such needs.⁵ Among breast cancer patients, FCR is, not only highly prevalent, but also associated with poor quality of life.^{2, 5-8}

Accordingly, there is an urgent need for an appropriate intervention for FCR. However, there is no standard intervention for ameliorating FCR.⁸ Recent studies have demonstrated that the following can improve FCR among breast cancer survivors: mindfulness stress reduction (six weekly group sessions); cognitive behavioral therapy (CBT; five individual face-to-face sessions and three e-consultations over a period of 3 months); and the novel theoretically based intervention of ConquerFear, which includes attention training, metacognition, and acceptance and mindfulness (five individual face-to-face sessions over 10 weeks).⁹⁻¹² These interventions may be promising;

1
2 however, one problem with this kind of intervention is the low participation rate owing to time and
3
4 distance issues (e.g., over 60% of potentially eligible subjects have been found to decline
5
6 participation).^{9, 11-14} In addition, the number of therapists who can provide such specialized care
7
8
9
10
11 may be severely limited, which is a serious problem in many countries.
12

13
14 Our past experience and some studies indicate the effectiveness of CBT, including problem-
15
16 solving therapy (PST) and behavioral activation (BA), for FCR among breast cancer survivors.¹⁵⁻¹⁸
17
18 We have demonstrated that patients' problem-solving skills were significantly associated with
19
20 FCR.¹⁵ PST and BA are straightforward interventions that can be administered by less experienced
21
22 therapists, including nurses.¹⁹ However, patients willing to undergo PST or BA are rarely able to do
23
24 so even in well-resourced countries because a typical course of PST or BA consists of eight to 12
25
26 face-to-face sessions lasting 1 or 1.5 hours led by an trained therapist.²⁰⁻²²
27
28
29
30
31
32

33
34 Though such programs seem promising, they appear to suffer similar limitations to those of the
35
36 above-mentioned therapeutic interventions.⁹⁻¹² Given the growing number of women annually
37
38 diagnosed with breast cancer and the high prevalence among them of unmet needs of FCR, a
39
40 completely novel approach to therapy provision is required. Recent studies have demonstrated the
41
42 effectiveness of computerized CBT.^{23, 24} In light of recent developments in information and
43
44 communication technology (ICT), CBT delivered via smartphones may be a better treatment option
45
46 for FCR—in terms of accessibility and portability—than a computer-based one.²⁵ We have recently
47
48 developed a smartphone CBT app, which teaches skills in BA and cognitive restructuring; we
49
50 demonstrated its efficacy for antidepressant-resistant major depression in a randomized controlled
51
52
53
54
55
56
57
58
59
60

1
2 trial.²⁶ We have also developed PST programs as a smartphone app and demonstrated the
3
4
5 acceptability and efficacy of the smartphone-based PST in a single-arm pilot study with breast
6
7
8 cancer survivors.²⁷ The purpose of the present randomized study is to examine the efficacy of
9
10
11 smartphone-based PST and BA interventions to reduce FCR in breast cancer patients in a
12
13
14 randomized controlled trial.

15 16 17 18 19 20 Methods and analysis

21
22 This protocol has been written in accordance with the SPIRIT guideline.²⁸
23
24
25
26
27

28 29 30 Trial design

31 The present study is an individually randomized, parallel-group trial (Figure 1). An independent
32
33
34 data center will provide computer-generated random allocation sequences. The allocation sequences
35
36
37 are maintained centrally, and the results of the assignment will be sent automatically to the study
38
39
40 participants by e-mail. The participants are randomized to smartphone-based intervention plus
41
42
43 treatment as usual (TAU) or wait-list control with TAU alone.
44
45
46
47

48 49 50 Interventions: Smartphone-based PST (Kaiketsu-App) and BA (Genki-App)

51 PST provides patients with a structured strategy for solving their problems. PST includes the
52
53
54 following five steps²⁹: (1) identification, definition, and breakdown of the problem; (2) establishing
55
56
57 achievable goals; (3) generating solutions; (4) evaluating and choosing the solution; and (5)

1
2 implementing the chosen solution and evaluating the outcome after implementation.
3
4

5 The smartphone-based PST program, called Kaiketsu-App (“Kaiketsu” means “Solution”
6 in Japanese), for iPhones and iPads (Apple Inc., Cupertino, CA, USA) was developed for this study
7
8 (Figure 2). The development was based on our empirically supported PST manual.¹⁸ Kaiketsu-App
9
10 comprises nine sessions: three introductory session; four sessions about learning the PST in five
11
12 steps; one session of actual training; and one concluding session. The shortest time necessary to
13
14 complete Kaiketsu-App is 2 weeks. The main program consists of dialogues between characters,
15
16 who explain the principles and skills of PST. After the first session, participants have to do
17
18 homework. The time necessary to complete one session is approximately 30 minutes.
19
20
21
22
23
24
25
26
27

28 BA intervention was developed based on the hypothesis that anxiety can lead to less
29
30 pleasurable behavior and more sedentary life, which then may lead to worsening anxiety.²⁹
31
32

33 The smartphone-based BA program Genki-App (“Genki” means “Energy or Vitality” in
34
35 Japanese), for iPhones and iPads (Figure 3) was developed as part of the smartphone-based CBT
36
37 program which was developed for our previous study.³⁰ Genki-App consists of two sessions, and
38
39 approximately 30 minutes is needed to complete each session.
40
41
42
43
44

45 Over the 8-week period of the programs, participants are encouraged to complete the
46
47 sessions and homework through automated e-mail reminders once a week.
48
49
50
51
52

53 *Participants*

54
55

56 The inclusion criteria for participants are as follows: (1) diagnosis of breast cancer and awareness of
57
58
59
60

1
2 the cancer diagnosis; (2) age 20–49 years; (3) 1 year following breast surgery; (4) currently disease
3
4 free; (5) ability to complete an electronic patient reported outcome (ePRO) using an iPhone or iPad;
5
6
7
8 (6) being an iPhone or iPad user and having an apple ID to install applications using App Store. We
9
10 limit the patients' age to 20–49 years because one study and our previous investigation
11
12 demonstrated that individuals of that age are at high risk of FCR and that more than 50% of such
13
14 people have smartphones.^{8, 31, 32}
15
16
17
18

19 The exclusion criteria for participants are as follows: (1) having active, serious physical
20
21 disease that affects household and light work and a current or past history of cancer other than
22
23 breast cancer; (2) inability to understand Japanese; (3) currently undergoing follow-up and
24
25 treatment in a psychiatry department or by other mental health professionals; (4) patients who have
26
27 previously undergone structured PST, BA therapy, or CBT; (5) judged inappropriate for
28
29 participation by the researchers.
30
31
32
33
34
35
36
37
38

39 Procedures

40 Newly developed research management system

41
42 To lessen patient inconvenience in visiting hospital for this study and oncologists' workload in
43
44 enrolling study participants, we developed a research management system making full use of ICT
45
46 technology (Figure 4). The study's Web site (<https://smile-project.org/>) provides information about
47
48 this study. A poster briefly introducing the study and including a QR code for the Web site has been
49
50 put up in several core cancer hospitals in Japan. The Web site explains the purpose of the study,
51
52
53
54
55
56
57
58
59
60

1
2 eligibility criteria, and methods used; it also features a video briefly introducing the study as well as
3
4
5 providing full written information about it. Potential participants who are interested in the study can
6
7
8 e-mail the study's central office, and clinical research coordinators (CRCs) at the central office
9
10
11 ascertain their eligibility by telephone (Table 1).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1 Schedule for outcome measurement

| | | Time points | | | | |
|------------|---------------------------------|-------------|---------|---------|---------|----------|
| | | 0 week | 2 weeks | 4 weeks | 8 weeks | 24 weeks |
| Assessment | Understanding of the e-Consent | ● | | | | |
| | Characteristic | ● | | | | |
| | CARS-J, HADS | ● | ● | ● | ● | ●* |
| | FCRI, SCNS-SF34, PTGI-J | ● | | | ● | ●* |
| | Satisfaction with interventions | | | | ●* | |
| | Qualitative assessment of apps | | | | ●* | |

CARS-J: Japanese version of the Concerns About Recurrence Scale

HADS: Hospital Anxiety and Depression Scale

Fear of Cancer Recurrence Inventory short form (FCRI-SF)

SCNS-SF34: Short-form Supportive Care Needs Survey questionnaire

PTGI-J: Posttraumatic Growth Inventory-Japanese

*These would be evaluated only for intervention group

1
2
3
4
5 Electronic informed consent and randomization at week 0
6
7

8 After screening, the CRCs will seek to obtain the subjects' electronic informed consent (e-consent)
9
10 via e-PRO system at week 0. Participants will be requested to upload a picture of identification
11
12 materials (patients will be especially encouraged to attach a photo of the ID card of the hospital
13
14 where they made regular follow-up visits for breast cancer). This e-consent procedure is in
15
16 accordance with the guidance of the US Food and Drug Administration (FDA).³³
17
18
19
20
21

22 After providing e-consent and completing the baseline investigation by e-PRO, the
23
24 participants will be randomly allocated to either the smartphone-based PST and BA group or the
25
26 wait-list control group in a 1:1 ratio using the electronic data-capturing Web program (EDC) at the
27
28 data management center (Figure 1). The random allocation will therefore be concealed.
29
30
31
32

33 If a participant is allocated to the intervention group, they will receive a password unique to
34
35 them for using Kaiketsu-App and Genki-App. Upon entering the password, participants will be able
36
37 to proceed to the sections for Kaiketsu-App and Genki-App. If participants are allocated to the
38
39 control group, they will be informed that use of Kaiketsu-App and Genki-App can be resumed if
40
41 they wish after week 8.
42
43
44
45
46
47
48
49

50 Data management, central monitoring, and auditing
51

52 We will collect all data except qualitative interview data through e-PRO; we will obtain qualitative
53
54 interview data by telephone (See below for details). If participants fail to provide their responses
55
56
57

1
2 regarding FCR, a CRC blinded to the assignment will telephone the subjects to elicit their answers.
3
4

5 Data management and central monitoring will be performed using the EDC. The EDC consists of
6
7
8 two different and independent parts, one including personal information and the other including
9
10
11 trial-related data (e.g., assignment, outcomes, etc.) for security. Auditing is not planned for this
12
13
14 study because the interventions are not invasive.
15
16
17
18

19 Dataset available 20

21
22 The de-identified anonymized dataset will be uploaded to UMIN-ICDR
23
24 (<http://www.umin.ac.jp/icdr/index-j.html>) and researchers approved by the Steering Committee will
25
26
27 be able to have access to the dataset.
28
29
30
31
32

33 Trial period: weeks 0–8 34

35
36 For participants allocated to the intervention group, an automated e-mail encouraging their
37
38 adherence to Kaiketsu-App and Genki-App will be sent every week for 8 weeks. The research team
39
40 can check the patient's progress (number of times and duration using each application) with
41
42 Kaiketsu-App and Genki-App using Google Analytics. At weeks 2, 4, and 8, participants will
43
44
45 receive an e-mail encouraging them to record their responses on e-PRO.
46
47
48
49
50
51
52

53 Follow-up period: weeks 8–24 54

55
56 Participants allocated to the control group can resume the Kaiketsu-App and Genki-App if they
57
58
59
60

1
2 wish. At week 24, participants allocated to the intervention group will receive an e-mail
3
4
5 encouraging them to provide their responses on e-PRO.
6
7
8
9

10 Concomitant treatments

11
12
13
14 There is no restriction on concomitant treatments.
15
16
17
18

19 Stopping rules for participants

20 Discontinuation of protocol treatment

21
22 If a participant meets any of the following conditions, the research team can discontinue the
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
If a participant meets any of the following conditions, the research team can discontinue the
Kaiketsu-App and Genki-App. However, the participant will not be considered to have dropped out
of the trial at that stage and will receive the protocol assessments: (1) the participant wishes to stop
the protocol treatment; (2) the research team judges that the risk of the protocol treatment is greater
than the benefit for any reason; (3) the research team judges that it is inappropriate to continue the
protocol treatment for any reason.

Stopping assessment

59
60
If a participant withdraws consent for assessment, she will not be followed up. Subjects will be
excluded from the intention-to-treat (ITT) cohort of the trial only if their characteristics are found to
meet any exclusion criteria at baseline (e.g., age over 50 years) after participation.

1
2
3 Assessment measures
4

5 Table 1 shows the schedule for outcome measurement.
6
7

8 Primary outcome measure
9

10
11 Fear of recurrence: CARS-J
12

13 Originally developed in the United States, CARS-J is a 26-item self-report scale to measure fear of
14 recurrence of breast cancer.³⁴ The reliability and validity of CARS-J has been confirmed among
15 Japanese breast cancer patients.³⁵ CARS-J assesses the overall fear of breast cancer recurrence and
16 four domains of specific fear of recurrence. Overall fear comprises four items: questions on
17 frequency; potential for upset; consistency; and intensity of fear. The overall fear score with CARS-
18 J is our primary outcome. The range of possible scores for overall fear is 4–24; a higher score
19 indicates greater fear of recurrence.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

36 Secondary outcome measures
37

38
39 Fear of Cancer Recurrence Inventory–Short Form
40
41

42 The Fear of Cancer Recurrence Inventory–Short Form (FCRI-SF) is a nine-item self-report scale,
43 originally developed in Canada.^{36, 37} The FCRI evaluates the presence and severity of intrusive
44 thoughts associated with FCR: scores range from 0 to 36; a higher score indicates severe FCR.
45
46
47
48
49
50 Unlike with CARS-J, the FCRI-SF can measure fear of recurrence of any type of cancer. The
51 Japanese version of the FCRI-SF was developed after obtaining permission from the original author
52 and using a forward-backward translation process. In this study, the measure will be included as a
53
54
55
56
57
58
59
60

1
2 secondary outcome after its validity and reliability have been ascertained.
3
4
5
6
7

8 Psychological distress: Hospital Anxiety and Depression Scale 9

10 The Hospital Anxiety and Depression Scale (HADS), a self-report questionnaire comprising
11 14 items, was developed for use with medically ill patients. The HADS consists of an anxiety and a
12 depression subscale (0–21 points each). The total score ranges from 0 to 42; a higher score indicates
13 more severe depression and anxiety.³⁸ The Japanese version of the HADS has been validated for
14 cancer populations.³⁹
15
16
17
18
19
20
21
22
23
24
25
26
27

28 Patients perceived needs: Short-form Supportive Care Needs Survey questionnaire 29

30 The Short-form Supportive Care Needs Survey questionnaire (SCNS-SF34) is a self-
31 administered instrument for assessing the perceived needs of cancer patients.⁴⁰ The SCNS-SF34
32 comprises 34 items covering five domains of need: psychological; health system and information;
33 physical and daily living; patient care and support; and sexuality. The total score is obtained by
34 summing all the subscales (range, 34–170). A higher score indicates a higher perceived need. The
35 validity and reliability of the Japanese version of SCNS-SF34 have been established.⁴¹
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 Posttraumatic Growth Inventory-Japanese version 51

52 The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report scale, originally developed in
53 the United States.⁴² The PTGI includes items that measure positive psychological change
54
55
56
57
58
59
60

1
2 experienced as a result of struggle with major life crises or traumatic events. The PTGI-J consists of
3
4
5 four subscales: relating to others; new possibilities; personal strength; and spiritual change and
6
7
8 appreciation of life. The total score ranges from 0 to 90; a higher score indicates more positive
9
10
11 changes.⁴³
12
13
14
15

16 Satisfaction with intervention

17
18
19 To assess patients' perceived satisfaction with the intervention, we ask two additional items. The
20
21
22 items are as follows. (1) "Please rate your satisfaction with the treatment in meeting your needs
23
24
25 during the past 2 months by assigning it a score from 0 to 100; a score of 100 indicates complete
26
27
28 satisfaction. A score of 60 is considered the passing level." (2) "Please rate your overall satisfaction
29
30
31 with the treatment during the past 2 months by assigning it a score from 0 to 100; a score of 100
32
33
34 indicates complete satisfaction. A score of 60 is considered the passing level." A lower score
35
36
37 indicates lower satisfaction. We used this method in our previous study.⁴⁴
38
39
40
41
42

43 Understanding e-consent

44
45 We will ask ten questions will be asked at week 0 related to the participants' understanding of e-
46
47
48 consent: purpose of the study; randomization; voluntarily participation; duration of study; risks and
49
50
51 benefits of study participation; free withdrawal anytime from the study; contact method for
52
53
54 questions and more detailed information about the study; method of participant identification
55
56
57 (uploading a photo of the hospital registration card); which of the video or written documentation in
58
59
60

1
2 the Web site was the more helpful in understanding the study contents ; and free opinions regarding
3
4
5 e-consent.
6
7
8
9

10 Qualitative evaluation of intervention

11
12
13 The intervention will consist of multiple complex components; accordingly, simple structured
14
15 telephone interviews will be conducted at 8 weeks for approximately 30 subjects willing to
16
17 participate in this additional survey to evaluate the effective parts of the complex intervention. The
18
19 interview items will be as follows. (1) “Please talk freely about the usefulness of the smartphone
20
21 PST and smartphone behavioral intervention.” (2) “Please talk freely about the usefulness of each
22
23 of the five steps of the smartphone PST and give your reasons for your opinions.” (3) “Please talk
24
25 freely about the usefulness of the two parts of the smartphone behavioral intervention and give your
26
27 reasons for your opinions.” (4) “Please talk freely about the effectiveness of the intervention, for
28
29 example, the regular encouraging e-mail, and if any other components contributed to improving
30
31 your fear of recurrence.” If the participants permit, the answers will be recorded using a voice
32
33 recorder.
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 Sociodemographic and biomedical factors

49
50 e-PRO will also be used to obtain information about the patients’ sociodemographic and biomedical
51
52 status (marital status, level of education, and employment status) and biomedical information
53
54 (physical function, time since diagnosis, clinical stage, and anti-cancer treatment).
55
56
57

Data analysis

Primary analyses

To examine the treatment effect parameters of all randomly assigned subjects in the primary analysis set according to the ITT principle, we will analyze the primary outcome (CARS-J score at weeks 2, 4, and 8) using a generalized linear model with unstructured covariance and robust standard errors. The fixed effects are CARS-J score at baseline, treatment allocation (intervention versus control), time (2, 4, and 8 weeks as categorical variable), and treatment-by-time interaction; the random effects are subjects (as intercepts). The primary outcome of interest is the difference in CARS-J scores between the two groups at week 8. A two-sided P value of less than 0.05 will be used to indicate statistical significance.

Secondary analyses

We will perform secondary analyses to supplement our primary analysis and to obtain a clearer understanding of our clinical questions. The secondary analyses will use models similar to that of the primary analysis and will also examine data for the secondary outcome measures. The secondary analyses will include an assessment of the validity and reliability of FCR-J. These analyses will be conducted for exploratory purposes.

Interim analyses

1
2 We do not plan any interim analysis.
3
4
5
6
7

8 Sample size estimation 9

10 Our previous phase II study revealed that the mean CARS-J scores were 12.8 at pre-intervention
11 (baseline), 12.4 at 4 weeks, and 11.2 at 8 weeks.²⁷ We assumed the following: the mean CARS-J
12 score at 2 weeks would be 12.6; the overall CARS-J scores in the control arms would not change
13 (12.8 at 0, 2, 4, and 8 weeks); the variance of the score would be 30 at all times; and the intra-class
14 correlation would be 0.82 (i.e., we assumed a compound symmetry working covariance structure).
15
16 Thus, for a sample size based on 0.8 power to detect a significant difference at $P = .05$ (two-sided),
17
18 211 participants would be required for each arm. Assuming that 5% of the initial entries would drop
19
20 out, we would need to recruit 444 participants into the trial.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 Publication policy 37

38
39 The protocol paper and study results will be submitted to peer-reviewed journals. The first author of
40
41 the main paper will be a member of the steering committee (authors of the protocol paper). Another
42
43 person could be the first author if approved by the steering committee. The list of co-authors will be
44
45 determined before submitting each paper.
46
47
48
49
50
51
52

53 Study period 54

55
56 The study period of this trial will be from April 2017 to March 2020; the participant entry period
57
58
59
60

1
2 will be April 2018 to September 2019.
3
4
5
6
7

8 Patient and public involvement statement 9

10 The study protocol was designed with a patient (breast cancer survivor) and she participated in this
11 study as a researcher. She appropriately discussed with other patients when a patient's preferences
12 and/or opinions should be considered. She will play a same role on implementing the study. Thus
13 patients were and will be always involved in the study. Results of the study will be shown in the
14 study home page.
15
16
17
18
19
20
21
22
23
24
25
26
27

28 Ethics and dissemination 29

30 The present study is subject to ethical guidelines for clinical studies published by Japan's Ministry
31 of Education, Science and Technology and Ministry of Health, Labour and Welfare and the
32 modified Act on the Protection of Personal Information as well as the ethical principles established
33 for research on humans stipulated in the Declaration of Helsinki and further amendments thereto.
34
35
36
37
38
39
40
41

42 The protocol was approved by the institutional review board of Nagoya City University on
43 January 15, 2018 (ID: 60-00-1171). If important protocol modifications are needed, the
44 investigators will discuss them and report to the review board for approval.
45
46
47
48
49

50 With regard to dissemination, the results obtained will be submitted for publication in peer-
51 reviewed journals. The main and relevant findings will be presented at conferences.
52
53
54
55
56
57

Discussion

To our knowledge, the present study is the first trial investigating the efficacy of smartphone-based psychological therapy for fear of recurrence among breast cancer survivors. Considering the huge number of breast cancer survivors and low participant rate with other types of therapeutic interventions, smartphone-based psychological therapy may offer a more accessible option. As many cancer survivors return to their households and to work, easily accessible therapeutic interventions may offer additional benefits in managing fear of recurrence. The present study focuses on younger breast cancer patients who are iPhone users. However, many other patients suffering from fear of recurrence use other types of smartphones (e.g., Android); in addition, including patients aged 50 years and above would constitute a broader targeted population. If the efficacy of the smartphone-based intervention program among our participants is confirmed, the program will have promising applicability in real clinical settings.

The present study has some methodological limitations. First, not all patients who are interested in and willing to use Kaiketsu-App and Genki-App possess a smartphone. This may weaken the applicability of the results from this trial to all breast cancer patients with fear of recurrence. Especially, the results may not be applicable to patients in developing countries and to those with poor ICT literacy.

Second, we will use a wait-list control as the comparator owing to feasibility and ethical considerations. The odds of response was found to be statistically significantly greater for no treatment than the wait list.⁴⁵ The wait list may therefore lead to some overestimation of the

1
2 efficacy of smartphone-based psychotherapy.
3
4

5 Third, we will apply two types of psychotherapy—BA and PST—as interventions. Both
6
7
8 psychotherapeutic interventions consist of complex, multifactorial components. Thus, if the
9
10
11 interventions prove superior to the wait-list controls, we cannot determine which intervention and
12
13
14 components are most efficacious or beneficial in managing fear of recurrence. However, to
15
16
17 overcome this limitation, we will adopt a mixed-method design and can check adherence with each
18
19
20 intervention (detailed in “Methods and analysis”) so that we can identify the most useful
21
22
23 components of the interventions.
24

25 Fourth, we will request that participants upload images for identification (they will be
26
27
28 especially encouraged to attach a photo of the hospital registration card) to avoid individuals
29
30
31 masquerading as breast cancer patients. However, possible deception cannot be completely
32
33
34 prevented in our recruitment system.
35
36
37
38
39
40
41

42 Author contributions

43
44 TA, TAF, and MH developed the smartphone applications and MU and FI also contributed to
45
46
47 modification of these applications. TA, TY, MK, FK, NS, TM, TAF, HI, and YU participated in the
48
49
50 design of the study. TY played a chief role of the statistical parts. TA drafted the manuscript. All
51
52
53 authors participated in, read and approved final manuscript.
54
55
56
57
58
59
60

Funding

This study is supported by a Grant-in-Aid for Japan Agency for Medical Research and Development (Number JP17ck0106324h). This study is also partly supported in part by a Grant-in-Aid for Scientific Research (Number 25285194) and Young scientists (Number 17k13942) from the Japanese Ministry of Education, Culture, Science, and Technology, grant from Nagoya City University, Foundation for Promotion of Cancer Research in Japan and The National Cancer Center Research and Development Fund (Number 27-A-3 & 30-A-11).

Competing interests

The authors have no conflicts of interests to declare that may be affected by the publication of the manuscript. TA has received lectures fees from AstraZeneca, Daiichi-Sankyo, Dainippon-Sumitomo, Eisai, Hisamitsu, Lilly, MSD, Meiji-seika Pharma, Mochida, Pfizer, Novartis, Otsuka, Shionogi, Takeda, Tanabe-Mitsubishi, Terumo, and Yoshitomi. TA has received research funds from Daiichi-Sankyo, Eisai, MSD, Pfizer, Novartis, and Tanabe-Mitsubishi. TY received research funds from AC MEDICAL INC., A2 Healthcare Corporation, CAC Croit Corporation, FMD K&L Japan K.K., Japan Tobacco Inc., Japan Media Corporation, Luminary Medical K.K., Medidata Solutions, Inc., ONO PHARMACEUTICAL CO., LTD., Kyowa Hakko Kirin Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED. Also TY received consulting fee from ONO PHARMACEUTICAL CO., LTD., Kowa Company, Ltd., Japan Tobacco Inc., CHUGAI PHARMACEUTICAL CO.,LTD.,

1
2 TSUMURA & CO., CAC Croit Corporation, TSUMURA & CO., ASAHI INTECC CO., LTD.,
3
4
5 Asahi Kasei Pharma Corporation, Clinical Trial Co.,Ltd. FK has received lecture fees from MSD.
6
7
8 TAF has received lecture fees from Janssen, Meiji, Mitsubishi-Tanabe, MSD and Pfizer. He has
9
10
11 received research support from Mitsubishi-Tanabe. HI has received lecture fees from Daiichi
12
13
14 Sankyo, Chugai, AstraZeneca, Pfizer, and Eisai. He has received research support from Daiichi
15
16
17 Sankyo, Chugai, AstraZeneca, Pfizer, MSD, Kyowahakou Kirin, GSK, Lilly, Novartis, and a Bayer.
18
19
20 YU has received lectures fees from Asters, Daiichi-Sankyo, Dainippon-Sumitomo, Eisai, Janssen,
21
22
23 Kyowahakko-Kirin, Ono, Meiji-seika Pharma, Mochida, Pfizer, Novartis, Otsuka, Sawai, Shionogi,
24
25
26 Taiho, Tanabe-Mitsubishi, Tsumura Pharma.
27
28
29
30

31 Trial status

32
33 The randomized trial, which commenced on 2th, April, 2018, currently enrolls participants. The
34
35
36 estimated end date for this study is in March 2020.
37
38
39
40
41

42 Acknowledgments

43
44
45 We thank to Ms. T Mashiko for her data management support. We also thank to Ms. Y Yanase, Ms.
46
47
48 A Nomura , Ms. K Tojima, Ms. I. Sakakima, and Ms. K Kobori for their support for the study. We
49
50
51 thank Edanz Group (www.edanzediting.com) for editing a draft of this manuscript.
52
53
54
55
56
57
58
59
60

1
2 Figure legend
3

4
5 Fig. 1 Participant flow diagram
6
7

8
9
10 Fig. 2 Kaiketsu App
11

12
13 Application for smartphone based problem-solving treatment
14
15

16
17
18 Fig. 3 Genki App
19

20
21 Application for smartphone based behavioral activation
22
23

24
25
26 Fig. 4 Study management system
27

28
29 e-Consent: electric informed consent; e-PRO: electric patient reported outcome
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

1. Ito Y, Miyashiro I, Ito H, et al. Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. *Cancer Sci*. 2014;105: 1480-1486.
2. Hodgkinson K, Butow P, Hunt GE, Pendlebury S, Hobbs KM, Wain G. Breast cancer survivors' supportive care needs 2-10 years after diagnosis. *Support Care Cancer*. 2007;15: 515-523.
3. Hartl K, Schennach R, Muller M, et al. Quality of life, anxiety, and oncological factors: a follow-up study of breast cancer patients. *Psychosomatics*. 2010;51: 112-123.
4. Gordon NH, Siminoff LA. Measuring quality of life of long-term breast cancer survivors: the Long Term Quality of Life-Breast Cancer (LTQOL-BC) Scale. *J Psychosoc Oncol*. 2010;28: 589-609.
5. Akechi T, Okuyama T, Endo C, et al. Patient's perceived need and psychological distress and/or quality of life in ambulatory breast cancer patients in Japan. *Psychooncology*. 2011;20: 497-505.
6. Harrison JD, Young JM, Price MA, Butow PN, Solomon MJ. What are the unmet supportive care needs of people with cancer? A systematic review. *Support Care Cancer*. 2009;17: 1117-1128.
7. Koch L, Jansen L, Brenner H, Arndt V. Fear of recurrence and disease progression in long-term (≥ 5 years) cancer survivors--a systematic review of quantitative studies. *Psychooncology*. 2013;22: 1-11.
8. Simard S, Thewes B, Humphris G, et al. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. *J Cancer Surviv*. 2013;7: 300-322.
9. Lengacher CA, Reich RR, Paterson CL, et al. Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial. *J Clin Oncol*. 2016.
10. Lengacher CA, Johnson-Mallard V, Post-White J, et al. Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. *Psychooncology*. 2009;18: 1261-1272.
11. Butow PN, Turner J, Gilchrist J, et al. Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence. *J Clin Oncol*. 2017;35: 4066-4077.
12. van de Wal M, Thewes B, Gielissen M, Speckens A, Prins J. Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial. *J Clin Oncol*. 2017;35: 2173-2183.
13. Fukui S, Kugaya A, Okamura H, et al. A psychosocial group intervention for Japanese women with primary breast carcinoma. *Cancer*. 2000;89: 1026-1036.
14. Fukui S, Kugaya A, Kamiya M, et al. Participation in psychosocial group intervention among Japanese women with primary breast cancer and its associated factors. *Psychooncology*. 2001;10: 419-427.
15. Akechi T, Momino K, Yamashita T, et al. Contribution of problem-solving skills to fear of recurrence in breast cancer survivors. *Breast Cancer Res Treat*. 2014;145: 205-210.
16. Akechi T, Hirai K, Motooka H, et al. Problem-solving therapy for psychological distress in Japanese cancer patients: preliminary clinical experience from psychiatric consultations. *Jpn J Clin Oncol*. 2008;38: 867-870.
17. Momino K, Miyashita M, Yamashita H, et al. Feasibility study of collaborative care intervention for the perceived care needs among breast cancer women undergoing adjuvant therapy after surgery. *Jpn J*

1 Clin Oncol. in submission.

2
3 18. Hirai K, Motooka H, Ito N, et al. Problem-solving therapy for psychological distress in Japanese
4 early-stage breast cancer patients. *Jpn J Clin Oncol.* 2012;42: 1168-1174.

5
6 19. Patel V, Weobong B, Weiss HA, et al. The Healthy Activity Program (HAP), a lay counsellor-
7 delivered brief psychological treatment for severe depression, in primary care in India: a randomised
8 controlled trial. *Lancet.* 2017;389: 176-185.

9
10 20. Nezu AM, Nezu CM, Felgoise SH, McClure KS, Houts PS. Project Genesis: assessing the efficacy of
11 problem-solving therapy for distressed adult cancer patients. *J Consult Clin Psychol.* 2003;71: 1036-
12 1048.

13
14 21. Dimidjian S, Goodman SH, Sherwood NE, et al. A pragmatic randomized clinical trial of behavioral
15 activation for depressed pregnant women. *J Consult Clin Psychol.* 2017;85: 26-36.

16
17 22. Hopko DR, Armento ME, Robertson SM, et al. Brief behavioral activation and problem-solving
18 therapy for depressed breast cancer patients: randomized trial. *J Consult Clin Psychol.* 2011;79: 834-
19 849.

20
21 23. Andrews G, Cuijpers P, Craske MG, McEvoy P, Titov N. Computer therapy for the anxiety and
22 depressive disorders is effective, acceptable and practical health care: a meta-analysis. *PLoS One.*
23 2010;5: e13196.

24
25 24. So M, Yamaguchi S, Hashimoto S, Sado M, Furukawa TA, McCrone P. Is computerised CBT really
26 helpful for adult depression?-A meta-analytic re-evaluation of CCBT for adult depression in terms of
27 clinical implementation and methodological validity. *BMC Psychiatry.* 2013;13: 113.

28
29 25. Watts S, Mackenzie A, Thomas C, et al. CBT for depression: a pilot RCT comparing mobile phone vs.
30 computer. *BMC Psychiatry.* 2013;13: 49.

31
32 26. Mantani A, Kato T, Furukawa TA, et al. Smartphone Cognitive Behavioral Therapy as an Adjunct to
33 Pharmacotherapy for Refractory Depression: Randomized Controlled Trial. *J Med Internet Res.*
34 2017;19: e373.

35
36 27. Imai F, Momino K, Katsuki F, et al. Smartphone problem-solving therapy to reduce fear of
37 recurrence among breast cancer survivors: A single-arm open pilot study in submission.

38
39 28. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for
40 protocols of clinical trials. *Bmj.* 2013;346: e7586.

41
42 29. Mynors-Wallis L. Problem-solving treatment for anxiety and depression: A practical guide. New
43 York: Oxford University Press, 2005.

44
45 30. Watanabe N, Horikoshi M, Yamada M, et al. Adding smartphone-based cognitive-behavior therapy
46 to pharmacotherapy for major depression (FLATT project): study protocol for a randomized controlled
47 trial. *Trials.* 2015;16: 293.

48
49 31. Momino K, Akechi T, Yamashita T, et al. Psychometric properties of the Japanese version of the
50 Concerns About Recurrence Scale (CARS-J). *Jpn J Clin Oncol.* 2014;44: 456-462.

51
52 32. Crist JV, Grunfeld EA. Factors reported to influence fear of recurrence in cancer patients: a
53 systematic review. *Psychooncology.* 2013;22: 978-986.

54
55 33. Services USDoHaH, (OHRP) OfHRP, Administration FaD, et al. Use of Electronic Informed Consent
56 Questions and Answers <https://www.fda.gov/downloads/drugs/guidances/ucm436811.pdf>. 2016.

- 1
2 34. Vickberg SM. The Concerns About Recurrence Scale (CARS): a systematic measure of women's fears
3 about the possibility of breast cancer recurrence. *Ann Behav Med.* 2003;25: 16-24.
4
5 35. Momino K, Akechi T, Yamashita T, et al. Psychometric properties of the Japanese version of the
6 Concerns about Recurrence Scale (CARS-J). *Jpn J Clin Oncol.* in press.
7
8 36. Simard S, Savard J. Fear of Cancer Recurrence Inventory: development and initial validation of a
9 multidimensional measure of fear of cancer recurrence. *Support Care Cancer.* 2009;17: 241-251.
10
11 37. Simard S, Savard J. Screening and comorbidity of clinical levels of fear of cancer recurrence. *J*
12 *Cancer Surviv.* 2015;9: 481-491.
13
14 38. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand.* 1983;67:
15 361-370.
16
17 39. Kugaya A, Akechi T, Okuyama T, Okamura H, Uchitomi Y. Screening for psychological distress in
18 Japanese cancer patients. *Jpn J Clin Oncol.* 1998;28: 333-338.
19
20 40. Boyes A, Girgis A, Lecathelinais C. Brief assessment of adult cancer patients' perceived needs:
21 development and validation of the 34-item Supportive Care Needs Survey (SCNS-SF34). *J Eval Clin*
22 *Pract.* 2009;15: 602-606.
23
24 41. Okuyama T, Akechi T, Yamashita H, et al. Reliability and validity of the Japanese version of the
25 Short-form Supportive Care Needs Survey questionnaire (SCNS-SF34-J). *Psychooncology.* 2009;18:
26 1003-1010.
27
28 42. Tedeschi RG, Calhoun LG. The Posttraumatic Growth Inventory: measuring the positive legacy of
29 trauma. *J Trauma Stress.* 1996;9: 455-471.
30
31 43. Taku K, Calhoun LG, Tedeschi RG, Gil-Rivas V, Kilmer RP, Cann A. Examining posttraumatic
32 growth among Japanese university students. *Anxiety Stress Coping.* 2007;20: 353-367.
33
34 44. Akizuki N, Akechi T, Nakanishi T, et al. Development of a brief screening interview for adjustment
35 disorders and major depression in patients with cancer. *Cancer.* 2003;97: 2605-2613.
36
37 45. Furukawa TA, Noma H, Caldwell DM, et al. Waiting list may be a placebo condition in
38 psychotherapy trials: a contribution from network meta-analysis. *Acta Psychiatr Scand.* 2014;130: 181-
39 192.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Fig. 1 Participant flow diagram

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Fig. 2 Kaiketsu App
Application for smartphone based problem-solving treatment

130x234mm (72 x 72 DPI)




Fig. 3 Genki App
Application for smartphone based behavioral activation

131x234mm (72 x 72 DPI)




Fig. 4 Study management system
e-Consent: electric informed consent; e-PRO: electric patient reported outcome

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

| | | Reporting Item | Page Number |
|---|---------------------|--|-------------|
| Title | #1 | Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym | 1 |
| Trial registration | #2a | Trial identifier and registry name. If not yet registered, name of intended registry | 5 |
| Trial registration: data set | #2b | All items from the World Health Organization Trial Registration Data Set | 5 |
| Protocol version | #3 | Date and version identifier | 3 |
| Funding | #4 | Sources and types of financial, material, and other support | 22-23 |
| Roles and responsibilities: contributorship | #5a | Names, affiliations, and roles of protocol contributors | 22 |
| Roles and responsibilities: | #5b | Name and contact information for the trial sponsor | 22 |

| | | | | |
|----|----------------------|----------------------|---|-------|
| 1 | sponsor contact | | | |
| 2 | information | | | |
| 3 | | | | |
| 4 | Roles and | #5c | Role of study sponsor and funders, if any, in study design; | 23 |
| 5 | responsibilities: | | collection, management, analysis, and interpretation of | |
| 6 | sponsor and funder | | data; writing of the report; and the decision to submit the | |
| 7 | | | report for publication, including whether they will have | |
| 8 | | | ultimate authority over any of these activities | |
| 9 | | | | |
| 10 | | | | |
| 11 | | | | |
| 12 | Roles and | #5d | Composition, roles, and responsibilities of the coordinating | 12 |
| 13 | responsibilities: | | centre, steering committee, endpoint adjudication | |
| 14 | committees | | committee, data management team, and other individuals or | |
| 15 | | | groups overseeing the trial, if applicable (see Item 21a for | |
| 16 | | | data monitoring committee) | |
| 17 | | | | |
| 18 | | | | |
| 19 | | | | |
| 20 | Background and | #6a | Description of research question and justification for | 6-8 |
| 21 | rationale | | undertaking the trial, including summary of relevant studies | |
| 22 | | | (published and unpublished) examining benefits and harms | |
| 23 | | | for each intervention | |
| 24 | | | | |
| 25 | | | | |
| 26 | | | | |
| 27 | Background and | #6b | Explanation for choice of comparators | 8 |
| 28 | rationale: choice of | | | |
| 29 | comparators | | | |
| 30 | | | | |
| 31 | | | | |
| 32 | Objectives | #7 | Specific objectives or hypotheses | 8 |
| 33 | | | | |
| 34 | | | | |
| 35 | Trial design | #8 | Description of trial design including type of trial (eg, parallel | 8 |
| 36 | | | group, crossover, factorial, single group), allocation ratio, | |
| 37 | | | and framework (eg, superiority, equivalence, non-inferiority, | |
| 38 | | | exploratory) | |
| 39 | | | | |
| 40 | | | | |
| 41 | | | | |
| 42 | Study setting | #9 | Description of study settings (eg, community clinic, | 10-11 |
| 43 | | | academic hospital) and list of countries where data will be | |
| 44 | | | collected. Reference to where list of study sites can be | |
| 45 | | | obtained | |
| 46 | | | | |
| 47 | | | | |
| 48 | Eligibility criteria | #10 | Inclusion and exclusion criteria for participants. If applicable, | 9-10 |
| 49 | | | eligibility criteria for study centres and individuals who will | |
| 50 | | | perform the interventions (eg, surgeons, psychotherapists) | |
| 51 | | | | |
| 52 | | | | |
| 53 | | | | |
| 54 | Interventions: | #11a | Interventions for each group with sufficient detail to allow | 8-9 |
| 55 | description | | replication, including how and when they will be | |
| 56 | | | administered | |
| 57 | | | | |
| 58 | | | | |
| 59 | | | | |
| 60 | | | | |

| | | | | |
|----|----------------------|----------------------|--|-------|
| 1 | Interventions: | #11b | Criteria for discontinuing or modifying allocated | 13 |
| 2 | modifications | | interventions for a given trial participant (eg, drug dose | |
| 3 | | | change in response to harms, participant request, or | |
| 4 | | | improving / worsening disease) | |
| 5 | | | | |
| 6 | | | | |
| 7 | Interventions: | #11c | Strategies to improve adherence to intervention protocols, | 12-13 |
| 8 | adherence | | and any procedures for monitoring adherence (eg, drug | |
| 9 | | | tablet return; laboratory tests) | |
| 10 | | | | |
| 11 | | | | |
| 12 | | | | |
| 13 | Interventions: | #11d | Relevant concomitant care and interventions that are | 13 |
| 14 | concomitant care | | permitted or prohibited during the trial | |
| 15 | | | | |
| 16 | | | | |
| 17 | Outcomes | #12 | Primary, secondary, and other outcomes, including the | 14-17 |
| 18 | | | specific measurement variable (eg, systolic blood pressure), | |
| 19 | | | analysis metric (eg, change from baseline, final value, time | |
| 20 | | | to event), method of aggregation (eg, median, proportion), | |
| 21 | | | and time point for each outcome. Explanation of the clinical | |
| 22 | | | relevance of chosen efficacy and harm outcomes is strongly | |
| 23 | | | recommended | |
| 24 | | | | |
| 25 | | | | |
| 26 | | | | |
| 27 | | | | |
| 28 | Participant timeline | #13 | Time schedule of enrolment, interventions (including any | Fig 1 |
| 29 | | | run-ins and washouts), assessments, and visits for | |
| 30 | | | participants. A schematic diagram is highly recommended | |
| 31 | | | (see Figure) | |
| 32 | | | | |
| 33 | | | | |
| 34 | | | | |
| 35 | Sample size | #14 | Estimated number of participants needed to achieve study | 19 |
| 36 | | | objectives and how it was determined, including clinical and | |
| 37 | | | statistical assumptions supporting any sample size | |
| 38 | | | calculations | |
| 39 | | | | |
| 40 | | | | |
| 41 | | | | |
| 42 | Recruitment | #15 | Strategies for achieving adequate participant enrolment to | 10-11 |
| 43 | | | reach target sample size | |
| 44 | | | | |
| 45 | | | | |
| 46 | Allocation: sequence | #16a | Method of generating the allocation sequence (eg, | 11 |
| 47 | generation | | computer-generated random numbers), and list of any | |
| 48 | | | factors for stratification. To reduce predictability of a random | |
| 49 | | | sequence, details of any planned restriction (eg, blocking) | |
| 50 | | | should be provided in a separate document that is | |
| 51 | | | unavailable to those who enrol participants or assign | |
| 52 | | | interventions | |
| 53 | | | | |
| 54 | | | | |
| 55 | | | | |
| 56 | | | | |
| 57 | Allocation | #16b | Mechanism of implementing the allocation sequence (eg, | 11 |
| 58 | concealment | | central telephone; sequentially numbered, opaque, sealed | |
| 59 | | | | |
| 60 | | | | |

| | | | | |
|----|------------------------|----------------------|--|------------------|
| 1 | mechanism | | envelopes), describing any steps to conceal the sequence until interventions are assigned | |
| 2 | | | | |
| 3 | | | | |
| 4 | Allocation: | #16c | Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions | 11 |
| 5 | implementation | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | Blinding (masking) | #17a | Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how | 12 |
| 10 | | | | |
| 11 | | | | |
| 12 | | | | |
| 13 | | | | |
| 14 | Blinding (masking): | #17b | If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial | 8, 12 |
| 15 | emergency | | | |
| 16 | unblinding | | | |
| 17 | | | | |
| 18 | | | | |
| 19 | | | | |
| 20 | Data collection plan | #18a | Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol | Table 1 14-18 |
| 21 | | | | |
| 22 | | | | |
| 23 | | | | |
| 24 | | | | |
| 25 | | | | |
| 26 | | | | |
| 27 | | | | |
| 28 | | | | |
| 29 | | | | |
| 30 | | | | |
| 31 | Data collection plan: | #18b | Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols | 12 |
| 32 | retention | | | |
| 33 | | | | |
| 34 | | | | |
| 35 | | | | |
| 36 | | | | |
| 37 | | | | |
| 38 | Data management | #19 | Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol | Table 1 12 |
| 39 | | | | |
| 40 | | | | |
| 41 | | | | |
| 42 | | | | |
| 43 | | | | |
| 44 | | | | |
| 45 | | | | |
| 46 | Statistics: outcomes | #20a | Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol | 18 |
| 47 | | | | |
| 48 | | | | |
| 49 | | | | |
| 50 | | | | |
| 51 | Statistics: additional | #20b | Methods for any additional analyses (eg, subgroup and adjusted analyses) | 18 |
| 52 | analyses | | | |
| 53 | | | | |
| 54 | | | | |
| 55 | Statistics: analysis | #20c | Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation) | 13-14 18 |
| 56 | population and | | | |
| 57 | missing data | | | |
| 58 | | | | |
| 59 | | | | |

| | | | | |
|----|--------------------|----------------------|--|-------|
| 1 | Data monitoring: | #21a | Composition of data monitoring committee (DMC); summary | 12 |
| 2 | formal committee | | of its role and reporting structure; statement of whether it is | |
| 3 | | | independent from the sponsor and competing interests; and | |
| 4 | | | reference to where further details about its charter can be | |
| 5 | | | found, if not in the protocol. Alternatively, an explanation of | |
| 6 | | | why a DMC is not needed | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |
| 11 | Data monitoring: | #21b | Description of any interim analyses and stopping guidelines, | 19 |
| 12 | interim analysis | | including who will have access to these interim results and | |
| 13 | | | make the final decision to terminate the trial | |
| 14 | | | | |
| 15 | | | | |
| 16 | Harms | #22 | Plans for collecting, assessing, reporting, and managing | 12 |
| 17 | | | solicited and spontaneously reported adverse events and | |
| 18 | | | other unintended effects of trial interventions or trial conduct | 17 |
| 19 | | | | |
| 20 | | | | |
| 21 | Auditing | #23 | Frequency and procedures for auditing trial conduct, if any, | 12 |
| 22 | | | and whether the process will be independent from | |
| 23 | | | investigators and the sponsor | |
| 24 | | | | |
| 25 | | | | |
| 26 | | | | |
| 27 | Research ethics | #24 | Plans for seeking research ethics committee / institutional | 20 |
| 28 | approval | | review board (REC / IRB) approval | |
| 29 | | | | |
| 30 | | | | |
| 31 | Protocol | #25 | Plans for communicating important protocol modifications | 20 |
| 32 | amendments | | (eg, changes to eligibility criteria, outcomes, analyses) to | |
| 33 | | | relevant parties (eg, investigators, REC / IRBs, trial | |
| 34 | | | participants, trial registries, journals, regulators) | |
| 35 | | | | |
| 36 | | | | |
| 37 | Consent or assent | #26a | Who will obtain informed consent or assent from potential | 11 |
| 38 | | | trial participants or authorised surrogates, and how (see | |
| 39 | | | Item 32) | |
| 40 | | | | |
| 41 | | | | |
| 42 | | | | |
| 43 | Consent or assent: | #26b | Additional consent provisions for collection and use of | 20 |
| 44 | ancillary studies | | participant data and biological specimens in ancillary | |
| 45 | | | studies, if applicable | |
| 46 | | | | |
| 47 | | | | |
| 48 | Confidentiality | #27 | How personal information about potential and enrolled | 12 |
| 49 | | | participants will be collected, shared, and maintained in | |
| 50 | | | order to protect confidentiality before, during, and after the | |
| 51 | | | trial | |
| 52 | | | | |
| 53 | | | | |
| 54 | | | | |
| 55 | Declaration of | #28 | Financial and other competing interests for principal | 23-24 |
| 56 | interests | | investigators for the overall trial and each study site | |
| 57 | | | | |
| 58 | | | | |
| 59 | Data access | #29 | Statement of who will have access to the final trial dataset, | 12 |
| 60 | | | | |

and disclosure of contractual agreements that limit such access for investigators

| | | | |
|----|-----------------------|----------------------|---|
| 1 | | | |
| 2 | | | |
| 3 | | | |
| 4 | Ancillary and post | #30 | Provisions, if any, for ancillary and post-trial care, and for |
| 5 | trial care | | compensation to those who suffer harm from trial |
| 6 | | | participation |
| 7 | | | |
| 8 | | | |
| 9 | Dissemination policy: | #31a | Plans for investigators and sponsor to communicate trial |
| 10 | trial results | | results to participants, healthcare professionals, the public, |
| 11 | | | and other relevant groups (eg, via publication, reporting in |
| 12 | | | results databases, or other data sharing arrangements), |
| 13 | | | including any publication restrictions |
| 14 | | | |
| 15 | | | |
| 16 | | | |
| 17 | Dissemination policy: | #31b | Authorship eligibility guidelines and any intended use of |
| 18 | authorship | | professional writers |
| 19 | | | |
| 20 | | | 24 |
| 21 | | | |
| 22 | Dissemination policy: | #31c | Plans, if any, for granting public access to the full protocol, |
| 23 | reproducible | | participant-level dataset, and statistical code |
| 24 | research | | |
| 25 | | | |
| 26 | | | |
| 27 | Informed consent | #32 | Model consent form and other related documentation given |
| 28 | materials | | to participants and authorised surrogates |
| 29 | | | |
| 30 | | | |
| 31 | Biological specimens | #33 | Plans for collection, laboratory evaluation, and storage of |
| 32 | | | biological specimens for genetic or molecular analysis in the |
| 33 | | | current trial and for future use in ancillary studies, if |
| 34 | | | applicable |
| 35 | | | |
| 36 | | | |
| 37 | | | |

38 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 39 BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made
 40 by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Smartphone problem-solving and behavioral activation therapy to reduce fear of recurrence among breast cancer patients (SMartphone Intervention to LEssen fear of cancer recurrence: SMILE project): protocol for a randomized controlled trial

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2018-024794.R1 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 29-Aug-2018 |
| Complete List of Authors: | Akechi, Tatsuo; Nagoya City University Graduate School of Medical Sciences and Medical School Yamaguchi, Takuhiro; Division of Biostatistics, Uchida, Megumi; Nagoya City University Graduate School of Medical Sciences and Medical School Imai, Fuminobu; Nagoya City University Graduate School of Medical Sciences and Medical School Momino, Kanae; Nagoya City University School of Nursing Katsuki, Fujika; Nagoya City University School of Nursing, Nagoya, Department of Psychiatric and Mental Health Nursing Sakurai, Naomi; Cancer Solutions, Co., Ltd. Miyaji, Tempei; Univ Tokyo Horikoshi, Masaru; National Center of Neurology and Psychiatry Furukawa, Toshi; Kyoto University, Graduate School of Medicine and School of Public Health Iwata, Hiroji; Aichi Cancer Center, Nagoya, Breast Oncology Uchitomi, Yosuke; Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, & Behavioral and Survivorship Research Group, Center for Public Health Sciences |
| Primary Subject Heading: | Mental health |
| Secondary Subject Heading: | Mental health |
| Keywords: | neoplasma, fear of recurrence, cancer survivorship, psychosocial intervention, information and communication technology, quality of life |
| | |

SCHOLARONE™
Manuscripts

1
2
3 Study protocol
4

5 Title: Smartphone problem-solving and behavioral activation therapy to reduce fear of recurrence
6
7
8 among breast cancer patients (SMartphone Intervention to LEssen fear of cancer recurrence:
9
10
11 SMILE project): protocol for a randomized **controlled** trial
12
13
14
15

16 Tatsuo Akechi, MD, PhD^{1,2}
17

18
19 Takuhiro Yamaguchi, PhD³
20

21
22 Megumi Uchida, MD, PhD^{1,2}
23

24
25 Fuminobu Imai, MD^{1,2}
26

27
28 Kanae Momino, RN, MHIthSci⁴
29

30
31 Fujika Katsuki, RN, PhD⁵
32

33
34 Naomi Sakurai,⁶
35

36
37 Tempei Miyaji,⁷
38

39
40 Masaru Horikoshi, PhD⁸
41

42
43 Toshi A Furukawa, MD, PhD⁹
44

45
46 Hiroji Iwata, MD, PhD¹⁰
47

48
49 Yosuke Uchitomi MD, PhD¹¹
50
51
52

53 1. Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate
54
55
56 School of Medical Sciences, Nagoya, Japan
57

- 1
2
3 2. Division of Palliative Care and Psycho-oncology, Nagoya City University Hospital, Nagoya,
4
5 Japan
6
7
- 8 3. Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan
9
- 10 4. Department of Nursing Administration and Management, Nagoya City University School of
11
12 Nursing. Nagoya, Japan
13
14
- 15 5. Department of Psychiatric and Mental Health Nursing, Nagoya City University School of
16
17 Nursing, Nagoya, Japan
18
19
- 20 6. Cancer Solutions, Co., Ltd., Tokyo, Japan
21
- 22 7. Department of Clinical Trial Data Management, Graduate School of Medicine, The
23
24 University of Tokyo, Tokyo, Japan
25
26
27
- 28 8. National Center for Cognitive Behavior Therapy and Research, National Center of Neurology
29
30 and Psychiatry, Tokyo, Japan
31
32
33
- 34 9. Kyoto University Graduate School of Medicine / School of Public Health Department of Health
35
36 Promotion of Human Behavior, Kyoto, Japan
37
38
- 39 10. Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
40
41
- 42 11. Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center
43
44 Hospital, & Behavioral and Survivorship Research Group, Center for Public Health Sciences,
45
46 National Cancer Center, Tokyo, Japan
47
48
49
50
51

52
53
54
55
56 Corresponding Author: Tatsuo Akechi, MD, PhD
57

1
2 Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate
3

4
5 School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601 Japan
6

7
8 Tel: +81-52-853-8271, Fax: +81-52-852-0837, Email: takechi@med.nagoya-cu.ac.jp
9

10
11
12
13
14 Key words: neoplasma; fear of recurrence; cancer survivorship; psychosocial intervention;
15
16
17 information and communication technology; quality of life
18
19
20
21

22
23 **Protocol version 4.3 (August 24, 2018)**
24

25
26
27
28 **Word count: 4577**
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: One of the most common distressing conditions experienced by breast cancer survivors is fear of cancer recurrence (FCR). There is, however, no standard intervention for ameliorating FCR. Our clinical experience and previous studies have suggested the potential benefits of problem-solving therapy (PST) and behavioral activation (BA). Given the huge number of cancer survivors and limited number of therapists to competently conduct PST and BA, we have developed PST and BA smartphone applications. This study aimed to evaluate the efficacy of the smartphone-based PST (Kaiketsu-App) and BA (Genki-App) apps in reducing FCR in breast cancer patients.

Methods and analysis: The SMartphone Intervention to LEssen fear of cancer recurrence (SMILE) project is an open-label, individually randomized, parallel-group trial. Allocation will be managed by a central server, using a computer-generated random allocation sequence provided by an independent data center. Participants will be randomized to smartphone-based intervention plus treatment as usual (TAU) or wait-list control with TAU alone. The primary end point of the study is the Japanese version of the Concerns About Recurrence Scale, which will be administered as an electronic patient-reported outcome on the patients' smartphone after 8 weeks.

Ethics and dissemination: The present study is subject to the ethical guidelines for clinical studies published by Japan's Ministry of Education, Science and Technology and Ministry of Health, Labour and Welfare and the modified Act on the Protection of Personal Information as well as the ethical principles established for research on humans stipulated in the Declaration of Helsinki and

1
2 further amendments thereto. The protocol was approved by the institutional review board of Nagoya
3
4
5 City University on January 15, 2018 (ID: 60-00-1171).
6
7

8 Trial registration: UMIN-CTR: UMIN000031140
9
10
11
12
13
14
15

16 Article Summary

17 Strengths and limitations of this study

18
19
20 -This study is the first trial investigating the efficacy of smartphone-based psychological therapy for
21
22 fear of cancer recurrence (FCR) among breast cancer survivors.
23
24
25

26
27
28 -Because many breast cancer survivors return to their households and work, easily accessible
29
30 therapeutic interventions without hospital visits may offer benefits.
31
32

33
34 -This study focuses on younger breast cancer survivors who are iPhone users; this focus could
35
36 reduce the external validity of the findings obtained.
37
38

39
40 -The use of the wait-list control conditions may overestimate the efficacy of the smartphone-based
41
42 psychotherapy.
43
44

45
46 -We will apply two types of psychotherapy and both interventions consist of complex, multifactorial
47
48 components; thus, we cannot be certain which intervention and components are most beneficial in
49
50 managing FCR; however, we will adopt a mixed-method design to overcome those issues.
51
52
53
54
55
56
57
58
59
60

Introduction

Worldwide, breast cancer is one of the most common cancers among women. In Japan, it is also the most common cancer among women, and the incidence is increasing. At present, approximately 90,000 women in Japan are annually diagnosed with breast cancer. Advances in early detection and individualized medical treatment have improved the survival rate of breast cancer patients. The current 10-year survival rate for breast cancer patients is over 90%, which contributes to the increasing number of breast cancer survivors.¹

Thus patients with breast cancer have on average a better prognosis than those with many other types of cancer; however, it has been suggested that many breast cancer survivors suffer from uncertainty anxiety and fear over recurrence.²⁻⁴ Our previous study found that the most common unmet needs experienced by ambulatory breast cancer patients are psychological—especially fear of cancer recurrence (FCR); over half of patients complained of such needs.⁵ Among breast cancer patients, FCR is, not only highly prevalent, but also associated with poor quality of life.^{2, 5-8}

Accordingly, there is an urgent need for an appropriate intervention for FCR. However, there is no standard intervention for ameliorating FCR.⁸ Recent studies have demonstrated that the following can improve FCR among breast cancer survivors: mindfulness stress reduction (six weekly group sessions); cognitive behavioral therapy (CBT; five individual face-to-face sessions and three e-consultations over a period of 3 months); and the novel theoretically based intervention of ConquerFear, which includes attention training, metacognition, and acceptance and mindfulness (five individual face-to-face sessions over 10 weeks).⁹⁻¹² These interventions may be promising;

1
2 however, one problem with this kind of intervention is the low participation rate owing to time and
3
4 distance issues (e.g., over 60% of potentially eligible subjects have been found to decline
5
6 participation).^{9, 11-14} In addition, the number of therapists who can provide such specialized care
7
8
9
10
11 may be severely limited, which is a serious problem in many countries.
12

13
14 Our past experience and some studies indicate the effectiveness of CBT, including problem-
15
16 solving therapy (PST) and behavioral activation (BA), for FCR among breast cancer survivors.¹⁵⁻¹⁸
17
18 We have demonstrated that patients' problem-solving skills were significantly associated with
19
20 FCR.¹⁵ **Our hypotheses of their underlying mechanisms are that PST contributes to patients'**
21
22 **better coping with situations commonly triggering FOR (e.g., pain, exposure to news about**
23
24 **cancer, regular visit to cancer hospital, etc.) and other stressful situations that increase FOR**
25
26 **and that BA also improves FOR through distraction and through increased sense of mastery**
27
28 **and pleasure.** PST and BA are straightforward interventions that can be administered by less
29
30 experienced therapists, including nurses.¹⁹ However, patients willing to undergo PST or BA are
31
32 rarely able to do so even in well-resourced countries because a typical course of PST or BA consists
33
34 of eight to 12 face-to-face sessions lasting 1 or 1.5 hours led by a trained therapist.²⁰⁻²²
35
36
37
38
39
40
41
42
43
44

45
46 Though such programs seem promising, they appear to suffer similar limitations to those of the
47
48 above-mentioned therapeutic interventions.⁹⁻¹² Given the growing number of women annually
49
50 diagnosed with breast cancer and the high prevalence among them of unmet needs of FCR, a
51
52 completely novel approach to therapy provision is required. Recent studies have demonstrated the
53
54 effectiveness of computerized CBT.^{23, 24} In light of recent developments in information and
55
56
57
58
59
60

1
2 communication technology (ICT), CBT delivered via smartphones may be a better treatment option
3
4
5 for FCR—in terms of accessibility and portability—than a computer-based one.²⁵ We have recently
6
7
8 developed a smartphone CBT app, which teaches skills in BA and cognitive restructuring; we
9
10
11 demonstrated its efficacy for antidepressant-resistant major depression in a randomized controlled
12
13
14 trial.²⁶ We have also developed PST programs as a smartphone app and demonstrated the
15
16
17 acceptability and efficacy of the smartphone-based PST in a single-arm pilot study with breast
18
19
20 cancer survivors.²⁷ The purpose of the present randomized study is to examine the efficacy of
21
22
23 smartphone-based PST and BA interventions to reduce FCR in breast cancer patients in a
24
25
26 randomized controlled trial. **Since there is no specific standard intervention for ameliorating**
27
28 **FCR as mentioned above and our research team's discussion suggests that setting wait-list**
29
30 **control will be more feasible than no intervention, wait-list control is used as a comparator.**
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods and analysis

This protocol has been written in accordance with the SPIRIT guideline.²⁸

Trial design

The present study is an individually randomized, parallel-group trial (Figure 1). An independent data center will provide computer-generated random allocation sequences. The allocation sequences are maintained centrally, and the results of the assignment will be sent automatically to the study participants by e-mail. The participants are randomized to smartphone-based intervention plus

1
2
3 treatment as usual (TAU) or wait-list control with TAU alone. **TAU means general treatment**
4
5 **and/or care commonly provided by each patient's hospital (e.g., nurse's support etc.).**
6
7

8
9
10 Interventions: Smartphone-based PST (Kaiketsu-App) and BA (Genki-App)

11
12
13 PST provides patients with a structured strategy for solving their problems. PST includes the
14 following five steps²⁹: (1) identification, definition, and breakdown of the problem; (2) establishing
15 achievable goals; (3) generating solutions; (4) evaluating and choosing the solution; and (5)
16 implementing the chosen solution and evaluating the outcome after implementation.
17
18
19
20
21
22
23
24

25 The smartphone-based PST program, called Kaiketsu-App ("Kaiketsu" means "Solution"
26 in Japanese), for iPhones and iPads (Apple Inc., Cupertino, CA, USA) was developed for this study
27 (Figure 2). The development was based on our empirically supported PST manual.¹⁸ Kaiketsu-App
28 comprises nine sessions (**An appendix table**): three introductory session; four sessions about learning
29 the PST in five steps; one session of actual training; and one concluding session. The shortest time
30 necessary to complete Kaiketsu-App is 2 weeks. The main program consists of dialogues between
31 characters, who explain the principles and skills of PST. After the first session, participants have to
32 do homework. The time necessary to complete one session is approximately 30 minutes.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

An appendix table

Details of sessions in smartphone problem-solving and behavioral activation therapies

| Smartphone app | Details of each session |
|---|---|
| Problem-solving therapy (9 sessions) | <ol style="list-style-type: none"> 1. Outline of problem-solving therapy 2. Introduction of 5 step of problem-solving 3. Example of problem-solving 4. First step (identification, definition, and breakdown of the problem) 5. Second step (establishing achievable goals) 6. Third step (generating solutions) 7. Fourth (evaluating and choosing the solution) and fifth step (implementing the chosen solution and evaluating the outcome after implementation) 8. Actual training 9. Concluding session |
| Behavioral activation therapy (2 sessions) | <ol style="list-style-type: none"> 1. Outline and introduction of behavioral activation therapy including two types of activation (e.g., do pleasurable activity again and challenge new activity) and their actual training 2. Review of the session, learning knack of behavioral activation and concluding session |

BA intervention was developed based on the hypothesis that anxiety can lead to less pleasurable behavior and more sedentary life, which then may lead to worsening anxiety.²⁹

The smartphone-based BA program Genki-App (“Genki” means “Energy or Vitality” in Japanese), for iPhones and iPads (Figure 3) was developed as part of the smartphone-based CBT program which was developed for our previous study.³⁰ Genki-App consists of two sessions (An appendix table), and approximately 30 minutes is needed to complete each session: **one is outline and introduction of behavioral activation therapy including two types of activation (e.g., do pleasurable activity again and challenge new activity) and their actual training; the other is review of the session, learning knack of behavioral activation and concluding session. The shortest time necessary to complete Genki-App is also 2 weeks. The Genki-App program also mainly consists of dialogues between characters and homework.**

1
2 Over the 8-week period of the programs, participants are encouraged to complete the
3 sessions and homework through automated e-mail reminders once a week. **Although we cannot**
4
5
6
7
8 **know the contents of homework for privacy security, treatment adherence (e.g., times and**
9
10 **length of using each App) can be checked by Google analytics.**

16 *Participants*

17
18
19 The inclusion criteria for participants are as follows: (1) diagnosis of breast cancer and awareness of
20 the cancer diagnosis; (2) age 20–49 years; (3) 1 year following breast surgery; (4) currently disease
21 free; (5) ability to complete an electronic patient reported outcome (ePRO) using an iPhone or iPad;
22
23
24
25
26
27
28 (6) being an iPhone or iPad user and having an apple ID to install applications using App Store. We
29
30 limit the patients' age to 20–49 years because one study and our previous investigation
31 demonstrated that individuals of that age are at high risk of FCR and that more than 50% of such
32
33
34
35
36 people have smartphones.^{8, 31, 32}

37
38
39 The exclusion criteria for participants are as follows: (1) having active, serious physical
40 disease that affects household and light work and a current or past history of cancer other than
41 breast cancer; (2) inability to understand Japanese; (3) currently undergoing follow-up and
42
43
44
45
46
47
48 treatment in a psychiatry department or by other mental health professionals; (4) patients who have
49
50
51 previously undergone structured PST, BA therapy, or CBT; (5) judged inappropriate for
52
53
54 participation by the researchers (**e.g., identity theft, duplicate entry, etc.**).

1
2 Procedures
3

4
5 Newly developed research management system
6

7
8 To lessen patient inconvenience in visiting hospital for this study and oncologists' workload in
9
10 enrolling study participants, we developed a research management system making full use of ICT
11
12 technology (Figure 4). The study's Web site (<https://smile-project.org/>) provides information about
13
14 this study. **A poster briefly introducing the study and including a QR code for the Web site has**
15
16 **been put up in 10 core cancer hospitals in Japan and study information will be disseminated**
17
18 **repeatedly by using several social networking systems (e.g., facebook, patient's mailing list**
19
20 **etc.).** The Web site explains the purpose of the study, eligibility criteria, and methods used; it also
21
22 features a video briefly introducing the study as well as providing full written information about it.
23
24 Potential participants who are interested in the study can e-mail the study's central office, and
25
26 clinical research coordinators (CRCs) at the central office ascertain their eligibility by telephone
27
28
29
30
31
32
33
34
35
36 (Table 1).
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Schedule for outcome measurement

| | | Time points | | | | |
|------------|---------------------------------|-------------|---------|--------|---------|----------|
| | | 0 week | 2 weeks | 4 wees | 8 weeks | 24 weeks |
| Assessment | Understanding of the e-Consent | ● | | | | |
| | Characteristic | ● | | | | |
| | CARS-J, HADS | ● | ● | ● | ● | ●* |
| | FCRI, SCNS-SF34, PTGI-J | ● | | | ● | ●* |
| | Satisfaction with interventions | | | | ●* | |
| | Qualitative assessment of apps | | | | ●* | |

CARS-J: Japanese version of the Concerns About Recurrence Scale

HADS: Hospital Anxiety and Depression Scale

Fear of Cancer Recurrence Inventory short form (FCRI-SF)

SCNS-SF34: Short-form Supportive Care Needs Survey questionnaire

PTGI-J: Posttraumatic Growth Inventory-Japanese

*These would be evaluated only for intervention group

1
2
3
4
5 Electronic informed consent and randomization at week 0
6
7

8 After screening, the CRCs will seek to obtain the subjects' electronic informed consent (e-consent)
9
10 via e-PRO system at week 0. Participants will be requested to upload a picture of identification
11
12 materials (patients will be especially encouraged to attach a photo of the ID card of the hospital
13
14 where they made regular follow-up visits for breast cancer). This e-consent procedure is in
15
16 accordance with the guidance of the US Food and Drug Administration (FDA).³³ **Informed consent**
17
18 **material-original is shown in an appendix.**
19
20
21
22
23
24

25 After providing e-consent and completing the baseline investigation by e-PRO, the
26
27 participants will be randomly allocated to either the smartphone-based PST and BA group or the
28
29 wait-list control group in a 1:1 ratio using the electronic data-capturing Web program (EDC) at the
30
31 data management center (Figure 1). The random allocation will therefore be concealed.
32
33
34
35

36 If a participant is allocated to the intervention group, they will receive a password unique to
37
38 them for using Kaiketsu-App and Genki-App. Upon entering the password, participants will be able
39
40 to proceed to the sections for Kaiketsu-App and Genki-App. If participants are allocated to the
41
42 control group, they will be informed that use of Kaiketsu-App and Genki-App can be resumed if
43
44 they wish after week 8.
45
46
47
48
49
50
51
52

53 Data management, central monitoring, **data monitoring**, and auditing
54
55

56 We will collect all data except qualitative interview data through e-PRO; we will obtain qualitative
57
58
59
60

1
2 interview data by telephone (See below for details). If participants fail to provide their responses
3
4
5 regarding FCR, a CRC blinded to the assignment will telephone the subjects to elicit their answers.
6
7
8 Data management and central monitoring will be performed using the EDC. The EDC consists of
9
10 two different and independent parts, one including personal information and the other including
11
12 trial-related data (e.g., assignment, outcomes, etc.) for security. **Since the psychological**
13
14 **intervention provided by apps will not be invasive and also not produce serious harms, data**
15
16 **monitoring committee will not be organized. Similarly auditing is not also planned for this**
17
18 **study.**
19
20
21
22
23
24
25
26
27

28 Dataset available

29
30 The de-identified anonymized dataset will be uploaded to UMIN-ICDR
31
32 (<http://www.umin.ac.jp/icdr/index-j.html>) and researchers approved by the Steering Committee will
33
34 be able to have access to the dataset.
35
36
37
38
39
40
41

42 Trial period: weeks 0–8

43
44 For participants allocated to the intervention group, an automated e-mail encouraging their
45
46 adherence to Kaiketsu-App and Genki-App will be sent every week for 8 weeks. The research team
47
48 can check the patient's progress (number of times and duration using each application) with
49
50 Kaiketsu-App and Genki-App using Google Analytics. At weeks 2, 4, and 8, participants will
51
52 receive an e-mail encouraging them to record their responses on e-PRO.
53
54
55
56
57

1
2
3
4
5 Follow-up period: weeks 8–24
6
7

8 Participants allocated to the control group can resume the Kaiketsu-App and Genki-App if they
9
10 wish. At week 24, participants allocated to the intervention group will receive an e-mail
11
12 encouraging them to provide their responses on e-PRO.
13
14

15
16
17
18
19 Concomitant treatments
20

21
22 There is no restriction on concomitant treatments.
23
24

25
26
27
28 Stopping rules for participants
29

30 Discontinuation of protocol treatment
31

32
33 If a participant meets any of the following conditions, the research team can discontinue the
34
35 Kaiketsu-App and Genki-App. However, the participant will not be considered to have dropped out
36
37 of the trial at that stage and will receive the protocol assessments: (1) the participant wishes to stop
38
39 the protocol treatment; (2) the research team judges that the risk of the protocol treatment is greater
40
41 than the benefit for any reason; **(3) the research team judges that it is difficult to continue the**
42
43 **protocol treatment because of clinical deterioration;** (4) the research team judges that it is
44
45 inappropriate to continue the protocol treatment for any reason (**e.g., when identity theft, duplicate**
46
47 **entry, etc. is detected**).
48
49
50
51
52
53
54
55
56
57
58
59
60

Stopping assessment

If a participant withdraws consent for assessment, she will not be followed up. Subjects will be excluded from the intention-to-treat (ITT) cohort of the trial only if their characteristics are found to meet any exclusion criteria at baseline (e.g., age over 50 years) after participation.

Assessment measures

Table 1 shows the schedule for outcome measurement.

Primary outcome measure

Fear of recurrence: CARS-J

Originally developed in the United States, CARS-J is a 26-item self-report scale to measure fear of recurrence of breast cancer.³⁴ The reliability and validity of CARS-J has been confirmed among Japanese breast cancer patients.³⁵ CARS-J assesses the overall fear of breast cancer recurrence and four domains of specific fear of recurrence. Overall fear comprises four items: questions on frequency; potential for upset; consistency; and intensity of fear. The overall fear score with CARS-J is our primary outcome. The range of possible scores for overall fear is 4–24; a higher score indicates greater fear of recurrence.

Secondary outcome measures

Fear of Cancer Recurrence Inventory–Short Form

The Fear of Cancer Recurrence Inventory–Short Form (FCRI-SF) is a nine-item self-report scale,

1
2 originally developed in Canada.^{36, 37} The FCRI evaluates the presence and severity of intrusive
3
4
5 thoughts associated with FCR: scores range from 0 to 36; a higher score indicates severe FCR.
6
7
8 Unlike with CARS-J, the FCRI-SF can measure fear of recurrence of any type of cancer. The
9
10
11 Japanese version of the FCRI-SF was developed after obtaining permission from the original author
12
13
14 and using a forward-backward translation process. In this study, the measure will be included as a
15
16
17 secondary outcome after its validity and reliability have been ascertained.
18
19
20
21

22 Psychological distress: Hospital Anxiety and Depression Scale

23
24
25 The Hospital Anxiety and Depression Scale (HADS), a self-report questionnaire comprising
26
27
28 14 items, was developed for use with medically ill patients. The HADS consists of an anxiety and a
29
30
31 depression subscale (0–21 points each). The total score ranges from 0 to 42; a higher score indicates
32
33
34 more severe depression and anxiety.³⁸ The Japanese version of the HADS has been validated for
35
36
37 cancer populations.³⁹
38
39
40
41

42 Patients perceived needs: Short-form Supportive Care Needs Survey questionnaire

43
44
45 The Short-form Supportive Care Needs Survey questionnaire (SCNS-SF34) is a self-
46
47
48 administered instrument for assessing the perceived needs of cancer patients.⁴⁰ The SCNS-SF34
49
50
51 comprises 34 items covering five domains of need: psychological; health system and information;
52
53
54 physical and daily living; patient care and support; and sexuality. The total score is obtained by
55
56
57 summing all the subscales (range, 34–170). A higher score indicates a higher perceived need. The
58
59
60

1
2 validity and reliability of the Japanese version of SCNS-SF34 have been established.⁴¹
3
4
5
6
7

8 Posttraumatic Growth Inventory-Japanese version 9

10 The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report scale, originally developed in
11 the United States.⁴² The PTGI includes items that measure positive psychological change
12 experienced as a result of struggle with major life crises or traumatic events. The PTGI-J consists of
13 four subscales: relating to others; new possibilities; personal strength; and spiritual change and
14 appreciation of life. The total score ranges from 0 to 90; a higher score indicates more positive
15 changes.⁴³
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 Satisfaction with intervention 32

33 To assess patients' perceived satisfaction with the intervention, we ask two additional items. The
34 items are as follows. (1) "Please rate your satisfaction with the treatment in meeting your needs
35 during the past 2 months by assigning it a score from 0 to 100; a score of 100 indicates complete
36 satisfaction. A score of 60 is considered the passing level." (2) "Please rate your overall satisfaction
37 with the treatment during the past 2 months by assigning it a score from 0 to 100; a score of 100
38 indicates complete satisfaction. A score of 60 is considered the passing level." A lower score
39 indicates lower satisfaction. We used this method in our previous study.⁴⁴
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 Understanding e-consent 57

1
2 We will ask ten questions will be asked at week 0 related to the participants' understanding of e-
3
4 consent: purpose of the study; randomization; voluntarily participation; duration of study; risks and
5
6 benefits of study participation; free withdrawal anytime from the study; contact method for
7
8 questions and more detailed information about the study; method of participant identification
9
10 (uploading a photo of the hospital registration card); which of the video or written documentation in
11
12 the Web site was the more helpful in understanding the study contents ; and free opinions regarding
13
14 e-consent.
15
16
17
18
19
20
21
22
23
24

25 Qualitative evaluation of intervention

26
27 The intervention will consist of multiple complex components; accordingly, simple structured
28
29 telephone interviews will be conducted at 8 weeks for approximately 30 subjects willing to
30
31 participate in this additional survey to evaluate the **perceived usability and/or merit** of the
32
33 complex intervention. The interview items will be as follows. (1) "Please talk freely about the
34
35 usefulness of the smartphone PST and smartphone behavioral intervention." (2) "Please talk freely
36
37 about the usefulness of each of the five steps of the smartphone PST and give your reasons for your
38
39 opinions." (3) "Please talk freely about the usefulness of the two parts of the smartphone behavioral
40
41 intervention and give your reasons for your opinions." (4) "Please talk freely about the effectiveness
42
43 and **harms** of the intervention, for example, the regular encouraging e-mail, and if any other
44
45 components contributed to improving **or deteriorating** your fear of recurrence." If the participants
46
47
48
49
50
51 permit, the answers will be recorded using a voice recorder.
52
53
54
55
56
57
58
59
60

1
2
3
4
5 Sociodemographic and biomedical factors
6
7

8 e-PRO will also be used to obtain information about the patients' sociodemographic and biomedical
9
10 status (marital status, level of education, and employment status) and biomedical information
11
12 (physical function, time since diagnosis, clinical stage, and anti-cancer treatment).
13
14
15

16 17 18 19 **Harms**

20
21
22 **No specific and serious adverse events are presumed in participants who use the Kaiketsu and**
23
24 **Genki-Apps. However, using these apps might lead to psychological distress in some**
25
26 **participants depending on their psychological state. We will evaluate these potential adverse**
27
28 **events by qualitative evaluation of intervention as mentioned before.**
29
30
31
32
33
34
35

36 37 **Compensation**

38
39 **Our previous and preliminary trials suggest that few harms occur in this trial. However, if any**
40
41 **health hazards occur, these will be covered by the National Health Insurance.**
42
43
44
45
46

47 Data analysis

48
49 Primary analyses

50
51
52
53 To examine the treatment effect parameters of all randomly assigned subjects in the primary
54
55 analysis set according to the ITT principle, we will analyze the primary outcome (CARS-J score at
56
57

1
2 weeks 2, 4, and 8) using a generalized linear model with unstructured covariance and robust
3
4
5 standard errors. The fixed effects are CARS-J score at baseline, treatment allocation (intervention
6
7 versus control), time (2, 4, and 8 weeks as categorical variable), and treatment-by-time interaction;
8
9 the random effects are subjects (as intercepts). The primary outcome of interest is the difference in
10
11 CARS-J scores between the two groups at week 8. A two-sided P value of less than 0.05 will be
12
13
14 used to indicate statistical significance.
15
16
17
18
19
20
21

22 Secondary analyses

23
24 We will perform secondary analyses to supplement our primary analysis and to obtain a clearer
25
26 understanding of our clinical questions. The secondary analyses will use models similar to that of
27
28 the primary analysis and will also examine data for the secondary outcome measures. The
29
30 secondary analyses will include an assessment of the validity and reliability of FCR-J. These
31
32 analyses will be conducted for exploratory purposes.
33
34
35
36
37
38
39
40
41

42 Interim analyses

43
44 We do not plan any interim analysis.
45
46
47
48
49

50 Sample size estimation

51
52 Our previous phase II study revealed that the mean CARS-J scores were 12.8 at pre-intervention
53
54 (baseline), 12.4 at 4 weeks, and 11.2 at 8 weeks.²⁷ We assumed the following: the mean CARS-J
55
56
57

1
2 score at 2 weeks would be 12.6; the overall CARS-J scores in the control arms would not change
3
4
5 (12.8 at 0, 2, 4, and 8 weeks); the variance of the score would be 30 at all times; and the intra-class
6
7
8 correlation would be 0.82 (i.e., we assumed a compound symmetry working covariance structure).
9
10
11 Thus, for a sample size based on 0.8 power to detect a significant difference at $P = .05$ (two-sided),
12
13
14 211 participants would be required for each arm. Assuming that 5% of the initial entries would drop
15
16
17 out, we would need to recruit 444 participants into the trial.
18
19
20
21

22 Publication policy

23
24
25 The protocol paper and study results will be submitted to peer-reviewed journals. The first author of
26
27
28 the main paper will be a member of the steering committee (authors of the protocol paper). Another
29
30
31 person could be the first author if approved by the steering committee. The list of co-authors will be
32
33
34 determined before submitting each paper.
35
36
37
38

39 Study period

40
41
42 The study period of this trial will be from April 2017 to March 2020; the participant entry period
43
44
45 will be April 2018 to September 2019.
46
47
48
49

50 Patient and public involvement statement

51
52
53 The study protocol was designed with a patient (breast cancer survivor) and she participated in this
54
55
56 study as a researcher. She appropriately discussed with other patients when a patient's preferences
57
58
59
60

1
2 and/or opinions should be considered. She will play a same role on implementing the study. Thus
3
4
5 patients were and will be always involved in the study. Results of the study will be shown in the
6
7
8 study home page.
9

10 11 12 13 14 Ethics and dissemination

15
16 The present study is subject to ethical guidelines for clinical studies published by Japan's Ministry
17
18 of Education, Science and Technology and Ministry of Health, Labour and Welfare and the
19
20 modified Act on the Protection of Personal Information as well as the ethical principles established
21
22 for research on humans stipulated in the Declaration of Helsinki and further amendments thereto.
23
24
25

26
27
28 The protocol was approved by the institutional review board of Nagoya City University on
29
30 January 15, 2018 (ID: 60-00-1171). If important protocol modifications are needed, the
31
32 investigators will discuss them and report to the review board for approval.
33
34
35

36
37 With regard to dissemination, the results obtained will be submitted for publication in peer-
38
39 reviewed journals. The main and relevant findings will be presented at conferences.
40
41
42
43

44 45 Discussion

46
47 To our knowledge, the present study is the first trial investigating the efficacy of
48
49 smartphone-based psychological therapy for fear of recurrence among breast cancer survivors.
50
51
52
53 Considering the huge number of breast cancer survivors and low participant rate with other types of
54
55 therapeutic interventions, smartphone-based psychological therapy may offer a more accessible
56
57
58
59
60

1
2 option. As many cancer survivors return to their households and to work, easily accessible
3
4
5 therapeutic interventions may offer additional benefits in managing fear of recurrence. The present
6
7
8 study focuses on younger breast cancer patients who are iPhone users. However, many other
9
10
11 patients suffering from fear of recurrence use other types of smartphones (e.g., Android); in
12
13
14 addition, including patients aged 50 years and above would constitute a broader targeted population.
15
16
17 If the efficacy of the smartphone-based intervention program among our participants is confirmed,
18
19
20 the program will have promising applicability in real clinical settings.
21

22
23 The present study has some methodological limitations. First, not all patients who are
24
25 interested in and willing to use Kaiketsu-App and Genki-App possess a smartphone. This may
26
27
28 weaken the applicability of the results from this trial to all breast cancer patients with fear of
29
30
31 recurrence. Especially, the results may not be applicable to patients in developing countries and to
32
33
34 those with poor ICT literacy.
35

36
37 Second, we will use a wait-list control as the comparator owing to feasibility and ethical
38
39
40 considerations. The odds of response was found to be statistically significantly greater for no
41
42
43 treatment than the wait list.⁴⁵ The wait list may therefore lead to some overestimation of the
44
45
46 efficacy of smartphone-based psychotherapy.
47

48
49 Third, we will apply two types of psychotherapy—BA and PST—as interventions. Both
50
51
52 psychotherapeutic interventions consist of complex, multifactorial components. Thus, if the
53
54
55 interventions prove superior to the wait-list controls, we cannot determine which intervention and
56
57
58 components are most efficacious or beneficial in managing fear of recurrence. However, to
59

1
2 overcome this limitation, we will adopt a mixed-method design and can check adherence with each
3
4
5 intervention (detailed in “Methods and analysis”) so that we can identify the most useful
6
7
8 components of the interventions.
9

10
11 Fourth, we will request that participants upload images for identification (they will be
12
13 especially encouraged to attach a photo of the hospital registration card) to avoid individuals
14
15 masquerading as breast cancer patients. However, possible deception cannot be completely
16
17 prevented in our recruitment system.
18
19
20
21
22
23
24
25
26
27

28 Author contributions

29
30 TA, TAF, and MH developed the smartphone applications and MU and FI also contributed to
31
32 modification of these applications. TA, TY, MK, FK, NS, TM, TAF, HI, and YU participated in the
33
34 design of the study. TY played a chief role of the statistical parts. TA drafted the manuscript. All
35
36 authors participated in, read and approved final manuscript.
37
38
39
40
41
42
43
44

45 Funding

46
47 This study is supported by a Grant-in-Aid for Japan Agency for Medical Research and Development
48
49 (Number JP17ck0106324h). This study is also partly supported in part by a Grant-in-Aid for
50
51 Scientific Research (Number 25285194) and Young scientists (Number 17k13942) from the
52
53 Japanese Ministry of Education, Culture, Science, and Technology, grant from Nagoya City
54
55
56
57

1
2 University, Foundation for Promotion of Cancer Research in Japan and The National Cancer Center
3
4
5 Research and Development Fund (Number 27-A-3 & 30-A-11).
6
7
8
9
10
11
12

13 Competing interests

14
15
16 The authors have no conflicts of interests to declare that may be affected by the publication of the
17
18 manuscript. TA has received lectures fees from AstraZeneca, Daiichi-Sankyo, Dainippon-
19
20 Sumitomo, Eisai, Hisamitsu, Lilly, MSD, Meiji-seika Pharma, Mochida, Pfizer, Novartis, Otsuka,
21
22 Shionogi, Takeda, Tanabe-Mitsubishi, Terumo, and Yoshitomi. TA has received research funds from
23
24 Daiichi-Sankyo, Eisai, MSD, Pfizer, Novartis, and Tanabe-Mitsubishi. TY received research funds
25
26 from AC MEDICAL INC., A2 Healthcare Corporation, CAC Croit Corporation, FMD K&L Japan
27
28 K.K., Japan Tobacco Inc., Japan Media Corporation, Luminary Medical K.K., Medidata Solutions,
29
30 Inc., ONO PHARMACEUTICAL CO., LTD., Kyowa Hakko Kirin Co., Ltd., DAIICHI SANKYO
31
32 COMPANY, LIMITED. Also TY received consulting fee from ONO PHARMACEUTICAL CO.,
33
34 LTD., Kowa Company, Ltd., Japan Tobacco Inc., CHUGAI PHARMACEUTICAL CO.,LTD.,
35
36 TSUMURA & CO., CAC Croit Corporation, TSUMURA & CO., ASAHI INTECC CO., LTD.,
37
38 Asahi Kasei Pharma Corporation, Clinical Trial Co.,Ltd. FK has received lecture fees from MSD.
39
40 TAF has received lecture fees from Janssen, Meiji, Mitsubishi-Tanabe, MSD and Pfizer. He has
41
42 received research support from Mitsubishi-Tanabe. HI has received lecture fees from Daiichi
43
44 Sankyo, Chugai, AstraZeneca, Pfizer, and Eisai. He has received research support from Daiichi
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 Sankyo, Chugai, AstraZeneca, Pfizer, MSD, Kyowahakou Kirin, GSK, Lilly, Novartis, and a Bayer.

3
4
5 YU has received lectures fees from Asteras, Daiichi-Sankyo, Dainippon-Sumitomo, Eizai, Janssen,

6
7
8 Kyowahakko-Kirin, Ono, Meiji-seika Pharma, Mochida, Pfizer, Novartis, Otsuka, Sawai, Shionogi,

9
10
11 Taiho, Tanabe-Mitsubishi, Tsumura Pharma.

12 13 14 15 16 Trial status

17
18
19 The randomized trial, which commenced on 2th, April, 2018, currently enrolls participants. The

20
21
22 estimated end date for this study is in March 2020.

23 24 25 26 27 Acknowledgments

28
29
30 We thank to Ms. T Mashiko for her data management support. We also thank to Ms. Y Yanase, Ms.

31
32
33 A Nomura , Ms. K Tojima, Ms. I. Sakakima, and Ms. K Kobori for their support for the study. We

34
35
36 thank Edanz Group (www.edanzediting.com) for editing a draft of this manuscript.

1
2 Figure legend
3

4
5 Fig. 1 Participant flow diagram
6
7

8
9
10 Fig. 2 Kaiketsu App
11

12
13 Application for smartphone based problem-solving treatment
14
15

16
17
18 Fig. 3 Genki App
19

20
21 Application for smartphone based behavioral activation
22
23

24
25
26 Fig. 4 Study management system
27

28
29 e-Consent: electric informed consent; e-PRO: electric patient reported outcome
30
31

For peer review only

References

1. Ito Y, Miyashiro I, Ito H, et al. Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. *Cancer Sci*. 2014;105: 1480-1486.
2. Hodgkinson K, Butow P, Hunt GE, Pendlebury S, Hobbs KM, Wain G. Breast cancer survivors' supportive care needs 2-10 years after diagnosis. *Support Care Cancer*. 2007;15: 515-523.
3. Hartl K, Schennach R, Muller M, et al. Quality of life, anxiety, and oncological factors: a follow-up study of breast cancer patients. *Psychosomatics*. 2010;51: 112-123.
4. Gordon NH, Siminoff LA. Measuring quality of life of long-term breast cancer survivors: the Long Term Quality of Life-Breast Cancer (LTQOL-BC) Scale. *J Psychosoc Oncol*. 2010;28: 589-609.
5. Akechi T, Okuyama T, Endo C, et al. Patient's perceived need and psychological distress and/or quality of life in ambulatory breast cancer patients in Japan. *Psychooncology*. 2011;20: 497-505.
6. Harrison JD, Young JM, Price MA, Butow PN, Solomon MJ. What are the unmet supportive care needs of people with cancer? A systematic review. *Support Care Cancer*. 2009;17: 1117-1128.
7. Koch L, Jansen L, Brenner H, Arndt V. Fear of recurrence and disease progression in long-term (≥ 5 years) cancer survivors--a systematic review of quantitative studies. *Psychooncology*. 2013;22: 1-11.
8. Simard S, Thewes B, Humphris G, et al. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. *J Cancer Surviv*. 2013;7: 300-322.
9. Lengacher CA, Reich RR, Paterson CL, et al. Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial. *J Clin Oncol*. 2016.
10. Lengacher CA, Johnson-Mallard V, Post-White J, et al. Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. *Psychooncology*. 2009;18: 1261-1272.
11. Butow PN, Turner J, Gilchrist J, et al. Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence. *J Clin Oncol*. 2017;35: 4066-4077.
12. van de Wal M, Thewes B, Gielissen M, Speckens A, Prins J. Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial. *J Clin Oncol*. 2017;35: 2173-2183.
13. Fukui S, Kugaya A, Okamura H, et al. A psychosocial group intervention for Japanese women with primary breast carcinoma. *Cancer*. 2000;89: 1026-1036.
14. Fukui S, Kugaya A, Kamiya M, et al. Participation in psychosocial group intervention among Japanese women with primary breast cancer and its associated factors. *Psychooncology*. 2001;10: 419-427.
15. Akechi T, Momino K, Yamashita T, et al. Contribution of problem-solving skills to fear of recurrence in breast cancer survivors. *Breast Cancer Res Treat*. 2014;145: 205-210.
16. Akechi T, Hirai K, Motooka H, et al. Problem-solving therapy for psychological distress in Japanese cancer patients: preliminary clinical experience from psychiatric consultations. *Jpn J Clin Oncol*. 2008;38: 867-870.
17. Momino K, Miyashita M, Yamashita H, et al. Feasibility study of collaborative care intervention for the perceived care needs among breast cancer women undergoing adjuvant therapy after surgery. *Jpn J*

1 Clin Oncol. in submission.

2
3 18. Hirai K, Motooka H, Ito N, et al. Problem-solving therapy for psychological distress in Japanese
4 early-stage breast cancer patients. *Jpn J Clin Oncol.* 2012;42: 1168-1174.

5
6 19. Patel V, Weobong B, Weiss HA, et al. The Healthy Activity Program (HAP), a lay counsellor-
7 delivered brief psychological treatment for severe depression, in primary care in India: a randomised
8 controlled trial. *Lancet.* 2017;389: 176-185.

9
10 20. Nezu AM, Nezu CM, Felgoise SH, McClure KS, Houts PS. Project Genesis: assessing the efficacy of
11 problem-solving therapy for distressed adult cancer patients. *J Consult Clin Psychol.* 2003;71: 1036-
12 1048.

13
14 21. Dimidjian S, Goodman SH, Sherwood NE, et al. A pragmatic randomized clinical trial of behavioral
15 activation for depressed pregnant women. *J Consult Clin Psychol.* 2017;85: 26-36.

16
17 22. Hopko DR, Armento ME, Robertson SM, et al. Brief behavioral activation and problem-solving
18 therapy for depressed breast cancer patients: randomized trial. *J Consult Clin Psychol.* 2011;79: 834-
19 849.

20
21 23. Andrews G, Cuijpers P, Craske MG, McEvoy P, Titov N. Computer therapy for the anxiety and
22 depressive disorders is effective, acceptable and practical health care: a meta-analysis. *PLoS One.*
23 2010;5: e13196.

24
25 24. So M, Yamaguchi S, Hashimoto S, Sado M, Furukawa TA, McCrone P. Is computerised CBT really
26 helpful for adult depression?-A meta-analytic re-evaluation of CCBT for adult depression in terms of
27 clinical implementation and methodological validity. *BMC Psychiatry.* 2013;13: 113.

28
29 25. Watts S, Mackenzie A, Thomas C, et al. CBT for depression: a pilot RCT comparing mobile phone vs.
30 computer. *BMC Psychiatry.* 2013;13: 49.

31
32 26. Mantani A, Kato T, Furukawa TA, et al. Smartphone Cognitive Behavioral Therapy as an Adjunct to
33 Pharmacotherapy for Refractory Depression: Randomized Controlled Trial. *J Med Internet Res.*
34 2017;19: e373.

35
36 27. Imai F, Momino K, Katsuki F, et al. Smartphone problem-solving therapy to reduce fear of
37 recurrence among breast cancer survivors: A single-arm open pilot study in submission.

38
39 28. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for
40 protocols of clinical trials. *Bmj.* 2013;346: e7586.

41
42 29. Mynors-Wallis L. Problem-solving treatment for anxiety and depression: A practical guide. New
43 York: Oxford University Press, 2005.

44
45 30. Watanabe N, Horikoshi M, Yamada M, et al. Adding smartphone-based cognitive-behavior therapy
46 to pharmacotherapy for major depression (FLATT project): study protocol for a randomized controlled
47 trial. *Trials.* 2015;16: 293.

48
49 31. Momino K, Akechi T, Yamashita T, et al. Psychometric properties of the Japanese version of the
50 Concerns About Recurrence Scale (CARS-J). *Jpn J Clin Oncol.* 2014;44: 456-462.

51
52 32. Crist JV, Grunfeld EA. Factors reported to influence fear of recurrence in cancer patients: a
53 systematic review. *Psychooncology.* 2013;22: 978-986.

54
55 33. Services USDoHaH, (OHRP) OfHRP, Administration FaD, et al. Use of Electronic Informed Consent
56 Questions and Answers <https://www.fda.gov/downloads/drugs/guidances/ucm436811.pdf>. 2016.

- 1
2 34. Vickberg SM. The Concerns About Recurrence Scale (CARS): a systematic measure of women's fears
3 about the possibility of breast cancer recurrence. *Ann Behav Med.* 2003;25: 16-24.
4
5 35. Momino K, Akechi T, Yamashita T, et al. Psychometric properties of the Japanese version of the
6 Concerns about Recurrence Scale (CARS-J). *Jpn J Clin Oncol.* in press.
7
8 36. Simard S, Savard J. Fear of Cancer Recurrence Inventory: development and initial validation of a
9 multidimensional measure of fear of cancer recurrence. *Support Care Cancer.* 2009;17: 241-251.
10
11 37. Simard S, Savard J. Screening and comorbidity of clinical levels of fear of cancer recurrence. *J*
12 *Cancer Surviv.* 2015;9: 481-491.
13
14 38. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand.* 1983;67:
15 361-370.
16
17 39. Kugaya A, Akechi T, Okuyama T, Okamura H, Uchitomi Y. Screening for psychological distress in
18 Japanese cancer patients. *Jpn J Clin Oncol.* 1998;28: 333-338.
19
20 40. Boyes A, Girgis A, Lecathelinais C. Brief assessment of adult cancer patients' perceived needs:
21 development and validation of the 34-item Supportive Care Needs Survey (SCNS-SF34). *J Eval Clin*
22 *Pract.* 2009;15: 602-606.
23
24 41. Okuyama T, Akechi T, Yamashita H, et al. Reliability and validity of the Japanese version of the
25 Short-form Supportive Care Needs Survey questionnaire (SCNS-SF34-J). *Psychooncology.* 2009;18:
26 1003-1010.
27
28 42. Tedeschi RG, Calhoun LG. The Posttraumatic Growth Inventory: measuring the positive legacy of
29 trauma. *J Trauma Stress.* 1996;9: 455-471.
30
31 43. Taku K, Calhoun LG, Tedeschi RG, Gil-Rivas V, Kilmer RP, Cann A. Examining posttraumatic
32 growth among Japanese university students. *Anxiety Stress Coping.* 2007;20: 353-367.
33
34 44. Akizuki N, Akechi T, Nakanishi T, et al. Development of a brief screening interview for adjustment
35 disorders and major depression in patients with cancer. *Cancer.* 2003;97: 2605-2613.
36
37 45. Furukawa TA, Noma H, Caldwell DM, et al. Waiting list may be a placebo condition in
38 psychotherapy trials: a contribution from network meta-analysis. *Acta Psychiatr Scand.* 2014;130: 181-
39 192.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Fig. 1 Participant flow diagram

190x285mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 2 Kaiketsu App
Application for smartphone based problem-solving treatment

190x285mm (300 x 300 DPI)




Fig. 3 Genki App
Application for smartphone based behavioral activation

190x285mm (300 x 300 DPI)




Fig. 4 Study management system
 e-Consent: electric informed consent; e-PRO: electric patient reported outcome

285x190mm (300 x 300 DPI)

An appendix table

Details of sessions in smartphone problem-solving and behavioral activation therapies

| Smartphone app | Details of each session |
|---|---|
| Problem-solving therapy (9 sessions) | <ol style="list-style-type: none"> 1. Outline of problem-solving therapy 2. Introduction of 5 step of problem-solving 3. Example of problem-solving 4. First step (identification, definition, and breakdown of the problem) 5. Second step (establishing achievable goals) 6. Third step (generating solutions) 7. Fourth (evaluating and choosing the solution) and fifth step (implementing the chosen solution and evaluating the outcome after implementation) 8. Actual training 9. Concluding session |
| Behavioral activation therapy (2 sessions) | <ol style="list-style-type: none"> 1. Outline and introduction of behavioral activation therapy including two types of activation (e.g., do pleasurable activity again and challenge new activity) and their actual training 2. Review of the session, learning knack of behavioral activation and concluding session |

SMILE project



乳がん患者の再発不安・恐怖に対するスマートフォン問題解決療法
および行動活性化療法の有効性のための無作為割付比較試験

メニュー

ホーム

研究説明ビデオ

研究概要

研究説明文書

Q & A

研究参加

ホーム

はじめに

このホームページは Smile project 研究の内容を説明しています。研究に参加を希望される方は、研究説明ビデオ、研究概要、研究説明文書をご覧ください。

研究説明文書

この試験は、公立大学法人 名古屋市立大学大学院 医学研究科長および名古屋市立大学病院長が設置する医学系研究倫理審査委員会（所在地：名古屋市瑞穂区瑞穂町字川澄1）において医学、歯学、薬学その他の医療又は臨床試験に関する専門家や専門以外の方々により倫理性や科学性が十分であるかどうかの審査を受け、実施することが承認されています。またこの委員会では、この試験が適正に実施されているか継続して審査を行います。なお、本委員会にかかわる規程等は、以下、ホームページよりご確認いただくことができます。

名古屋市立大学病院 臨床研究開発支援センター ホームページ “患者の皆様へ” <http://ncu-cr.jp/patient>

1 説明書の趣旨

【研究参加をお願いする理由】

皆様におかれましては、療養しながら様々な負担を抱えた日々を送っていらっしゃるかと推察いたします。私たちのグループは、がんの患者さんによりよいケアを提供するための研究に取り組んでおります。がんの手術後再発なく過ごされていらっしゃる皆様において、再発に対して不安に思われていることを深く理解しております。現在、私たちの研究グループは、スマー

トフォンを用いて日常生活の困り事を解決し、活動の幅を広げることで、再発の不安をどれくらい和らげることができるのかを知るための研究を行っています。この支援方法は有用である可能性がありますが、まだ科学的に証明されていません。

以下に研究の内容について説明してありますので、よくお読みになった上で、ご協力いただける場合には、ウェブで同意をお願いいたします。操作が難しい場合、[こちらから文書をダウンロード](#)していただき、書面として同意書にご署名をお願いいたします。

【研究目的】

多くのがんの患者さんが、治療後の再発の不安を抱えていらっしゃる事が明らかになっています。がんの患者さんの不安や恐怖に対し、日常生活の困り事を解決していくこと（これを「問題解決療法」といいます）、楽しくやりがいのある活動を生活に取り入れること（これを「行動活性化療法」といいます）を通して気持ちを和らげることが有効であると言われています。また、近年、スマートフォンが普及し、生活のうえで身近なものになってきていることを踏まえ、私たちのグループはスマートフォンを用いた問題解決療法、行動活性化療法を開発いたしました。この研究は、スマートフォンを

1
2
3
4
5
6 用いてこれら支援を行うことによって、どの程度、精神的な苦痛を和らげる
7
8
9 ことができるかを調べます。

12 【研究への協力について】

15 1) 研究方法について

16
17
18 このスマートフォンを用いたアプリによる治療が、皆様にとって本当に有
19
20 用であるかどうかを明らかにするために、コンピューターを使ってランダム
21
22 に五分五分の確率で、2つのグループに分けて研究を行います。この研究を
23
24 無作為割り付け対照試験といいます。この方法では患者さんの希望でもな
25
26 無作為割り付け対照試験とい
27
28 く、医師が選択するのでもなく、誰の意志も入れずに決めることができま
29
30 す。この方法は世界中の臨床試験や医学研究で使われており、治療法に対す
31
32 る医師の先入観が入らずに、より客観的に治療法の効果を確認することが出
33
34 来ます。

35
36
37
38
39
40 今回、研究への参加に同意をいただけましたら、皆様は a) 「すぐにスマ
41
42 ホアプリを開始するグループ」または b) 「2ヶ月（8週間）後からスマホア
43
44 プリ開始するグループ」のどちらかに割り付けられます。b) 「2ヶ月後から
45
46 スマホアプリ開始するグループ」に割り当てられた場合は、研究開始後2カ
47
48 月（8週間）たって皆様のご希望があれば、アプリを使用し参加して頂くこ
49
50 とができます。

2) 皆様に具体的にお願いしたいこと

①アンケート調査

研究に参加していただく皆様に対して、普段の治療やスマートフォンを用いた問題解決療法、行動活性化療法が行われる前後の状態を把握するために、アンケート調査を行います。これによって不安などの気持ちの状態、皆様が必要とする援助（これをニードといいます）、生活の質（クオリティ・オブ・ライフ）などを把握します。

a) 「すぐにスマホアプリを開始するグループ」に割り付けられた方は、調査を5回実施させて頂く予定で、時期は研究に参加されてから同意時（第0週）、第2週、第4週、第8週、第24週になります。

b) 「2ヶ月（8週間）後からスマホアプリ開始するグループ」に割り付けられた方は、調査を4回実施させて頂く予定で、時期は研究に参加されてから同意時（第0週）、第2週、第4週、第8週になります。

この時期になりましたら、iPhoneのウェブ上でアンケートにお答えください。（アンケートの入力が完了していない場合、研究事務局からメールやお電話をさせて頂く予定ですのでご了承ください）。

また、a) 「すぐにスマホアプリを開始するグループ」に割り付けられた方の中でご協力がいただける方に、8週後の時点で、アプリの有用性をどれぐ

1
2
3
4
5
6 らい感じたか、またどのような点がよかったかなど、電話で聞き取りをさせ
7
8
9 ていただく予定です。

10 11 12 ②スマートフォンを用いた問題解決療法、行動活性化療法への参加

13
14
15 1回目、同意時（第0週）のアンケート記入後、a) 「すぐにスマホアプリ
16
17 を開始するグループ」に割り付けられた方は、スマートフォンを用いた問題
18
19 解決療法、行動活性化療法をすぐに実施していただきます。スマートフォン
20
21 を用いた問題解決療法、行動活性化療法は「解決アプリ」「元気アプリ」を
22
23 使い、ご自分で進めていただきます（アプリは週におおよそ各30分程度かか
24
25 ります。アプリはたくさん実施していただいたほうがより効果的ですので、
26
27 みなさんの自習を励ますために、事務局からメールを第8週までは毎週お送
28
29 りいたします。）。b) 「2ヶ月（8週間）後からスマホアプリ開始するグル
30
31 ープ」に割り付けられた方は、ご希望に応じて、2ヶ月（8週間）後からア
32
33 プリを使っていただきます。


34 35 36 ③アプリ内容についての調査

37
38
39 【a) 「すぐにスマホアプリを開始するグループ」に割り付けられた方の
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

51
52 研究が終了した時点（第8週）で、協力して頂ける方に、アプリを使って
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

由について調査をさせていただきます。調査は電話で行わせて頂きます（10分程度を予定しております）。

【研究の流れと研究参加基準】



以下のすべてに当てはまる方は、研究に参加いただけます。

- 1) 同意するときに 20 歳以上 49 歳以下の女性
- 2) 乳がん患者
- 3) 再発や転移がない
- 4) 同意するときに手術から 1 年以上経過していること
- 5) アンケートに記入・協力できる
- 6) iPhone または iPad を使用していること (iPad についてはネット環境下での使用をお願いできる方)

また、以下の条件に 1 つでも当てはまる方は、この研究に参加いただけません。

- 1) 重い身体疾患 (症状のために家事や軽作業ができない) や乳がん以外のがんをもっている、または、かかったことがある (完治を含む)
- 2) 日本語の読み書きが難しい
- 3) 現在、心療内科、精神科に受診している
- 4) 問題解決療法、行動活性化療法、認知行動療法を経験したことがある
- 5) 研究者が研究への参加を不適當であると判断させていただいた場合

| | 項目 | 第0週 | 第2週 | 第4週 | 第8週 | 第24週 |
|-------------|--------------|-----|-----|-----|--------------|------|
| 研究者 | 説明と同意 | ○ | | | | |
| データセンタ ー | 割り付け | ○ | | | | |
| 参加者 | アンケート | ○ | ○ | ○ | ○ | ○(*) |
| | 治療満足度 | | | | ○(*) | |
| | アプリの内 容調査 | | | | ○(*) (**) | |

(*) すぐにスマホアプリを開始するグループのみ

(**) 対象はご協力いただける一部の方のみ

【研究参加は自由意思に任されること】

本研究へのご協力は皆様個人の自由意思によるものです。いったん同意された後でも、理由を明確にすることなくいつでも同意を撤回することができます。不参加や途中撤回の場合でも、何ら不利益は生じません。

2 研究に参加した場合に予想される利益および不利益

本研究では、再発の不安や恐怖に対してスマートフォンを用いた問題解決療法、行動活性化療法を行います。研究に参加して頂くことによって、精神的な負担が軽減し、生活の質が改善する可能性があります。

また、本研究は、アンケートへの記入、メール、スマートフォンのアプリ操作が主で、皆様の身体に与える悪影響はございません。しかしながら、肉体的なことに触れることで皆様に不快感を与えることがあるかもしれません。一方、これまでの私どもの同様の研究の経験からは、不利益はほとんどないと考えております。

3 健康被害等への補償

本研究は、ほぼ危険性は伴わないため、研究を行うことによる健康被害に対して補償や賠償保険などは準備しておりません。もし、身体状態や精神状態が悪化した場合には、お手数ですがかかりつけの医療機関でご相談いただければ幸いです。

4 研究の資金源等

本研究は以下の研究費の支援のもと行われています。

- 日本医療研究開発機構研究費「乳がん患者の再発不安・恐怖に対するスマートフォン行動活性化および問題解決療法の有効性-無作為割付比較試験（主任研究者 明智龍男）」
- 名古屋市立大学特別研究奨励費「乳がんサバイバーの再発不安・恐怖に対する Information and communication technology (ICT) を応用した問題解決療法の有用性に関する予備的検討（研究代表者 明智龍男）」
- 文部科学省科学研究費補助金基盤研究 B 「致命的疾患の再発・転移の不安、恐怖の評価法の確立および新規心理学的介入方法の開発（主任研究者 明智龍男）」
- 国立がん研究センター研究開発費「支持療法の開発および検証のための基盤整備（主任研究者 内富庸介）」
- 文部科学省科学研究費補助金若手研究 B 「がん罹患に伴う心理的成長を促すスマートフォンによる問題解決療法の開発と効果検証（主任研究者 今井文信）」

5 個人情報情報の保護

研究において得られたプライバシーに関する情報は厳重に守られます。皆様の名前などの個人を識別する情報は、この研究の結果の報告や発表に使用されることはありません。

6 研究計画等の開示

皆様が希望すれば、他の参加者の個人情報や本研究の独創性の確保に支障がない範囲内で、研究計画および研究の方法に関する資料を閲覧することができます。閲覧希望の場合は事務局までお問合せください。

7 研究結果及び記録の公表

個人情報が分からないようにした上で、本研究の結果を統計学的に分析し、結果及び臨床試験を通じて得られた皆様に係わる記録が、医学および看護学の発展のため学会や学術雑誌等で公表される予定であることをご了承下さい。なお、アプリによる治療経過における治療内容、アンケートの結果などすべてが分析の対象となります。研究の進み具合やその成果については、ご希望がありましたら説明いたします。

8 研究から生ずる知的所有権について

本研究によって特許が生じた場合は、名古屋市立大学に帰属するものいたします。

9 研究期間中のデータ等について

この研究で得られたアンケート（データ）の結果は、主にスマートフォンを用いた問題解決療法、行動活性化療法の介入前後の状態を比較するために

1
2
3
4
5
6 用います。これらデータ（要配慮個人情報）は、別に作成した対応表で名前
7
8
9 や年齢などの個人情報と照合できるような形にいたします。なお前述の対応
10
11
12 表は、名古屋市立大学大学院医学研究科精神・認知・行動医学分野内の金庫
13
14
15 にて厳重に保管いたします。

10 研究終了後のデータ等について

21 この研究で得られたデータは、原則として研究終了後5年で、名古屋市立
22
23
24 大学病院の機密書類として廃棄します。

26 将来、本データを別の医学・看護学の研究に用いる場合には、改めてその
27
28
29
30 研究について倫理審査委員会に申請し、承認を得た上で実施いたします。

11 費用負担について

37 スマホアプリはすべて無料でご利用いただけます。ただし、ご利用の携帯
38
39
40 電話会社にはアプリの使用時やデータの送受信にかかる通信料はお支払い
41
42
43 いただく必要があります。アプリを使って頂くためにパケット定額サービスの
44
45
46 加入をお勧めします。また、本研究へのご参加に関して、些少なから謝礼
47
48
49
50
51
52
53
54
55
56
57
58
59
60 (アマゾンギフト券を予定) をお送りさせていただきます。

研究組織

研究責任者

明智龍男 名古屋市立大学大学院医学研究科・精神・認知・行動医学 教授

研究分担者

岩田 広治 愛知県がんセンター中央病院乳腺科 部長兼副院長

桜井 なおみ キャンサー・ソリューションズ株式会社 代表取締役社長

古川 壽亮 京都大学大学院医学研究科健康増進・行動学分野 教授

堀越 勝 国立精神・神経医療研究センター認知行動療法センター セ

ンター長

内富 庸介 国立がん研究センター支持療法開発センター センター長

今井 文信 名古屋市立大学病院緩和ケア部 臨床研究医

内田 恵 名古屋市立大学病院緩和ケア部 助教

香月 富士日 名古屋市立大学看護学部 教授

樫野 香苗 名古屋市立大学看護学部 准教授

山口 拓洋 東北大学大学院医学系研究科 教授

宮地 天平 国立がん研究センター社会と健康研究センター健康支援研究

部

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

益子 友恵 国立がん研究センター社会と健康研究センター健康支援研究

部

For peer review only

研究参加

本研究への参加を希望される方は、必要事項をご記入いただき、参加に関する条件に該当しているかを確認の上「参加する」ボタンを1回押してください。

| | |
|---|-------------------------------|
| 氏名 | 姓 名 |
| ふりがな | 姓 名 |
| 年齢 | ※20-49歳がプルダウン等で選択できるようにしてはどうか |
| 携帯番号 | |
| メールアドレス 携帯電話のメールアドレスを入力される方は、予めドメイン「mail.sports-web.jp (仮)」からのメールを受信できる設定にしてください。 Gmail アドレスをご使用の方は必ず「迷惑メール」をご確認ください。 | |
| メールアドレス (確認用) | |
| 乳がん治療のため通院 されている病院名 | |

- ホームページ上の研究説明ビデオおよび研究概要を確認した
- 申込時の年齢が 20 歳以上から 49 歳以下である
- 乳がんと診断されており、現在までに再発・転移はない
- 乳がんの手術後 1 年以上経過している
- iPhone または iPad を日常的に使用している

研究に参加する

(研究参加ボタンを押した後)

研究に申込みいただき、ありがとうございました。

参加受付のメールが登録いただいたメールアドレスに届きますので、ご確認をお願いいたします。後日、事務局から問い合わせの電話をさせていただきます。

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

| | | Reporting Item | Page Number |
|---|---------------------|--|-------------|
| Title | #1 | Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym | 1 |
| Trial registration | #2a | Trial identifier and registry name. If not yet registered, name of intended registry | 5 |
| Trial registration: data set | #2b | All items from the World Health Organization Trial Registration Data Set | 5 |
| Protocol version | #3 | Date and version identifier | 3 |
| Funding | #4 | Sources and types of financial, material, and other support | 25 |
| Roles and responsibilities: contributorship | #5a | Names, affiliations, and roles of protocol contributors | 25 |
| Roles and responsibilities: | #5b | Name and contact information for the trial sponsor | 25 |

| | | | | |
|----|----------------------|----------------------|---|-------|
| 1 | sponsor contact | | | |
| 2 | information | | | |
| 3 | | | | |
| 4 | Roles and | #5c | Role of study sponsor and funders, if any, in study design; | 25 |
| 5 | responsibilities: | | collection, management, analysis, and interpretation of | |
| 6 | sponsor and funder | | data; writing of the report; and the decision to submit the | |
| 7 | | | report for publication, including whether they will have | |
| 8 | | | ultimate authority over any of these activities | |
| 9 | | | | |
| 10 | | | | |
| 11 | | | | |
| 12 | Roles and | #5d | Composition, roles, and responsibilities of the coordinating | 13-14 |
| 13 | responsibilities: | | centre, steering committee, endpoint adjudication | |
| 14 | committees | | committee, data management team, and other individuals or | |
| 15 | | | groups overseeing the trial, if applicable (see Item 21a for | |
| 16 | | | data monitoring committee) | |
| 17 | | | | |
| 18 | | | | |
| 19 | | | | |
| 20 | Background and | #6a | Description of research question and justification for | 6-8 |
| 21 | rationale | | undertaking the trial, including summary of relevant studies | |
| 22 | | | (published and unpublished) examining benefits and harms | |
| 23 | | | for each intervention | |
| 24 | | | | |
| 25 | | | | |
| 26 | | | | |
| 27 | Background and | #6b | Explanation for choice of comparators | 8 |
| 28 | rationale: choice of | | | |
| 29 | comparators | | | |
| 30 | | | | |
| 31 | | | | |
| 32 | Objectives | #7 | Specific objectives or hypotheses | 8 |
| 33 | | | | |
| 34 | | | | |
| 35 | Trial design | #8 | Description of trial design including type of trial (eg, parallel | 8-9 |
| 36 | | | group, crossover, factorial, single group), allocation ratio, | |
| 37 | | | and framework (eg, superiority, equivalence, non-inferiority, | |
| 38 | | | exploratory) | |
| 39 | | | | |
| 40 | | | | |
| 41 | | | | |
| 42 | Study setting | #9 | Description of study settings (eg, community clinic, | 10-11 |
| 43 | | | academic hospital) and list of countries where data will be | |
| 44 | | | collected. Reference to where list of study sites can be | |
| 45 | | | obtained | |
| 46 | | | | |
| 47 | | | | |
| 48 | Eligibility criteria | #10 | Inclusion and exclusion criteria for participants. If applicable, | 10-11 |
| 49 | | | eligibility criteria for study centres and individuals who will | |
| 50 | | | perform the interventions (eg, surgeons, psychotherapists) | |
| 51 | | | | |
| 52 | | | | |
| 53 | | | | |
| 54 | Interventions: | #11a | Interventions for each group with sufficient detail to allow | 9-10 |
| 55 | description | | replication, including how and when they will be | |
| 56 | | | administered | |
| 57 | | | | |
| 58 | | | | |
| 59 | | | | |
| 60 | | | | |

| | | | | |
|----|----------------------|----------------------|--|-------|
| 1 | Interventions: | #11b | Criteria for discontinuing or modifying allocated | 15 |
| 2 | modifications | | interventions for a given trial participant (eg, drug dose | |
| 3 | | | change in response to harms, participant request, or | |
| 4 | | | improving / worsening disease) | |
| 5 | | | | |
| 6 | | | | |
| 7 | Interventions: | #11c | Strategies to improve adherence to intervention protocols, | 10 |
| 8 | adherence | | and any procedures for monitoring adherence (eg, drug | |
| 9 | | | tablet return; laboratory tests) | |
| 10 | | | | |
| 11 | | | | |
| 12 | | | | |
| 13 | Interventions: | #11d | Relevant concomitant care and interventions that are | 15 |
| 14 | concomitant care | | permitted or prohibited during the trial | |
| 15 | | | | |
| 16 | | | | |
| 17 | Outcomes | #12 | Primary, secondary, and other outcomes, including the | 16-20 |
| 18 | | | specific measurement variable (eg, systolic blood pressure), | |
| 19 | | | analysis metric (eg, change from baseline, final value, time | |
| 20 | | | to event), method of aggregation (eg, median, proportion), | |
| 21 | | | and time point for each outcome. Explanation of the clinical | |
| 22 | | | relevance of chosen efficacy and harm outcomes is strongly | |
| 23 | | | recommended | |
| 24 | | | | |
| 25 | | | | |
| 26 | | | | |
| 27 | | | | |
| 28 | Participant timeline | #13 | Time schedule of enrolment, interventions (including any | Fig 1 |
| 29 | | | run-ins and washouts), assessments, and visits for | |
| 30 | | | participants. A schematic diagram is highly recommended | |
| 31 | | | (see Figure) | |
| 32 | | | | |
| 33 | | | | |
| 34 | | | | |
| 35 | Sample size | #14 | Estimated number of participants needed to achieve study | 21-22 |
| 36 | | | objectives and how it was determined, including clinical and | |
| 37 | | | statistical assumptions supporting any sample size | |
| 38 | | | calculations | |
| 39 | | | | |
| 40 | | | | |
| 41 | | | | |
| 42 | Recruitment | #15 | Strategies for achieving adequate participant enrolment to | 11 |
| 43 | | | reach target sample size | |
| 44 | | | | |
| 45 | | | | |
| 46 | Allocation: sequence | #16a | Method of generating the allocation sequence (eg, | 8, 13 |
| 47 | generation | | computer-generated random numbers), and list of any | |
| 48 | | | factors for stratification. To reduce predictability of a random | |
| 49 | | | sequence, details of any planned restriction (eg, blocking) | |
| 50 | | | should be provided in a separate document that is | |
| 51 | | | unavailable to those who enrol participants or assign | |
| 52 | | | interventions | |
| 53 | | | | |
| 54 | | | | |
| 55 | | | | |
| 56 | | | | |
| 57 | Allocation | #16b | Mechanism of implementing the allocation sequence (eg, | 8, 13 |
| 58 | concealment | | central telephone; sequentially numbered, opaque, sealed | |
| 59 | | | | |
| 60 | | | | |

| | | | | |
|----|------------------------|----------------------|--|----------|
| 1 | mechanism | | envelopes), describing any steps to conceal the sequence | |
| 2 | | | until interventions are assigned | |
| 3 | | | | |
| 4 | Allocation: | #16c | Who will generate the allocation sequence, who will enrol | 8, 13 |
| 5 | implementation | | participants, and who will assign participants to | |
| 6 | | | interventions | |
| 7 | | | | |
| 8 | | | | |
| 9 | Blinding (masking) | #17a | Who will be blinded after assignment to interventions (eg, | 13-14 |
| 10 | | | trial participants, care providers, outcome assessors, data | |
| 11 | | | analysts), and how | |
| 12 | | | | |
| 13 | | | | |
| 14 | Blinding (masking): | #17b | If blinded, circumstances under which unblinding is | 8-9, 13- |
| 15 | emergency | | permissible, and procedure for revealing a participant's | 14 |
| 16 | unblinding | | allocated intervention during the trial | |
| 17 | | | | |
| 18 | | | | |
| 19 | | | | |
| 20 | Data collection plan | #18a | Plans for assessment and collection of outcome, baseline, | Table 1 |
| 21 | | | and other trial data, including any related processes to | |
| 22 | | | promote data quality (eg, duplicate measurements, training | 16-20 |
| 23 | | | of assessors) and a description of study instruments (eg, | |
| 24 | | | questionnaires, laboratory tests) along with their reliability | |
| 25 | | | and validity, if known. Reference to where data collection | |
| 26 | | | forms can be found, if not in the protocol | |
| 27 | | | | |
| 28 | | | | |
| 29 | | | | |
| 30 | | | | |
| 31 | Data collection plan: | #18b | Plans to promote participant retention and complete follow- | 15 |
| 32 | retention | | up, including list of any outcome data to be collected for | |
| 33 | | | participants who discontinue or deviate from intervention | |
| 34 | | | protocols | |
| 35 | | | | |
| 36 | | | | |
| 37 | | | | |
| 38 | Data management | #19 | Plans for data entry, coding, security, and storage, including | Table 1 |
| 39 | | | any related processes to promote data quality (eg, double | |
| 40 | | | data entry; range checks for data values). Reference to | 13-14 |
| 41 | | | where details of data management procedures can be | |
| 42 | | | found, if not in the protocol | |
| 43 | | | | |
| 44 | | | | |
| 45 | | | | |
| 46 | Statistics: outcomes | #20a | Statistical methods for analysing primary and secondary | 20-21 |
| 47 | | | outcomes. Reference to where other details of the statistical | |
| 48 | | | analysis plan can be found, if not in the protocol | |
| 49 | | | | |
| 50 | | | | |
| 51 | Statistics: additional | #20b | Methods for any additional analyses (eg, subgroup and | 20-21 |
| 52 | analyses | | adjusted analyses) | |
| 53 | | | | |
| 54 | | | | |
| 55 | Statistics: analysis | #20c | Definition of analysis population relating to protocol non- | 15-16 |
| 56 | population and | | adherence (eg, as randomised analysis), and any statistical | |
| 57 | missing data | | methods to handle missing data (eg, multiple imputation) | 20-21 |
| 58 | | | | |
| 59 | | | | |
| 60 | | | | |

| | | | | |
|----|--------------------|----------------------|--|--------|
| 1 | Data monitoring: | #21a | Composition of data monitoring committee (DMC); summary | 13-14 |
| 2 | formal committee | | of its role and reporting structure; statement of whether it is | |
| 3 | | | independent from the sponsor and competing interests; and | |
| 4 | | | reference to where further details about its charter can be | |
| 5 | | | found, if not in the protocol. Alternatively, an explanation of | |
| 6 | | | why a DMC is not needed | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |
| 11 | Data monitoring: | #21b | Description of any interim analyses and stopping guidelines, | 21 |
| 12 | interim analysis | | including who will have access to these interim results and | |
| 13 | | | make the final decision to terminate the trial | |
| 14 | | | | |
| 15 | | | | |
| 16 | Harms | #22 | Plans for collecting, assessing, reporting, and managing | 19, 20 |
| 17 | | | solicited and spontaneously reported adverse events and | |
| 18 | | | other unintended effects of trial interventions or trial conduct | |
| 19 | | | | |
| 20 | | | | |
| 21 | Auditing | #23 | Frequency and procedures for auditing trial conduct, if any, | 13-14 |
| 22 | | | and whether the process will be independent from | |
| 23 | | | investigators and the sponsor | |
| 24 | | | | |
| 25 | | | | |
| 26 | | | | |
| 27 | Research ethics | #24 | Plans for seeking research ethics committee / institutional | 22-23 |
| 28 | approval | | review board (REC / IRB) approval | |
| 29 | | | | |
| 30 | | | | |
| 31 | Protocol | #25 | Plans for communicating important protocol modifications | 23 |
| 32 | amendments | | (eg, changes to eligibility criteria, outcomes, analyses) to | |
| 33 | | | relevant parties (eg, investigators, REC / IRBs, trial | |
| 34 | | | participants, trial registries, journals, regulators) | |
| 35 | | | | |
| 36 | | | | |
| 37 | Consent or assent | #26a | Who will obtain informed consent or assent from potential | 13 |
| 38 | | | trial participants or authorised surrogates, and how (see | |
| 39 | | | Item 32) | |
| 40 | | | | |
| 41 | | | | |
| 42 | | | | |
| 43 | Consent or assent: | #26b | Additional consent provisions for collection and use of | NA |
| 44 | ancillary studies | | participant data and biological specimens in ancillary | |
| 45 | | | studies, if applicable | |
| 46 | | | | |
| 47 | | | | |
| 48 | Confidentiality | #27 | How personal information about potential and enrolled | 13-14 |
| 49 | | | participants will be collected, shared, and maintained in | |
| 50 | | | order to protect confidentiality before, during, and after the | |
| 51 | | | trial | |
| 52 | | | | |
| 53 | | | | |
| 54 | | | | |
| 55 | Declaration of | #28 | Financial and other competing interests for principal | 25-26 |
| 56 | interests | | investigators for the overall trial and each study site | |
| 57 | | | | |
| 58 | | | | |
| 59 | Data access | #29 | Statement of who will have access to the final trial dataset, | 14 |
| 60 | | | | |

and disclosure of contractual agreements that limit such access for investigators

| | | | |
|----|-----------------------|----------------------|---|
| 1 | | | |
| 2 | | | |
| 3 | | | |
| 4 | Ancillary and post | #30 | Provisions, if any, for ancillary and post-trial care, and for |
| 5 | trial care | | compensation to those who suffer harm from trial |
| 6 | | | participation |
| 7 | | | |
| 8 | | | |
| 9 | Dissemination policy: | #31a | Plans for investigators and sponsor to communicate trial |
| 10 | trial results | | results to participants, healthcare professionals, the public, |
| 11 | | | and other relevant groups (eg, via publication, reporting in |
| 12 | | | results databases, or other data sharing arrangements), |
| 13 | | | including any publication restrictions |
| 14 | | | |
| 15 | | | |
| 16 | | | |
| 17 | Dissemination policy: | #31b | Authorship eligibility guidelines and any intended use of |
| 18 | authorship | | professional writers |
| 19 | | | |
| 20 | | | |
| 21 | Dissemination policy: | #31c | Plans, if any, for granting public access to the full protocol, |
| 22 | reproducible | | participant-level dataset, and statistical code |
| 23 | research | | |
| 24 | | | |
| 25 | | | |
| 26 | | | |
| 27 | Informed consent | #32 | Model consent form and other related documentation given |
| 28 | materials | | to participants and authorised surrogates |
| 29 | | | |
| 30 | | | |
| 31 | Biological specimens | #33 | Plans for collection, laboratory evaluation, and storage of |
| 32 | | | biological specimens for genetic or molecular analysis in the |
| 33 | | | current trial and for future use in ancillary studies, if |
| 34 | | | applicable |
| 35 | | | |
| 36 | | | |

The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Smartphone problem-solving and behavioral activation therapy to reduce fear of recurrence among breast cancer patients (SMartphone Intervention to LEssen fear of cancer recurrence: SMILE project): protocol for a randomized controlled trial

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2018-024794.R2 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 27-Sep-2018 |
| Complete List of Authors: | Akechi, Tatsuo; Nagoya City University Graduate School of Medical Sciences and Medical School Yamaguchi, Takuhiro; Division of Biostatistics, Uchida, Megumi; Nagoya City University Graduate School of Medical Sciences and Medical School Imai, Fuminobu; Nagoya City University Graduate School of Medical Sciences and Medical School Momino, Kanae; Nagoya City University School of Nursing Katsuki, Fujika; Nagoya City University School of Nursing, Nagoya, Department of Psychiatric and Mental Health Nursing Sakurai, Naomi; Cancer Solutions, Co., Ltd. Miyaji, Tempei; Tokyo University Graduate School of Medicine Horikoshi, Masaru; National Center of Neurology and Psychiatry Furukawa, Toshi; Kyoto University, Graduate School of Medicine and School of Public Health Iwata, Hiroji; Aichi Cancer Center, Nagoya, Breast Oncology Uchitomi, Yosuke; Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, & Behavioral and Survivorship Research Group, Center for Public Health Sciences |
| Primary Subject Heading: | Mental health |
| Secondary Subject Heading: | Mental health |
| Keywords: | neoplasma, fear of recurrence, cancer survivorship, psychosocial intervention, information and communication technology, quality of life |
| | |

SCHOLARONE™
Manuscripts

1
2
3 Study protocol

4
5 Title: Smartphone problem-solving and behavioral activation therapy to reduce fear of recurrence
6
7
8 among breast cancer patients (SMartphone Intervention to LEssen fear of cancer recurrence:
9
10
11 SMILE project): protocol for a randomized controlled trial
12
13
14
15

16 Tatsuo Akechi, MD, PhD^{1,2}

17 Takuhiro Yamaguchi, PhD³

18
19
20
21
22 Megumi Uchida, MD, PhD^{1,2}

23
24
25 Fuminobu Imai, MD^{1,2}

26
27
28 Kanae Momino, RN, MHIthSci⁴

29
30
31 Fujika Katsuki, RN, PhD⁵

32
33
34 Naomi Sakurai,⁶

35
36
37 Tempei Miyaji,⁷

38
39
40 Masaru Horikoshi, PhD⁸

41
42
43 Toshi A Furukawa, MD, PhD⁹

44
45
46 Hiroji Iwata, MD, PhD¹⁰

47
48
49 Yosuke Uchitomi MD, PhD¹¹

50
51
52
53 1. Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate
54
55
56 School of Medical Sciences, Nagoya, Japan
57

- 1
2
3 2. Division of Palliative Care and Psycho-oncology, Nagoya City University Hospital, Nagoya,
4
5 Japan
6
7
- 8 3. Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan
9
- 10 4. Department of Nursing Administration and Management, Nagoya City University School of
11
12 Nursing. Nagoya, Japan
13
14
- 15 5. Department of Psychiatric and Mental Health Nursing, Nagoya City University School of
16
17 Nursing, Nagoya, Japan
18
19
- 20 6. Cancer Solutions, Co., Ltd., Tokyo, Japan
21
- 22 7. Department of Clinical Trial Data Management, Tokyo University Graduate School of Medicine,
23
24 Tokyo, Japan
25
26
27
28
- 29 8. National Center for Cognitive Behavior Therapy and Research, National Center of Neurology
30
31 and Psychiatry, Tokyo, Japan
32
33
34
- 35 9. Kyoto University Graduate School of Medicine / School of Public Health Department of Health
36
37 Promotion of Human Behavior, Kyoto, Japan
38
39
- 40 10. Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
41
42
- 43 11. Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center
44
45 Hospital, & Behavioral and Survivorship Research Group, Center for Public Health Sciences,
46
47
48
49
50 National Cancer Center, Tokyo, Japan
51
52
53
54

55
56 Corresponding Author: Tatsuo Akechi, MD, PhD
57

1
2 Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate
3

4
5 School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601 Japan
6

7
8 Tel: +81-52-853-8271, Fax: +81-52-852-0837, Email: takechi@med.nagoya-cu.ac.jp
9

10
11
12
13
14 Key words: neoplasma; fear of recurrence; cancer survivorship; psychosocial intervention;
15
16 information and communication technology; quality of life
17
18

19
20
21
22 Protocol version 4.3 (Augst 24, 2018)
23
24
25

26
27
28 Word count: 4577
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: One of the most common distressing conditions experienced by breast cancer survivors is fear of cancer recurrence (FCR). There is, however, no standard intervention for ameliorating FCR. Our clinical experience and previous studies have suggested the potential benefits of problem-solving therapy (PST) and behavioral activation (BA). Given the huge number of cancer survivors and limited number of therapists to competently conduct PST and BA, we have developed PST and BA smartphone applications. This study aimed to evaluate the efficacy of the smartphone-based PST (Kaiketsu-App) and BA (Genki-App) apps in reducing FCR in breast cancer patients.

Methods and analysis: The SMartphone Intervention to LEssen fear of cancer recurrence (SMILE) project is an open-label, individually randomized, parallel-group trial. Allocation will be managed by a central server, using a computer-generated random allocation sequence provided by an independent data center. Participants will be randomized to smartphone-based intervention plus treatment as usual (TAU) or wait-list control with TAU alone. The primary end point of the study is the Japanese version of the Concerns About Recurrence Scale, which will be administered as an electronic patient-reported outcome on the patients' smartphone after 8 weeks.

Ethics and dissemination: The present study is subject to the ethical guidelines for clinical studies published by Japan's Ministry of Education, Science and Technology and Ministry of Health, Labour and Welfare and the modified Act on the Protection of Personal Information as well as the ethical principles established for research on humans stipulated in the Declaration of Helsinki and

1
2 further amendments thereto. The protocol was approved by the institutional review board of Nagoya
3
4
5 City University on January 15, 2018 (ID: 60-00-1171).
6
7

8 Trial registration: UMIN-CTR: UMIN000031140
9
10
11
12
13
14
15

16 Article Summary

17 Strengths and limitations of this study

18
19
20 -This study is the first trial investigating the efficacy of smartphone-based psychological therapy for
21
22 fear of cancer recurrence (FCR) among breast cancer survivors.
23
24

25
26 -Because many breast cancer survivors return to their households and work, easily accessible
27
28 therapeutic interventions without hospital visits may offer benefits.
29
30

31
32 -This study focuses on younger breast cancer survivors who are iPhone users; this focus could
33
34 reduce the external validity of the findings obtained.
35
36

37
38 -The use of the wait-list control conditions may overestimate the efficacy of the smartphone-based
39
40 psychotherapy.
41
42

43
44 -We will apply two types of psychotherapy and both interventions consist of complex, multifactorial
45
46 components; thus, we cannot be certain which intervention and components are most beneficial in
47
48 managing FCR; however, we will adopt a mixed-method design to overcome those issues.
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Worldwide, breast cancer is one of the most common cancers among women. In Japan, it is also the most common cancer among women, and the incidence is increasing. At present, approximately 90,000 women in Japan are annually diagnosed with breast cancer. Advances in early detection and individualized medical treatment have improved the survival rate of breast cancer patients. The current 10-year survival rate for breast cancer patients is over 90%, which contributes to the increasing number of breast cancer survivors is increasing.¹

Thus patients with breast cancer have on average a better prognosis than those with many other types of cancer; however, it has been suggested that many breast cancer survivors suffer from uncertainty anxiety and fear over recurrence.²⁻⁴ Our previous study found that the most common unmet needs experienced by ambulatory breast cancer patients are psychological—especially fear of cancer recurrence (FCR); over half of patients complained of such needs.⁵ Among breast cancer patients, FCR is, not only highly prevalent, but also associated with poor quality of life.^{2, 5-8}

Accordingly, there is an urgent need for an appropriate intervention for FCR. However, there is no standard intervention for ameliorating FCR.⁸ Recent studies have demonstrated that the following can improve FCR among breast cancer survivors: mindfulness stress reduction (six weekly group sessions); cognitive behavioral therapy (CBT; five individual face-to-face sessions and three e-consultations over a period of 3 months); and the novel theoretically based intervention of ConquerFear, which includes attention training, metacognition, and acceptance and mindfulness (five individual face-to-face sessions over 10 weeks).⁹⁻¹² These interventions may be promising;

1
2 however, one problem with this kind of intervention is the low participation rate owing to time and
3
4 distance issues (e.g., over 60% of potentially eligible subjects have been found to decline
5
6 participation).^{9, 11-14} In addition, the number of therapists who can provide such specialized care
7
8
9
10
11 may be severely limited, which is a serious problem in many countries.
12

13
14 Our past experience and some studies indicate the effectiveness of CBT, including problem-
15
16 solving therapy (PST) and behavioral activation (BA), for FCR among breast cancer survivors.¹⁵⁻¹⁸
17
18 We have demonstrated that patients' problem-solving skills were significantly associated with
19
20 FCR.¹⁵ Our hypotheses of their underlying mechanisms are that PST contributes to patients' better
21
22 coping with situations commonly triggering FOR (e.g., pain, exposure to news about cancer, regular
23
24 visit to cancer hospital, etc.) and other stressful situations that increase FOR and that BA also
25
26 improves FOR through distraction and through increased sense of mastery and pleasure. PST and
27
28 BA are straightforward interventions that can be administered by less experienced therapists,
29
30 including nurses.¹⁹ However, patients willing to undergo PST or BA are rarely able to do so even in
31
32 well-resourced countries because a typical course of PST or BA consists of eight to 12 face-to-face
33
34 sessions lasting 1 or 1.5 hours led by a trained therapist.²⁰⁻²²
35
36
37
38
39
40
41
42
43
44

45
46 Though such programs seem promising, they appear to suffer similar limitations to those of the
47
48 above-mentioned therapeutic interventions.⁹⁻¹² Given the growing number of women annually
49
50 diagnosed with breast cancer and the high prevalence among them of unmet needs of FCR, a
51
52 completely novel approach to therapy provision is required. Recent studies have demonstrated the
53
54 effectiveness of computerized CBT.^{23, 24} In light of recent developments in information and
55
56
57
58
59
60

1
2 communication technology (ICT), CBT delivered via smartphones may be a better treatment option
3
4
5 for FCR—in terms of accessibility and portability—than a computer-based one.²⁵ We have recently
6
7
8 developed a smartphone CBT app, which teaches skills in BA and cognitive restructuring; we
9
10
11 demonstrated its efficacy for antidepressant-resistant major depression in a randomized controlled
12
13
14 trial.²⁶ We have also developed PST programs as a smartphone app and demonstrated the
15
16
17 acceptability and efficacy of the smartphone-based PST in a single-arm pilot study with breast
18
19
20 cancer survivors.²⁷ The purpose of the present randomized study is to examine the efficacy of
21
22
23 smartphone-based PST and BA interventions to reduce FCR in breast cancer patients in a
24
25
26 randomized controlled trial. Since there is no specific standard intervention for ameliorating FCR as
27
28
29 mentioned above and our research team's discussion suggests that setting wait-list control will be
30
31
32 more feasible than no intervention, wait-list control is used as a comparator.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods and analysis

This protocol has been written in accordance with the SPIRIT guideline.²⁸

Trial design

The present study is an individually randomized, parallel-group trial (Figure 1). An independent data center will provide computer-generated random allocation sequences. The allocation sequences are maintained centrally, and the results of the assignment will be sent automatically to the study participants by e-mail. The participants are randomized to smartphone-based intervention plus

1
2 treatment as usual (TAU) or wait-list control with TAU alone. TAU means general treatment and/or
3
4
5 care commonly provided by each patient's hospital (e.g., nurse's support etc.).
6
7
8
9

10
11 Interventions: Smartphone-based PST (Kaiketsu-App) and BA (Genki-App)
12

13
14 PST provides patients with a structured strategy for solving their problems. PST includes the
15
16 following five steps²⁹: (1) identification, definition, and breakdown of the problem; (2) establishing
17
18 achievable goals; (3) generating solutions; (4) evaluating and choosing the solution; and (5)
19
20 implementing the chosen solution and evaluating the outcome after implementation.
21
22
23
24

25 The smartphone-based PST program, called Kaiketsu-App ("Kaiketsu" means "Solution"
26
27 in Japanese), for iPhones and iPads (Apple Inc., Cupertino, CA, USA) was developed for this study
28
29 (Figure 2). The development was based on our empirically supported PST manual.¹⁸ Kaiketsu-App
30
31 comprises nine sessions (**An appendix table**): three introductory session; four sessions about learning
32
33 the PST in five steps; one session of actual training; and one concluding session. The shortest time
34
35 necessary to complete Kaiketsu-App is 2 weeks. The main program consists of dialogues between
36
37 characters, who explain the principles and skills of PST. After the first session, participants have to
38
39 do homework. The time necessary to complete one session is approximately 30 minutes.
40
41
42
43
44
45
46

47 BA intervention was developed based on the hypothesis that anxiety can lead to less
48
49 pleasurable behavior and more sedentary life, which then may lead to worsening anxiety.²⁹
50
51
52

53 The smartphone-based BA program Genki-App ("Genki" means "Energy or Vitality" in
54
55 Japanese), for iPhones and iPads (Figure 3) was developed as part of the smartphone-based CBT
56
57
58
59
60

1
2 program which was developed for our previous study.³⁰ Genki-App consists of two sessions (An
3
4 appendix table), and approximately 30 minutes is needed to complete each session: one is outline
5
6 and introduction of behavioral activation therapy including two types of activation (e.g., do
7
8 pleasurable activity again and challenge new activity) and their actual training (**Genki-App**
9
10 **includes a self-learning sheet for planning and doing pleasurable and new activity, and for**
11 **evaluating achievement after conducting its activity.**); the other is review of the session, learning
12
13 knack of behavioral activation (**Start an activity to be able to conduct by yourself; divide big**
14 **aim into some smaller ones; plan a schedule to conduct an activity; image a situation when**
15 **you can do it well**) and concluding session. The shortest time necessary to complete Genki-App is
16
17 also 2 weeks. The Genki-App program also mainly consists of dialogues between characters and
18
19 homework.
20
21
22
23
24
25
26
27
28
29
30
31

32
33 Over the 8-week period of the programs, participants are encouraged to complete the
34
35 sessions and homework through automated e-mail reminders once a week. Although we cannot
36
37 know the contents of homework for privacy security, treatment adherence (e.g., times and length of
38
39 using each App) can be checked by Google analytics.
40
41
42
43
44
45
46
47

48 *Participants*

49
50 The inclusion criteria for participants are as follows: (1) diagnosis of breast cancer and awareness of
51
52 the cancer diagnosis; (2) age 20–49 years; (3) 1 year following breast surgery; (4) currently disease
53
54 free; (5) ability to complete an electronic patient reported outcome (ePRO) using an iPhone or iPad;
55
56
57

1
2 (6) being an iPhone or iPad user and having an apple ID to install applications using App Store. We
3
4
5 limit the patients' age to 20–49 years because one study and our previous investigation
6
7
8 demonstrated that individuals of that age are at high risk of FCR and that more than 50% of such
9
10
11 people have smartphones.^{8, 31, 32}
12

13
14 The exclusion criteria for participants are as follows: (1) having active, serious physical
15
16 disease that affects household and light work and a current or past history of cancer other than
17
18 breast cancer; (2) inability to understand Japanese; (3) currently undergoing follow-up and
19
20 treatment in a psychiatry department or by other mental health professionals; (4) patients who have
21
22 previously undergone structured PST, BA therapy, or CBT; (5) judged inappropriate for
23
24 participation by the researchers (e.g., identity theft, duplicate entry, etc.).
25
26
27
28
29
30
31
32

33 Procedures

34 Newly developed research management system

35
36
37 To lessen patient inconvenience in visiting hospital for this study and oncologists' workload in
38
39 enrolling study participants, we developed a research management system making full use of ICT
40
41 technology (Figure 4). The study's Web site (<https://smile-project.org/>) provides information about
42
43 this study. A poster briefly introducing the study and including a QR code for the Web site has been
44
45 put up in 10 core cancer hospitals in Japan and study information will be disseminated repeatedly
46
47
48 by using several social networking systems (e.g., facebook, patient's mailing list etc.). The Web
49
50
51 site explains the purpose of the study, eligibility criteria, and methods used; it also features a video
52
53
54
55
56
57
58
59
60

1
2 briefly introducing the study as well as providing full written information about it. Potential
3
4
5 participants who are interested in the study can e-mail the study's central office, and clinical
6
7
8 research coordinators (CRCs) at the central office ascertain their eligibility by telephone (Table 1).
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1 Schedule for outcome measurement

| | | Time points | | | | |
|------------|---------------------------------|-------------|---------|--------|---------|----------|
| | | 0 week | 2 weeks | 4 wees | 8 weeks | 24 weeks |
| Assessment | Understanding of the e-Consent | ● | | | | |
| | Characteristic | ● | | | | |
| | CARS-J, HADS | ● | ● | ● | ● | ●* |
| | FCRI, SCNS-SF34, PTGI-J | ● | | | ● | ●* |
| | Satisfaction with interventions | | | | ●* | |
| | Qualitative assessment of apps | | | | ●* | |

CARS-J: Japanese version of the Concerns About Recurrence Scale

HADS: Hospital Anxiety and Depression Scale

Fear of Cancer Recurrence Inventory short form (FCRI-SF)

SCNS-SF34: Short-form Supportive Care Needs Survey questionnaire

PTGI-J: Posttraumatic Growth Inventory-Japanese

*These would be evaluated only for intervention group

1
2
3
4
5 Electronic informed consent and randomization at week 0
6
7

8 After screening, the CRCs will seek to obtain the subjects' electronic informed consent (e-consent)
9
10 via e-PRO system at week 0. Participants will be requested to upload a picture of identification
11
12 materials (patients will be especially encouraged to attach a photo of the ID card of the hospital
13
14 where they made regular follow-up visits for breast cancer). This e-consent procedure is in
15
16 accordance with the guidance of the US Food and Drug Administration (FDA).³³ Informed consent
17
18 material-original is shown in an appendix.
19
20
21
22
23
24

25 After providing e-consent and completing the baseline investigation by e-PRO, the
26
27 participants will be randomly allocated to either the smartphone-based PST and BA group or the
28
29 wait-list control group in a 1:1 ratio using the electronic data-capturing Web program (EDC) at the
30
31 data management center (Figure 1). The random allocation will therefore be concealed.
32
33
34
35

36 If a participant is allocated to the intervention group, they will receive a password unique to
37
38 them for using Kaiketsu-App and Genki-App. Upon entering the password, participants will be able
39
40 to proceed to the sections for Kaiketsu-App and Genki-App. If participants are allocated to the
41
42 control group, they will be informed that use of Kaiketsu-App and Genki-App can be resumed if
43
44 they wish after week 8.
45
46
47
48
49
50
51
52

53 Data management, central monitoring, data monitoring, and auditing
54
55

56 We will collect all data except qualitative interview data through e-PRO; we will obtain qualitative
57
58

1
2 interview data by telephone (See below for details). If participants fail to provide their responses
3
4
5 regarding FCR, a CRC blinded to the assignment will telephone the subjects to elicit their answers.
6

7
8 Data management and central monitoring will be performed using the EDC. The EDC consists of
9
10 two different and independent parts, one including personal information and the other including
11
12 trial-related data (e.g., assignment, outcomes, etc.) for security. Since the psychological intervention
13
14 provided by apps will not be invasive and also not produce serious harms, data monitoring
15
16 committee will not be organized. Similarly auditing is not also planned for this study.
17
18
19
20
21
22
23
24

25 Dataset available

26
27 The de-identified anonymized dataset will be uploaded to UMIN-ICDR
28
29 (<http://www.umin.ac.jp/icdr/index-j.html>) and researchers approved by the Steering Committee will
30
31 be able to have access to the dataset.
32
33
34
35
36
37
38

39 Trial period: weeks 0–8

40
41 For participants allocated to the intervention group, an automated e-mail encouraging their
42
43 adherence to Kaiketsu-App and Genki-App will be sent every week for 8 weeks. The research team
44
45 can check the patient's progress (number of times and duration using each application) with
46
47 Kaiketsu-App and Genki-App using Google Analytics. At weeks 2, 4, and 8, participants will
48
49 receive an e-mail encouraging them to record their responses on e-PRO.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Follow-up period: weeks 8–24
4

5 Participants allocated to the control group can resume the Kaiketsu-App and Genki-App if they
6
7 wish. At week 24, participants allocated to the intervention group will receive an e-mail
8
9 encouraging them to provide their responses on e-PRO.
10
11
12
13

14
15
16 Concomitant treatments
17

18
19 There is no restriction on concomitant treatments.
20
21
22
23

24
25 Stopping rules for participants
26

27
28 Discontinuation of protocol treatment
29

30
31 If a participant meets any of the following conditions, the research team can discontinue the
32
33 Kaiketsu-App and Genki-App. However, the participant will not be considered to have dropped out
34
35 of the trial at that stage and will receive the protocol assessments: (1) the participant wishes to stop
36
37 the protocol treatment; (2) the research team judges that the risk of the protocol treatment is greater
38
39 than the benefit for any reason; (3) the research team judges that it is difficult to continue the
40
41 protocol treatment because of clinical deterioration; (4) the research team judges that it is
42
43 inappropriate to continue the protocol treatment for any reason (e.g., when identity theft, duplicate
44
45 entry, etc. is detected).
46
47
48
49
50
51

52
53
54
55
56 Stopping assessment
57

1
2 If a participant withdraws consent for assessment, she will not be followed up. Subjects will be
3
4
5 excluded from the intention-to-treat (ITT) cohort of the trial only if their characteristics are found to
6
7
8 meet any exclusion criteria at baseline (e.g., age over 50 years) after participation.
9

10 11 12 13 14 Assessment measures

15
16 Table 1 shows the schedule for outcome measurement.

17 18 19 Primary outcome measure

20 21 22 Fear of recurrence: CARS-J

23
24 Originally developed in the United States, CARS-J is a 26-item self-report scale to measure fear of
25
26
27 recurrence of breast cancer.³⁴ The reliability and validity of CARS-J has been confirmed among
28
29
30 Japanese breast cancer patients.³⁵ CARS-J assesses the overall fear of breast cancer recurrence and
31
32
33 four domains of specific fear of recurrence. Overall fear comprises four items: questions on
34
35
36 frequency; potential for upset; consistency; and intensity of fear. The overall fear score with CARS-
37
38
39 J is our primary outcome. The range of possible scores for overall fear is 4–24; a higher score
40
41
42 indicates greater fear of recurrence.
43
44
45
46
47

48 49 50 Secondary outcome measures

51 52 53 Fear of Cancer Recurrence Inventory–Short Form

54
55 The Fear of Cancer Recurrence Inventory–Short Form (FCRI-SF) is a nine-item self-report scale,
56
57
58 originally developed in Canada.^{36, 37} The FCRI evaluates the presence and severity of intrusive
59
60

1
2 thoughts associated with FCR: scores range from 0 to 36; a higher score indicates severe FCR.
3
4
5 Unlike with CARS-J, the FCRI-SF can measure fear of recurrence of any type of cancer. The
6
7
8 Japanese version of the FCRI-SF was developed after obtaining permission from the original author
9
10
11 and using a forward-backward translation process. In this study, the measure will be included as a
12
13
14 secondary outcome after its validity and reliability have been ascertained.
15
16
17
18

19 Psychological distress: Hospital Anxiety and Depression Scale

20
21
22 The Hospital Anxiety and Depression Scale (HADS), a self-report questionnaire comprising
23
24
25 14 items, was developed for use with medically ill patients. The HADS consists of an anxiety and a
26
27
28 depression subscale (0–21 points each). The total score ranges from 0 to 42; a higher score indicates
29
30
31 more severe depression and anxiety.³⁸ The Japanese version of the HADS has been validated for
32
33
34 cancer populations.³⁹
35
36
37
38

39 Patients perceived needs: Short-form Supportive Care Needs Survey questionnaire

40
41
42 The Short-form Supportive Care Needs Survey questionnaire (SCNS-SF34) is a self-
43
44
45 administered instrument for assessing the perceived needs of cancer patients.⁴⁰ The SCNS-SF34
46
47
48 comprises 34 items covering five domains of need: psychological; health system and information;
49
50
51 physical and daily living; patient care and support; and sexuality. The total score is obtained by
52
53
54 summing all the subscales (range, 34–170). A higher score indicates a higher perceived need. The
55
56
57 validity and reliability of the Japanese version of SCNS-SF34 have been established.⁴¹
58
59
60

Posttraumatic Growth Inventory-Japanese version

The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report scale, originally developed in the United States.⁴² The PTGI includes items that measure positive psychological change experienced as a result of struggle with major life crises or traumatic events. The PTGI-J consists of four subscales: relating to others; new possibilities; personal strength; and spiritual change and appreciation of life. The total score ranges from 0 to 90; a higher score indicates more positive changes.⁴³

Satisfaction with intervention

To assess patients' perceived satisfaction with the intervention, we ask two additional items. The items are as follows. (1) "Please rate your satisfaction with the treatment in meeting your needs during the past 2 months by assigning it a score from 0 to 100; a score of 100 indicates complete satisfaction. A score of 60 is considered the passing level." (2) "Please rate your overall satisfaction with the treatment during the past 2 months by assigning it a score from 0 to 100; a score of 100 indicates complete satisfaction. A score of 60 is considered the passing level." A lower score indicates lower satisfaction. We used this method in our previous study.⁴⁴

Understanding e-consent

We will ask ten questions will be asked at week 0 related to the participants' understanding of e-

1
2 consent: purpose of the study; randomization; voluntarily participation; duration of study; risks and
3
4 benefits of study participation; free withdrawal anytime from the study; contact method for
5
6 questions and more detailed information about the study; method of participant identification
7
8 (uploading a photo of the hospital registration card); which of the video or written documentation in
9
10 the Web site was the more helpful in understanding the study contents ; and free opinions regarding
11
12 e-consent.
13
14
15
16
17
18
19
20
21

22 Qualitative evaluation of intervention

23
24 The intervention will consist of multiple complex components; accordingly, simple structured
25
26 telephone interviews will be conducted at 8 weeks for approximately 30 subjects willing to
27
28 participate in this additional survey to evaluate the perceived usability and/or merit of the complex
29
30 intervention. The interview items will be as follows. (1) “Please talk freely about the usefulness of
31
32 the smartphone PST and smartphone behavioral intervention.” (2) “Please talk freely about the
33
34 usefulness of each of the five steps of the smartphone PST and give your reasons for your
35
36 opinions.” (3) “Please talk freely about the usefulness of the two parts of the smartphone behavioral
37
38 intervention and give your reasons for your opinions.” (4) “Please talk freely about the effectiveness
39
40 and harms of the intervention, for example, the regular encouraging e-mail, and if any other
41
42 components contributed to improving or deteriorating your fear of recurrence.” If the participants
43
44 permit, the answers will be recorded using a voice recorder.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Sociodemographic and biomedical factors

e-PRO will also be used to obtain information about the patients' sociodemographic and biomedical status (marital status, level of education, and employment status) and biomedical information (physical function, time since diagnosis, clinical stage, and anti-cancer treatment).

Harms

No specific and serious adverse events are presumed in participants who use the Kaiketsu and Genki-Apps. However, using these apps might lead to psychological distress in some participants depending on their psychological state. We will evaluate these potential adverse events by qualitative evaluation of intervention as mentioned before.

Compensation

Our previous and preliminary trials suggest that few harms occur in this trial. However, if any health hazards occur, these will be covered by the National Health Insurance.

Data analysis

Primary analyses

To examine the treatment effect parameters of all randomly assigned subjects in the primary analysis set according to the ITT principle, we will analyze the primary outcome (CARS-J score at weeks 2, 4, and 8) using a generalized linear model with unstructured covariance and robust

1
2 standard errors. The fixed effects are CARS-J score at baseline, treatment allocation (intervention
3 versus control), time (2, 4, and 8 weeks as categorical variable), and treatment-by-time interaction;
4
5 the random effects are subjects (as intercepts). The primary outcome of interest is the difference in
6
7 CARS-J scores between the two groups at week 8. A two-sided P value of less than 0.05 will be
8
9 used to indicate statistical significance.
10
11
12
13
14
15
16
17
18

19 Secondary analyses

20
21 We will perform secondary analyses to supplement our primary analysis and to obtain a clearer
22
23 understanding of our clinical questions. The secondary analyses will use models similar to that of
24
25 the primary analysis and will also examine data for the secondary outcome measures. The
26
27 secondary analyses will include an assessment of the validity and reliability of FCR-J. These
28
29 analyses will be conducted for exploratory purposes.
30
31
32
33
34
35
36
37
38

39 Interim analyses

40
41 We do not plan any interim analysis.
42
43
44
45
46
47

48 Sample size estimation

49
50 Our previous phase II study revealed that the mean CARS-J scores were 12.8 at pre-intervention
51
52 (baseline), 12.4 at 4 weeks, and 11.2 at 8 weeks.²⁷ We assumed the following: the mean CARS-J
53
54 score at 2 weeks would be 12.6; the overall CARS-J scores in the control arms would not change
55
56
57
58
59
60

1
2 (12.8 at 0, 2, 4, and 8 weeks); the variance of the score would be 30 at all times; and the intra-class
3
4
5 correlation would be 0.82 (i.e., we assumed a compound symmetry working covariance structure).
6
7
8 Thus, for a sample size based on 0.8 power to detect a significant difference at $P = .05$ (two-sided),
9
10
11 211 participants would be required for each arm. Assuming that 5% of the initial entries would drop
12
13
14 out, we would need to recruit 444 participants into the trial.
15
16
17
18

19 Publication policy

20
21
22 The protocol paper and study results will be submitted to peer-reviewed journals. The first author of
23
24 the main paper will be a member of the steering committee (authors of the protocol paper). Another
25
26 person could be the first author if approved by the steering committee. The list of co-authors will be
27
28 determined before submitting each paper.
29
30
31
32
33
34
35

36 Study period

37
38
39 The study period of this trial will be from April 2017 to March 2020; the participant entry period
40
41 will be April 2018 to September 2019.
42
43
44
45
46
47

48 Patient and public involvement statement

49
50 The study protocol was designed with a patient (breast cancer survivor) and she participated in this
51
52 study as a researcher. She appropriately discussed with other patients when a patient's preferences
53
54 and/or opinions should be considered. She will play a same role on implementing the study. Thus
55
56
57

1
2 patients were and will be always involved in the study. Results of the study will be shown in the
3
4
5 study home page.
6
7
8
9

10 Ethics and dissemination

11
12
13 The present study is subject to ethical guidelines for clinical studies published by Japan's Ministry
14 of Education, Science and Technology and Ministry of Health, Labour and Welfare and the
15
16 modified Act on the Protection of Personal Information as well as the ethical principles established
17
18
19 for research on humans stipulated in the Declaration of Helsinki and further amendments thereto.
20
21
22

23
24
25 The protocol was approved by the institutional review board of Nagoya City University on
26
27
28 January 15, 2018 (ID: 60-00-1171). If important protocol modifications are needed, the
29
30
31 investigators will discuss them and report to the review board for approval.
32

33
34 With regard to dissemination, the results obtained will be submitted for publication in peer-
35
36 reviewed journals. The main and relevant findings will be presented at conferences.
37
38
39
40
41

42 Discussion

43
44
45 To our knowledge, the present study is the first trial investigating the efficacy of
46
47
48 smartphone-based psychological therapy for fear of recurrence among breast cancer survivors.
49
50
51 Considering the huge number of breast cancer survivors and low participant rate with other types of
52
53
54 therapeutic interventions, smartphone-based psychological therapy may offer a more accessible
55
56
57 option. As many cancer survivors return to their households and to work, easily accessible
58
59
60

1
2 therapeutic interventions may offer additional benefits in managing fear of recurrence. The present
3
4
5 study focuses on younger breast cancer patients who are iPhone users. However, many other
6
7
8 patients suffering from fear of recurrence use other types of smartphones (e.g., Android); in
9
10
11 addition, including patients aged 50 years and above would constitute a broader targeted population.
12
13
14 If the efficacy of the smartphone-based intervention program among our participants is confirmed,
15
16
17 the program will have promising applicability in real clinical settings.
18

19
20 The present study has some methodological limitations. First, not all patients who are
21
22 interested in and willing to use Kaiketsu-App and Genki-App possess a smartphone. This may
23
24
25 weaken the applicability of the results from this trial to all breast cancer patients with fear of
26
27
28 recurrence. Especially, the results may not be applicable to patients in developing countries and to
29
30
31 those with poor ICT literacy.
32

33
34 Second, we will use a wait-list control as the comparator owing to feasibility and ethical
35
36
37 considerations. The odds of response was found to be statistically significantly greater for no
38
39
40 treatment than the wait list.⁴⁵ The wait list may therefore lead to some overestimation of the
41
42
43 efficacy of smartphone-based psychotherapy.
44

45
46 Third, we will apply two types of psychotherapy—BA and PST—as interventions. Both
47
48
49 psychotherapeutic interventions consist of complex, multifactorial components. Thus, if the
50
51
52 interventions prove superior to the wait-list controls, we cannot determine which intervention and
53
54
55 components are most efficacious or beneficial in managing fear of recurrence. However, to
56
57
58 overcome this limitation, we will adopt a mixed-method design and can check adherence with each
59
60

1
2 intervention (detailed in “Methods and analysis”) so that we can identify the most useful
3
4
5 components of the interventions.
6

7
8 Fourth, we will request that participants upload images for identification (they will be
9
10 especially encouraged to attach a photo of the hospital registration card) to avoid individuals
11
12 masquerading as breast cancer patients. However, possible deception cannot be completely
13
14 prevented in our recruitment system.
15
16

17
18
19 **Finally, lack of the third group, which is the in-person PST and BA treatment arm,**
20
21 **would lessen the impact of this study. If we set the in-person PST and BA treatment arm to**
22
23 **compare effect sizes in this group to the other two groups, we would be able to dissect the**
24
25 **specific mechanisms of change.**
26
27
28
29
30
31
32

33 Author contributions

34
35
36 TA, TAF, and MH developed the smartphone applications and MU and FI also contributed to
37
38 modification of these applications. TA, TY, MK, FK, NS, TM, TAF, HI, and YU participated in the
39
40 design of the study. TY played a chief role of the statistical parts. TA drafted the manuscript. All
41
42 authors participated in, read and approved final manuscript.
43
44
45
46
47
48
49

50 Funding

51
52
53 This study is supported by a Grant-in-Aid for Japan Agency for Medical Research and Development
54
55 (Number JP17ck0106324h). This study is also partly supported in part by a Grant-in-Aid for
56
57

1
2 Scientific Research (Number 25285194) and Young scientists (Number 17k13942) from the
3
4 Japanese Ministry of Education, Culture, Science, and Technology, grant from Nagoya City
5
6 University, Foundation for Promotion of Cancer Research in Japan and The National Cancer Center
7
8
9
10 Research and Development Fund (Number 27-A-3 & 30-A-11).
11
12
13
14
15
16
17
18

19 Competing interests

20
21
22 The authors have no conflicts of interests to declare that may be affected by the publication of the
23
24 manuscript. TA has received lectures fees from AstraZeneca, Daiichi-Sankyo, Dainippon-
25
26 Sumitomo, Eizai, Hisamitsu, Lilly, MSD, Meiji-seika Pharma, Mochida, Pfizer, Novartis, Otsuka,
27
28 Shionogi, Takeda, Tanabe-Mitsubishi, Terumo, and Yoshitomi. TA has received research funds from
29
30 Daiichi-Sankyo, Eizai, MSD, Pfizer, Novartis, and Tanabe-Mitsubishi. TY received research funds
31
32 from AC MEDICAL INC., A2 Healthcare Corporation, CAC Croit Corporation, FMD K&L Japan
33
34 K.K., Japan Tobacco Inc., Japan Media Corporation, Luminary Medical K.K., Medidata Solutions,
35
36 Inc., ONO PHARMACEUTICAL CO., LTD., Kyowa Hakko Kirin Co., Ltd., DAIICHI SANKYO
37
38 COMPANY, LIMITED. Also TY received consulting fee from ONO PHARMACEUTICAL CO.,
39
40 LTD., Kowa Company, Ltd., Japan Tobacco Inc., CHUGAI PHARMACEUTICAL CO.,LTD.,
41
42 TSUMURA & CO., CAC Croit Corporation, TSUMURA & CO., ASAHI INTECC CO., LTD.,
43
44 Asahi Kasei Pharma Corporation, Clinical Trial Co.,Ltd. FK has received lecture fees from MSD.
45
46
47
48
49
50
51
52
53
54
55
56 TAF has received lecture fees from Janssen, Meiji, Mitsubishi-Tanabe, MSD and Pfizer. He has
57
58
59
60

1
2 received research support from Mitsubishi-Tanabe. HI has received lecture fees from Daiichi
3
4
5 Sankyo, Chugai, AstraZeneca, Pfizer, and Eisai. He has received research support from Daiichi
6
7
8 Sankyo, Chugai, AstraZeneca, Pfizer, MSD, Kyowahakou Kirin, GSK, Lilly, Novartis, and a Bayer.
9
10
11 YU has received lectures fees from Asteras, Daiichi-Sankyo, Dainippon-Sumitomo, Eizai, Janssen,
12
13
14 Kyowahakko-Kirin, Ono, Meiji-seika Pharma, Mochida, Pfizer, Novartis, Otsuka, Sawai, Shionogi,
15
16
17 Taiho, Tanabe-Mitsubishi, Tsumura Pharma.
18
19
20
21

22 Trial status

23
24
25 The randomized trial, which commenced on 2th, April, 2018, currently enrolls participants. The
26
27
28 estimated end date for this study is in March 2020.
29
30
31
32

33 Acknowledgments

34
35
36 We thank to Ms. T Mashiko for her data management support. We also thank to Ms. Y Yanase, Ms.
37
38
39 A Nomura , Ms. K Tojima, Ms. I. Sakakima, and Ms. K Kobori for their support for the study. We
40
41
42 thank Edanz Group (www.edanzediting.com) for editing a draft of this manuscript.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 Figure legend
3

4
5 Fig. 1 Participant flow diagram
6
7

8
9
10
11 Fig. 2 Kaiketsu App
12

13
14 Application for smartphone based problem-solving treatment
15
16
17
18

19
20 Fig. 3 Genki App
21

22
23 Application for smartphone based behavioral activation
24
25
26
27

28
29 Fig. 4 Study management system
30

31 e-Consent: electric informed consent; e-PRO: electric patient reported outcome
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Ito Y, Miyashiro I, Ito H, et al. Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. *Cancer Sci*. 2014;105: 1480-1486.
2. Hodgkinson K, Butow P, Hunt GE, Pendlebury S, Hobbs KM, Wain G. Breast cancer survivors' supportive care needs 2-10 years after diagnosis. *Support Care Cancer*. 2007;15: 515-523.
3. Hartl K, Schennach R, Muller M, et al. Quality of life, anxiety, and oncological factors: a follow-up study of breast cancer patients. *Psychosomatics*. 2010;51: 112-123.
4. Gordon NH, Siminoff LA. Measuring quality of life of long-term breast cancer survivors: the Long Term Quality of Life-Breast Cancer (LTQOL-BC) Scale. *J Psychosoc Oncol*. 2010;28: 589-609.
5. Akechi T, Okuyama T, Endo C, et al. Patient's perceived need and psychological distress and/or quality of life in ambulatory breast cancer patients in Japan. *Psychooncology*. 2011;20: 497-505.
6. Harrison JD, Young JM, Price MA, Butow PN, Solomon MJ. What are the unmet supportive care needs of people with cancer? A systematic review. *Support Care Cancer*. 2009;17: 1117-1128.
7. Koch L, Jansen L, Brenner H, Arndt V. Fear of recurrence and disease progression in long-term (≥ 5 years) cancer survivors--a systematic review of quantitative studies. *Psychooncology*. 2013;22: 1-11.
8. Simard S, Thewes B, Humphris G, et al. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. *J Cancer Surviv*. 2013;7: 300-322.
9. Lengacher CA, Reich RR, Paterson CL, et al. Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial. *J Clin Oncol*. 2016.
10. Lengacher CA, Johnson-Mallard V, Post-White J, et al. Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. *Psychooncology*. 2009;18: 1261-1272.
11. Butow PN, Turner J, Gilchrist J, et al. Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence. *J Clin Oncol*. 2017;35: 4066-4077.
12. van de Wal M, Thewes B, Gielissen M, Speckens A, Prins J. Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial. *J Clin Oncol*. 2017;35: 2173-2183.
13. Fukui S, Kugaya A, Okamura H, et al. A psychosocial group intervention for Japanese women with primary breast carcinoma. *Cancer*. 2000;89: 1026-1036.
14. Fukui S, Kugaya A, Kamiya M, et al. Participation in psychosocial group intervention among Japanese women with primary breast cancer and its associated factors. *Psychooncology*. 2001;10: 419-427.
15. Akechi T, Momino K, Yamashita T, et al. Contribution of problem-solving skills to fear of recurrence in breast cancer survivors. *Breast Cancer Res Treat*. 2014;145: 205-210.
16. Akechi T, Hirai K, Motooka H, et al. Problem-solving therapy for psychological distress in Japanese cancer patients: preliminary clinical experience from psychiatric consultations. *Jpn J Clin Oncol*. 2008;38: 867-870.
17. Momino K, Miyashita M, Yamashita H, et al. Feasibility study of collaborative care intervention for the perceived care needs among breast cancer women undergoing adjuvant therapy after surgery. *Jpn J*

1 Clin Oncol. in submission.

2
3 18. Hirai K, Motooka H, Ito N, et al. Problem-solving therapy for psychological distress in Japanese
4 early-stage breast cancer patients. *Jpn J Clin Oncol.* 2012;42: 1168-1174.

5
6 19. Patel V, Weobong B, Weiss HA, et al. The Healthy Activity Program (HAP), a lay counsellor-
7 delivered brief psychological treatment for severe depression, in primary care in India: a randomised
8 controlled trial. *Lancet.* 2017;389: 176-185.

9
10 20. Nezu AM, Nezu CM, Felgoise SH, McClure KS, Houts PS. Project Genesis: assessing the efficacy of
11 problem-solving therapy for distressed adult cancer patients. *J Consult Clin Psychol.* 2003;71: 1036-
12 1048.

13
14 21. Dimidjian S, Goodman SH, Sherwood NE, et al. A pragmatic randomized clinical trial of behavioral
15 activation for depressed pregnant women. *J Consult Clin Psychol.* 2017;85: 26-36.

16
17 22. Hopko DR, Armento ME, Robertson SM, et al. Brief behavioral activation and problem-solving
18 therapy for depressed breast cancer patients: randomized trial. *J Consult Clin Psychol.* 2011;79: 834-
19 849.

20
21 23. Andrews G, Cuijpers P, Craske MG, McEvoy P, Titov N. Computer therapy for the anxiety and
22 depressive disorders is effective, acceptable and practical health care: a meta-analysis. *PLoS One.*
23 2010;5: e13196.

24
25 24. So M, Yamaguchi S, Hashimoto S, Sado M, Furukawa TA, McCrone P. Is computerised CBT really
26 helpful for adult depression?-A meta-analytic re-evaluation of CCBT for adult depression in terms of
27 clinical implementation and methodological validity. *BMC Psychiatry.* 2013;13: 113.

28
29 25. Watts S, Mackenzie A, Thomas C, et al. CBT for depression: a pilot RCT comparing mobile phone vs.
30 computer. *BMC Psychiatry.* 2013;13: 49.

31
32 26. Mantani A, Kato T, Furukawa TA, et al. Smartphone Cognitive Behavioral Therapy as an Adjunct to
33 Pharmacotherapy for Refractory Depression: Randomized Controlled Trial. *J Med Internet Res.*
34 2017;19: e373.

35
36 27. Imai F, Momino K, Katsuki F, et al. Smartphone problem-solving therapy to reduce fear of
37 recurrence among breast cancer survivors: A single-arm open pilot study in submission.

38
39 28. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for
40 protocols of clinical trials. *Bmj.* 2013;346: e7586.

41
42 29. Mynors-Wallis L. Problem-solving treatment for anxiety and depression: A practical guide. New
43 York: Oxford University Press, 2005.

44
45 30. Watanabe N, Horikoshi M, Yamada M, et al. Adding smartphone-based cognitive-behavior therapy
46 to pharmacotherapy for major depression (FLATT project): study protocol for a randomized controlled
47 trial. *Trials.* 2015;16: 293.

48
49 31. Momino K, Akechi T, Yamashita T, et al. Psychometric properties of the Japanese version of the
50 Concerns About Recurrence Scale (CARS-J). *Jpn J Clin Oncol.* 2014;44: 456-462.

51
52 32. Crist JV, Grunfeld EA. Factors reported to influence fear of recurrence in cancer patients: a
53 systematic review. *Psychooncology.* 2013;22: 978-986.

54
55 33. Services USDoHaH, (OHRP) OfHRP, Administration FaD, et al. Use of Electronic Informed Consent
56 Questions and Answers <https://www.fda.gov/downloads/drugs/guidances/ucm436811.pdf>. 2016.

- 1
2 34. Vickberg SM. The Concerns About Recurrence Scale (CARS): a systematic measure of women's fears
3 about the possibility of breast cancer recurrence. *Ann Behav Med.* 2003;25: 16-24.
4
5 35. Momino K, Akechi T, Yamashita T, et al. Psychometric properties of the Japanese version of the
6 Concerns about Recurrence Scale (CARS-J). *Jpn J Clin Oncol.* in press.
7
8 36. Simard S, Savard J. Fear of Cancer Recurrence Inventory: development and initial validation of a
9 multidimensional measure of fear of cancer recurrence. *Support Care Cancer.* 2009;17: 241-251.
10
11 37. Simard S, Savard J. Screening and comorbidity of clinical levels of fear of cancer recurrence. *J*
12 *Cancer Surviv.* 2015;9: 481-491.
13
14 38. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand.* 1983;67:
15 361-370.
16
17 39. Kugaya A, Akechi T, Okuyama T, Okamura H, Uchitomi Y. Screening for psychological distress in
18 Japanese cancer patients. *Jpn J Clin Oncol.* 1998;28: 333-338.
19
20 40. Boyes A, Girgis A, Lecathelinais C. Brief assessment of adult cancer patients' perceived needs:
21 development and validation of the 34-item Supportive Care Needs Survey (SCNS-SF34). *J Eval Clin*
22 *Pract.* 2009;15: 602-606.
23
24 41. Okuyama T, Akechi T, Yamashita H, et al. Reliability and validity of the Japanese version of the
25 Short-form Supportive Care Needs Survey questionnaire (SCNS-SF34-J). *Psychooncology.* 2009;18:
26 1003-1010.
27
28 42. Tedeschi RG, Calhoun LG. The Posttraumatic Growth Inventory: measuring the positive legacy of
29 trauma. *J Trauma Stress.* 1996;9: 455-471.
30
31 43. Taku K, Calhoun LG, Tedeschi RG, Gil-Rivas V, Kilmer RP, Cann A. Examining posttraumatic
32 growth among Japanese university students. *Anxiety Stress Coping.* 2007;20: 353-367.
33
34 44. Akizuki N, Akechi T, Nakanishi T, et al. Development of a brief screening interview for adjustment
35 disorders and major depression in patients with cancer. *Cancer.* 2003;97: 2605-2613.
36
37 45. Furukawa TA, Noma H, Caldwell DM, et al. Waiting list may be a placebo condition in
38 psychotherapy trials: a contribution from network meta-analysis. *Acta Psychiatr Scand.* 2014;130: 181-
39 192.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Fig. 1 Participant flow diagram

190x285mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 2 Kaiketsu App
Application for smartphone based problem-solving treatment

190x285mm (300 x 300 DPI)




Fig. 3 Genki App
Application for smartphone based behavioral activation

190x285mm (300 x 300 DPI)




Fig. 4 Study management system
e-Consent: electric informed consent; e-PRO: electric patient reported outcome

285x190mm (300 x 300 DPI)

An appendix table

Details of sessions in smartphone problem-solving and behavioral activation therapies

| Smartphone app | Details of each session |
|---|---|
| Problem-solving therapy (9 sessions) | <ol style="list-style-type: none"> 1. Outline of problem-solving therapy 2. Introduction of 5 step of problem-solving 3. Example of problem-solving 4. First step (identification, definition, and breakdown of the problem) 5. Second step (establishing achievable goals) 6. Third step (generating solutions) 7. Fourth (evaluating and choosing the solution) and fifth step (implementing the chosen solution and evaluating the outcome after implementation) 8. Actual training 9. Concluding session |
| Behavioral activation therapy (2 sessions) | <ol style="list-style-type: none"> 1. Outline and introduction of behavioral activation therapy including two types of activation (e.g., do pleasurable activity again and challenge new activity) and their actual training 2. Review of the session, learning knack of behavioral activation and concluding session |

SMILE project



乳がん患者の再発不安・恐怖に対するスマートフォン問題解決療法
および行動活性化療法の有効性のための無作為割付比較試験

メニュー

ホーム

研究説明ビデオ

研究概要

研究説明文書

Q & A

研究参加

ホーム

はじめに

このホームページは Smile project 研究の内容を説明しています。研究に参加を希望される方は、研究説明ビデオ、研究概要、研究説明文書をご覧ください。

研究説明文書

この試験は、公立大学法人 名古屋市立大学大学院 医学研究科長および名古屋市立大学病院長が設置する医学系研究倫理審査委員会（所在地：名古屋市瑞穂区瑞穂町字川澄1）において医学、歯学、薬学その他の医療又は臨床試験に関する専門家や専門以外の方々により倫理性や科学性が十分であるかどうかの審査を受け、実施することが承認されています。またこの委員会では、この試験が適正に実施されているか継続して審査を行います。なお、本委員会にかかわる規程等は、以下、ホームページよりご確認いただくことができます。

名古屋市立大学病院 臨床研究開発支援センター ホームページ “患者の皆様へ” <http://ncu-cr.jp/patient>

1 説明書の趣旨

【研究参加をお願いする理由】

皆様におかれましては、療養しながら様々な負担を抱えた日々を送っていらっしゃるかと推察いたします。私たちのグループは、がんの患者さんによりよいケアを提供するための研究に取り組んでおります。がんの手術後再発なく過ごされていらっしゃる皆様において、再発に対して不安に思われていることを深く理解しております。現在、私たちの研究グループは、スマー

トフォンを用いて日常生活の困り事を解決し、活動の幅を広げることで、再発の不安をどれくらい和らげることができるのかを知るための研究を行っています。この支援方法は有用である可能性がありますが、まだ科学的に証明されていません。

以下に研究の内容について説明してありますので、よくお読みになった上で、ご協力いただける場合には、ウェブで同意をお願いいたします。操作が難しい場合、[こちらから文書をダウンロード](#)していただき、書面として同意書にご署名をお願いいたします。

【研究目的】

多くのがんの患者さんが、治療後の再発の不安を抱えていらっしゃる事が明らかになっています。がんの患者さんの不安や恐怖に対し、日常生活の困り事を解決していくこと（これを「問題解決療法」といいます）、楽しくやりがいのある活動を生活に取り入れること（これを「行動活性化療法」といいます）を通して気持ちを和らげることが有効であると言われています。また、近年、スマートフォンが普及し、生活のうえで身近なものになってきていることを踏まえ、私たちのグループはスマートフォンを用いた問題解決療法、行動活性化療法を開発いたしました。この研究は、スマートフォンを

1
2
3
4
5
6 用いてこれら支援を行うことによって、どの程度、精神的な苦痛を和らげる
7
8
9 ことができるかを調べます。

12 【研究への協力について】

15 1) 研究方法について

18 このスマートフォンを用いたアプリによる治療が、皆様にとって本当に有
19
20 用であるかどうかを明らかにするために、コンピューターを使ってランダム
21
22 に五分五分の確率で、2つのグループに分けて研究を行います。この研究を
23
24 無作為割り付け対照試験といいます。この方法では患者さんの希望でもな
25
26 く、医師が選択するのでもなく、誰の意志も入れずに決めることができま
27
28 す。この方法は世界中の臨床試験や医学研究で使われており、治療法に対す
29
30 る医師の先入観が入らずに、より客観的に治療法の効果を確認することが出
31
32 来ます。

33
34
35
36
37
38
39
40 今回、研究への参加に同意をいただけましたら、皆様は a) 「すぐにスマ
41
42 ホアプリを開始するグループ」または b) 「2ヶ月（8週間）後からスマホア
43
44 プリ開始するグループ」のどちらかに割り付けられます。b) 「2ヶ月後から
45
46 スマホアプリ開始するグループ」に割り当てられた場合は、研究開始後2カ
47
48 月（8週間）たって皆様のご希望があれば、アプリを使用し参加して頂くこ
49
50 とができます。

2) 皆様に具体的にお願いしたいこと

①アンケート調査

研究に参加していただく皆様に対して、普段の治療やスマートフォンを用いた問題解決療法、行動活性化療法が行われる前後の状態を把握するために、アンケート調査を行います。これによって不安などの気持ちの状態、皆様が必要とする援助（これをニードといいます）、生活の質（クオリティ・オブ・ライフ）などを把握します。

a) 「すぐにスマホアプリを開始するグループ」に割り付けられた方は、調査を5回実施させて頂く予定で、時期は研究に参加されてから同意時（第0週）、第2週、第4週、第8週、第24週になります。

b) 「2ヶ月（8週間）後からスマホアプリ開始するグループ」に割り付けられた方は、調査を4回実施させて頂く予定で、時期は研究に参加されてから同意時（第0週）、第2週、第4週、第8週になります。

この時期になりましたら、iPhoneのウェブ上でアンケートにお答えください。（アンケートの入力が完了していない場合、研究事務局からメールやお電話をさせて頂く予定ですのでご了承ください）。

また、a) 「すぐにスマホアプリを開始するグループ」に割り付けられた方の中でご協力がいただける方に、8週後の時点で、アプリの有用性をどれぐ

1
2
3
4
5
6 らい感じたか、またどのような点がよかったかなど、電話で聞き取りをさせ
7
8
9 ていただく予定です。

10 11 12 ②スマートフォンを用いた問題解決療法、行動活性化療法への参加

13
14
15 1回目、同意時（第0週）のアンケート記入後、a) 「すぐにスマホアプリ
16
17 を開始するグループ」に割り付けられた方は、スマートフォンを用いた問題
18
19 解決療法、行動活性化療法をすぐに実施していただきます。スマートフォン
20
21 を用いた問題解決療法、行動活性化療法は「解決アプリ」「元気アプリ」を
22
23 使い、ご自分で進めていただきます（アプリは週におおよそ各30分程度かか
24
25 ります。アプリはたくさん実施していただいたほうがより効果的ですので、
26
27 みなさんの自習を励ますために、事務局からメールを第8週までは毎週お送
28
29 りいたします。）。b) 「2ヶ月（8週間）後からスマホアプリ開始するグル
30
31 ープ」に割り付けられた方は、ご希望に応じて、2ヶ月（8週間）後からア
32
33 プリを使っていただきます。


34 35 36 ③アプリ内容についての調査

37
38
39 【a) 「すぐにスマホアプリを開始するグループ」に割り付けられた方の
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
み】

51
52 研究が終了した時点（第8週）で、協力して頂ける方に、アプリを使って
53
54
55
56
57
58
59
60
みてよかった点や問題解決療法、行動活性化療法で役に立った部分とその理

由について調査をさせていただきます。調査は電話で行わせて頂きます（10分程度を予定しております）。

【研究の流れと研究参加基準】



以下のすべてに当てはまる方は、研究に参加いただけます。

- 1) 同意するときに 20 歳以上 49 歳以下の女性
- 2) 乳がん患者
- 3) 再発や転移がない
- 4) 同意するときに手術から 1 年以上経過していること
- 5) アンケートに記入・協力できる
- 6) iPhone または iPad を使用していること (iPad についてはネット環境下での使用をお願いできる方)

また、以下の条件に 1 つでも当てはまる方は、この研究に参加いただけません。

- 1) 重い身体疾患 (症状のために家事や軽作業ができない) や乳がん以外のがんをもっている、または、かかったことがある (完治を含む)
- 2) 日本語の読み書きが難しい
- 3) 現在、心療内科、精神科に受診している
- 4) 問題解決療法、行動活性化療法、認知行動療法を経験したことがある
- 5) 研究者が研究への参加を不適當であると判断させていただいた場合

| | 項目 | 第0週 | 第2週 | 第4週 | 第8週 | 第24週 |
|-------------|--------------|-----|-----|-----|--------------|------|
| 研究者 | 説明と同意 | ○ | | | | |
| データセンタ ー | 割り付け | ○ | | | | |
| 参加者 | アンケート | ○ | ○ | ○ | ○ | ○(*) |
| | 治療満足度 | | | | ○(*) | |
| | アプリの内 容調査 | | | | ○(*) (**) | |

(*) すぐにスマホアプリを開始するグループのみ

(**) 対象はご協力いただける一部の方のみ

【研究参加は自由意思に任されること】

本研究へのご協力は皆様個人の自由意思によるものです。いったん同意された後でも、理由を明確にすることなくいつでも同意を撤回することができます。不参加や途中撤回の場合でも、何ら不利益は生じません。

2 研究に参加した場合に予想される利益および不利益

本研究では、再発の不安や恐怖に対してスマートフォンを用いた問題解決療法、行動活性化療法を行います。研究に参加して頂くことによって、精神的な負担が軽減し、生活の質が改善する可能性があります。

また、本研究は、アンケートへの記入、メール、スマートフォンのアプリ操作が主で、皆様の身体に与える悪影響はございません。しかしながら、肉体的なことに触れることで皆様に不快感を与えることがあるかもしれません。一方、これまでの私どもの同様の研究の経験からは、不利益はほとんどないと考えております。

3 健康被害等への補償

本研究は、ほぼ危険性は伴わないため、研究を行うことによる健康被害に対して補償や賠償保険などは準備しておりません。もし、身体状態や精神状態が悪化した場合には、お手数ですがかかりつけの医療機関でご相談いただければ幸いです。

4 研究の資金源等

本研究は以下の研究費の支援のもと行われています。

- 日本医療研究開発機構研究費「乳がん患者の再発不安・恐怖に対するスマートフォン行動活性化および問題解決療法の有効性-無作為割付比較試験（主任研究者 明智龍男）」
- 名古屋市立大学特別研究奨励費「乳がんサバイバーの再発不安・恐怖に対する Information and communication technology (ICT) を応用した問題解決療法の有用性に関する予備的検討（研究代表者 明智龍男）」
- 文部科学省科学研究費補助金基盤研究 B 「致命的疾患の再発・転移の不安、恐怖の評価法の確立および新規心理学的介入方法の開発（主任研究者 明智龍男）」
- 国立がん研究センター研究開発費「支持療法の開発および検証のための基盤整備（主任研究者 内富庸介）」
- 文部科学省科学研究費補助金若手研究 B 「がん罹患に伴う心理的成長を促すスマートフォンによる問題解決療法の開発と効果検証（主任研究者 今井文信）」

5 個人情報情報の保護

研究において得られたプライバシーに関する情報は厳重に守られます。皆様の名前などの個人を識別する情報は、この研究の結果の報告や発表に使用されることはありません。

6 研究計画等の開示

皆様が希望すれば、他の参加者の個人情報や本研究の独創性の確保に支障がない範囲内で、研究計画および研究の方法に関する資料を閲覧することができます。閲覧希望の場合は事務局までお問合せください。

7 研究結果及び記録の公表

個人情報が分からないようにした上で、本研究の結果を統計学的に分析し、結果及び臨床試験を通じて得られた皆様に係わる記録が、医学および看護学の発展のため学会や学術雑誌等で公表される予定であることをご了承下さい。なお、アプリによる治療経過における治療内容、アンケートの結果などすべてが分析の対象となります。研究の進み具合やその成果については、ご希望がありましたら説明いたします。

8 研究から生ずる知的所有権について

本研究によって特許が生じた場合は、名古屋市立大学に帰属するものいたします。

9 研究期間中のデータ等について

この研究で得られたアンケート（データ）の結果は、主にスマートフォンを用いた問題解決療法、行動活性化療法の介入前後の状態を比較するために

1
2
3
4
5
6 用います。これらデータ（要配慮個人情報）は、別に作成した対応表で名前
7
8
9 や年齢などの個人情報と照合できるような形にいたします。なお前述の対応
10
11
12 表は、名古屋市立大学大学院医学研究科精神・認知・行動医学分野内の金庫
13
14
15 にて厳重に保管いたします。

10 研究終了後のデータ等について

21 この研究で得られたデータは、原則として研究終了後5年で、名古屋市立
22
23
24 大学病院の機密書類として廃棄します。

25
26
27 将来、本データを別の医学・看護学の研究に用いる場合には、改めてその
28
29
30 研究について倫理審査委員会に申請し、承認を得た上で実施いたします。

11 費用負担について

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

スマホアプリはすべて無料をご利用いただけます。ただし、ご利用の携帯
電話会社にはアプリの使用時やデータの送受信にかかる通信料はお支払い
いただく必要があります。アプリを使って頂くためにパケット定額サービスの
加入をお勧めします。また、本研究へのご参加に関して、些少なから謝礼
(アマゾンギフト券を予定)をお送りさせていただきます。

研究組織

研究責任者

明智龍男 名古屋市立大学大学院医学研究科・精神・認知・行動医学 教授

研究分担者

岩田 広治 愛知県がんセンター中央病院乳腺科 部長兼副院長

桜井 なおみ キャンサー・ソリューションズ株式会社 代表取締役社長

古川 壽亮 京都大学大学院医学研究科健康増進・行動学分野 教授

堀越 勝 国立精神・神経医療研究センター認知行動療法センター セ

ンター長

内富 庸介 国立がん研究センター支持療法開発センター センター長

今井 文信 名古屋市立大学病院緩和ケア部 臨床研究医

内田 恵 名古屋市立大学病院緩和ケア部 助教

香月 富士日 名古屋市立大学看護学部 教授

樫野 香苗 名古屋市立大学看護学部 准教授

山口 拓洋 東北大学大学院医学系研究科 教授

宮地 天平 国立がん研究センター社会と健康研究センター健康支援研究

部

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

益子 友恵 国立がん研究センター社会と健康研究センター健康支援研究

部

For peer review only

研究参加

本研究への参加を希望される方は、必要事項をご記入いただき、参加に関する条件に該当しているかを確認の上「参加する」ボタンを1回押してください。

| | |
|---|-------------------------------|
| 氏名 | 姓 名 |
| ふりがな | 姓 名 |
| 年齢 | ※20-49歳がプルダウン等で選択できるようにしてはどうか |
| 携帯番号 | |
| メールアドレス 携帯電話のメールアドレスを入力される方は、予めドメイン「mail.sports-web.jp (仮)」からのメールを受信できる設定にしてください。 Gmail アドレスをご使用の方は必ず「迷惑メール」をご確認ください。 | |
| メールアドレス (確認用) | |
| 乳がん治療のため通院 されている病院名 | |

- ホームページ上の研究説明ビデオおよび研究概要を確認した
- 申込時の年齢が 20 歳以上から 49 歳以下である
- 乳がんと診断されており、現在までに再発・転移はない
- 乳がんの手術後 1 年以上経過している
- iPhone または iPad を日常的に使用している

研究に参加する

(研究参加ボタンを押した後)

研究に申込みいただき、ありがとうございました。

参加受付のメールが登録いただいたメールアドレスに届きますので、ご確認をお願いいたします。後日、事務局から問い合わせの電話をさせていただきます。

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

| | | Reporting Item | Page Number |
|---|---------------------|--|-------------|
| Title | #1 | Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym | 1 |
| Trial registration | #2a | Trial identifier and registry name. If not yet registered, name of intended registry | 5 |
| Trial registration: data set | #2b | All items from the World Health Organization Trial Registration Data Set | 5 |
| Protocol version | #3 | Date and version identifier | 3 |
| Funding | #4 | Sources and types of financial, material, and other support | 25 |
| Roles and responsibilities: contributorship | #5a | Names, affiliations, and roles of protocol contributors | 25 |
| Roles and responsibilities: | #5b | Name and contact information for the trial sponsor | 25 |

| | | | | |
|----|----------------------|----------------------|---|-------|
| 1 | sponsor contact | | | |
| 2 | information | | | |
| 3 | | | | |
| 4 | Roles and | #5c | Role of study sponsor and funders, if any, in study design; | 25 |
| 5 | responsibilities: | | collection, management, analysis, and interpretation of | |
| 6 | sponsor and funder | | data; writing of the report; and the decision to submit the | |
| 7 | | | report for publication, including whether they will have | |
| 8 | | | ultimate authority over any of these activities | |
| 9 | | | | |
| 10 | | | | |
| 11 | | | | |
| 12 | Roles and | #5d | Composition, roles, and responsibilities of the coordinating | 13-14 |
| 13 | responsibilities: | | centre, steering committee, endpoint adjudication | |
| 14 | committees | | committee, data management team, and other individuals or | |
| 15 | | | groups overseeing the trial, if applicable (see Item 21a for | |
| 16 | | | data monitoring committee) | |
| 17 | | | | |
| 18 | | | | |
| 19 | | | | |
| 20 | Background and | #6a | Description of research question and justification for | 6-8 |
| 21 | rationale | | undertaking the trial, including summary of relevant studies | |
| 22 | | | (published and unpublished) examining benefits and harms | |
| 23 | | | for each intervention | |
| 24 | | | | |
| 25 | | | | |
| 26 | | | | |
| 27 | Background and | #6b | Explanation for choice of comparators | 8 |
| 28 | rationale: choice of | | | |
| 29 | comparators | | | |
| 30 | | | | |
| 31 | | | | |
| 32 | Objectives | #7 | Specific objectives or hypotheses | 8 |
| 33 | | | | |
| 34 | | | | |
| 35 | Trial design | #8 | Description of trial design including type of trial (eg, parallel | 8-9 |
| 36 | | | group, crossover, factorial, single group), allocation ratio, | |
| 37 | | | and framework (eg, superiority, equivalence, non-inferiority, | |
| 38 | | | exploratory) | |
| 39 | | | | |
| 40 | | | | |
| 41 | | | | |
| 42 | Study setting | #9 | Description of study settings (eg, community clinic, | 10-11 |
| 43 | | | academic hospital) and list of countries where data will be | |
| 44 | | | collected. Reference to where list of study sites can be | |
| 45 | | | obtained | |
| 46 | | | | |
| 47 | | | | |
| 48 | Eligibility criteria | #10 | Inclusion and exclusion criteria for participants. If applicable, | 10-11 |
| 49 | | | eligibility criteria for study centres and individuals who will | |
| 50 | | | perform the interventions (eg, surgeons, psychotherapists) | |
| 51 | | | | |
| 52 | | | | |
| 53 | | | | |
| 54 | Interventions: | #11a | Interventions for each group with sufficient detail to allow | 9-10 |
| 55 | description | | replication, including how and when they will be | |
| 56 | | | administered | |
| 57 | | | | |
| 58 | | | | |
| 59 | | | | |
| 60 | | | | |

| | | | | |
|----|----------------------|----------------------|--|-------|
| 1 | Interventions: | #11b | Criteria for discontinuing or modifying allocated | 15 |
| 2 | modifications | | interventions for a given trial participant (eg, drug dose | |
| 3 | | | change in response to harms, participant request, or | |
| 4 | | | improving / worsening disease) | |
| 5 | | | | |
| 6 | | | | |
| 7 | Interventions: | #11c | Strategies to improve adherence to intervention protocols, | 10 |
| 8 | adherence | | and any procedures for monitoring adherence (eg, drug | |
| 9 | | | tablet return; laboratory tests) | |
| 10 | | | | |
| 11 | | | | |
| 12 | | | | |
| 13 | Interventions: | #11d | Relevant concomitant care and interventions that are | 15 |
| 14 | concomitant care | | permitted or prohibited during the trial | |
| 15 | | | | |
| 16 | | | | |
| 17 | Outcomes | #12 | Primary, secondary, and other outcomes, including the | 16-20 |
| 18 | | | specific measurement variable (eg, systolic blood pressure), | |
| 19 | | | analysis metric (eg, change from baseline, final value, time | |
| 20 | | | to event), method of aggregation (eg, median, proportion), | |
| 21 | | | and time point for each outcome. Explanation of the clinical | |
| 22 | | | relevance of chosen efficacy and harm outcomes is strongly | |
| 23 | | | recommended | |
| 24 | | | | |
| 25 | | | | |
| 26 | | | | |
| 27 | | | | |
| 28 | Participant timeline | #13 | Time schedule of enrolment, interventions (including any | Fig 1 |
| 29 | | | run-ins and washouts), assessments, and visits for | |
| 30 | | | participants. A schematic diagram is highly recommended | |
| 31 | | | (see Figure) | |
| 32 | | | | |
| 33 | | | | |
| 34 | | | | |
| 35 | Sample size | #14 | Estimated number of participants needed to achieve study | 21-22 |
| 36 | | | objectives and how it was determined, including clinical and | |
| 37 | | | statistical assumptions supporting any sample size | |
| 38 | | | calculations | |
| 39 | | | | |
| 40 | | | | |
| 41 | | | | |
| 42 | Recruitment | #15 | Strategies for achieving adequate participant enrolment to | 11 |
| 43 | | | reach target sample size | |
| 44 | | | | |
| 45 | | | | |
| 46 | Allocation: sequence | #16a | Method of generating the allocation sequence (eg, | 8, 13 |
| 47 | generation | | computer-generated random numbers), and list of any | |
| 48 | | | factors for stratification. To reduce predictability of a random | |
| 49 | | | sequence, details of any planned restriction (eg, blocking) | |
| 50 | | | should be provided in a separate document that is | |
| 51 | | | unavailable to those who enrol participants or assign | |
| 52 | | | interventions | |
| 53 | | | | |
| 54 | | | | |
| 55 | | | | |
| 56 | | | | |
| 57 | Allocation | #16b | Mechanism of implementing the allocation sequence (eg, | 8, 13 |
| 58 | concealment | | central telephone; sequentially numbered, opaque, sealed | |
| 59 | | | | |
| 60 | | | | |

| | | | | |
|----|------------------------|----------------------|--|----------|
| 1 | mechanism | | envelopes), describing any steps to conceal the sequence | |
| 2 | | | until interventions are assigned | |
| 3 | | | | |
| 4 | Allocation: | #16c | Who will generate the allocation sequence, who will enrol | 8, 13 |
| 5 | implementation | | participants, and who will assign participants to | |
| 6 | | | interventions | |
| 7 | | | | |
| 8 | | | | |
| 9 | Blinding (masking) | #17a | Who will be blinded after assignment to interventions (eg, | 13-14 |
| 10 | | | trial participants, care providers, outcome assessors, data | |
| 11 | | | analysts), and how | |
| 12 | | | | |
| 13 | | | | |
| 14 | Blinding (masking): | #17b | If blinded, circumstances under which unblinding is | 8-9, 13- |
| 15 | emergency | | permissible, and procedure for revealing a participant's | 14 |
| 16 | unblinding | | allocated intervention during the trial | |
| 17 | | | | |
| 18 | | | | |
| 19 | | | | |
| 20 | Data collection plan | #18a | Plans for assessment and collection of outcome, baseline, | Table 1 |
| 21 | | | and other trial data, including any related processes to | |
| 22 | | | promote data quality (eg, duplicate measurements, training | 16-20 |
| 23 | | | of assessors) and a description of study instruments (eg, | |
| 24 | | | questionnaires, laboratory tests) along with their reliability | |
| 25 | | | and validity, if known. Reference to where data collection | |
| 26 | | | forms can be found, if not in the protocol | |
| 27 | | | | |
| 28 | | | | |
| 29 | | | | |
| 30 | | | | |
| 31 | Data collection plan: | #18b | Plans to promote participant retention and complete follow- | 15 |
| 32 | retention | | up, including list of any outcome data to be collected for | |
| 33 | | | participants who discontinue or deviate from intervention | |
| 34 | | | protocols | |
| 35 | | | | |
| 36 | | | | |
| 37 | | | | |
| 38 | Data management | #19 | Plans for data entry, coding, security, and storage, including | Table 1 |
| 39 | | | any related processes to promote data quality (eg, double | |
| 40 | | | data entry; range checks for data values). Reference to | 13-14 |
| 41 | | | where details of data management procedures can be | |
| 42 | | | found, if not in the protocol | |
| 43 | | | | |
| 44 | | | | |
| 45 | | | | |
| 46 | Statistics: outcomes | #20a | Statistical methods for analysing primary and secondary | 20-21 |
| 47 | | | outcomes. Reference to where other details of the statistical | |
| 48 | | | analysis plan can be found, if not in the protocol | |
| 49 | | | | |
| 50 | | | | |
| 51 | Statistics: additional | #20b | Methods for any additional analyses (eg, subgroup and | 20-21 |
| 52 | analyses | | adjusted analyses) | |
| 53 | | | | |
| 54 | | | | |
| 55 | Statistics: analysis | #20c | Definition of analysis population relating to protocol non- | 15-16 |
| 56 | population and | | adherence (eg, as randomised analysis), and any statistical | |
| 57 | missing data | | methods to handle missing data (eg, multiple imputation) | 20-21 |
| 58 | | | | |
| 59 | | | | |
| 60 | | | | |

| | | | | |
|----|--------------------|----------------------|--|--------|
| 1 | Data monitoring: | #21a | Composition of data monitoring committee (DMC); summary | 13-14 |
| 2 | formal committee | | of its role and reporting structure; statement of whether it is | |
| 3 | | | independent from the sponsor and competing interests; and | |
| 4 | | | reference to where further details about its charter can be | |
| 5 | | | found, if not in the protocol. Alternatively, an explanation of | |
| 6 | | | why a DMC is not needed | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |
| 11 | Data monitoring: | #21b | Description of any interim analyses and stopping guidelines, | 21 |
| 12 | interim analysis | | including who will have access to these interim results and | |
| 13 | | | make the final decision to terminate the trial | |
| 14 | | | | |
| 15 | | | | |
| 16 | Harms | #22 | Plans for collecting, assessing, reporting, and managing | 19, 20 |
| 17 | | | solicited and spontaneously reported adverse events and | |
| 18 | | | other unintended effects of trial interventions or trial conduct | |
| 19 | | | | |
| 20 | | | | |
| 21 | Auditing | #23 | Frequency and procedures for auditing trial conduct, if any, | 13-14 |
| 22 | | | and whether the process will be independent from | |
| 23 | | | investigators and the sponsor | |
| 24 | | | | |
| 25 | | | | |
| 26 | | | | |
| 27 | Research ethics | #24 | Plans for seeking research ethics committee / institutional | 22-23 |
| 28 | approval | | review board (REC / IRB) approval | |
| 29 | | | | |
| 30 | | | | |
| 31 | Protocol | #25 | Plans for communicating important protocol modifications | 23 |
| 32 | amendments | | (eg, changes to eligibility criteria, outcomes, analyses) to | |
| 33 | | | relevant parties (eg, investigators, REC / IRBs, trial | |
| 34 | | | participants, trial registries, journals, regulators) | |
| 35 | | | | |
| 36 | | | | |
| 37 | Consent or assent | #26a | Who will obtain informed consent or assent from potential | 13 |
| 38 | | | trial participants or authorised surrogates, and how (see | |
| 39 | | | Item 32) | |
| 40 | | | | |
| 41 | | | | |
| 42 | | | | |
| 43 | Consent or assent: | #26b | Additional consent provisions for collection and use of | NA |
| 44 | ancillary studies | | participant data and biological specimens in ancillary | |
| 45 | | | studies, if applicable | |
| 46 | | | | |
| 47 | | | | |
| 48 | Confidentiality | #27 | How personal information about potential and enrolled | 13-14 |
| 49 | | | participants will be collected, shared, and maintained in | |
| 50 | | | order to protect confidentiality before, during, and after the | |
| 51 | | | trial | |
| 52 | | | | |
| 53 | | | | |
| 54 | | | | |
| 55 | Declaration of | #28 | Financial and other competing interests for principal | 25-26 |
| 56 | interests | | investigators for the overall trial and each study site | |
| 57 | | | | |
| 58 | | | | |
| 59 | Data access | #29 | Statement of who will have access to the final trial dataset, | 14 |
| 60 | | | | |

| | | | |
|----|-----------------------|--|-----------|
| 1 | | and disclosure of contractual agreements that limit such | |
| 2 | | access for investigators | |
| 3 | | | |
| 4 | Ancillary and post | #30 Provisions, if any, for ancillary and post-trial care, and for | 20 |
| 5 | trial care | compensation to those who suffer harm from trial | |
| 6 | | participation | |
| 7 | | | |
| 8 | | | |
| 9 | Dissemination policy: | #31a Plans for investigators and sponsor to communicate trial | 22-23 |
| 10 | trial results | results to participants, healthcare professionals, the public, | |
| 11 | | and other relevant groups (eg, via publication, reporting in | |
| 12 | | results databases, or other data sharing arrangements), | |
| 13 | | including any publication restrictions | |
| 14 | | | |
| 15 | | | |
| 16 | | | |
| 17 | Dissemination policy: | #31b Authorship eligibility guidelines and any intended use of | 22, 27 |
| 18 | authorship | professional writers | |
| 19 | | | |
| 20 | | | |
| 21 | Dissemination policy: | #31c Plans, if any, for granting public access to the full protocol, | 14 |
| 22 | reproducible | participant-level dataset, and statistical code | |
| 23 | research | | |
| 24 | | | |
| 25 | | | |
| 26 | | | |
| 27 | Informed consent | #32 Model consent form and other related documentation given | 13 |
| 28 | materials | to participants and authorised surrogates | |
| 29 | | | |
| 30 | | | |
| 31 | Biological specimens | #33 Plans for collection, laboratory evaluation, and storage of | NA |
| 32 | | biological specimens for genetic or molecular analysis in the | |
| 33 | | current trial and for future use in ancillary studies, if | |
| 34 | | applicable | |
| 35 | | | |
| 36 | | | |

37 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 38 BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made
 39 by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

Note from the Editors: Instructions for reviewers of study protocols

Since launching in 2011, BMJ Open has published study protocols for planned or ongoing research studies. If data collection is complete, we will not consider the manuscript.

Publishing study protocols enables researchers and funding bodies to stay up to date in their fields by providing exposure to research activity that may not otherwise be widely publicised. This can help prevent unnecessary duplication of work and will hopefully enable collaboration. Publishing protocols in full also makes available more information than is currently required by trial registries and increases transparency, making it easier for others (editors, reviewers and readers) to see and understand any deviations from the protocol that occur during the conduct of the study.

The scientific integrity and the credibility of the study data depend substantially on the study design and methodology, which is why the study protocol requires a thorough peer-review.

BMJ Open will consider for publication protocols for any study design, including observational studies and systematic reviews.

Some things to keep in mind when reviewing the study protocol:

- Protocol papers should report planned or ongoing studies. The dates of the study should be included in the manuscript.
- Unfortunately we are unable to customize the reviewer report form for study protocols. As such, some of the items (i.e., those pertaining to results) on the form should be scored as Not Applicable (N/A).
- While some baseline data can be presented, there should be no results or conclusions present in the study protocol.
- For studies that are ongoing, it is generally the case that very few changes can be made to the methodology. As such, requests for revisions are generally clarifications for the rationale or details relating to the methods. If there is a major flaw in the study that would prevent a sound interpretation of the data, we would expect the study protocol to be rejected.